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Abstract 
 
The selectins play a key role in the inflammatory cascade. The initial tethering 
and rolling of the leukocytes on the vascular endothelial cells, mediated by the 
selectins, is an essential mechanism of the host immune defense. Excessive 
infiltration of leukocytes into inflamed tissue can, however, lead to severe 
pathological consequences as observed in various diseases (e.g. rheumatoid 
arthritis, stroke or reperfusion injury). Therefore, blocking of the selectins is a 
valuable pharmaceutical approach. 
 
The tetrasaccharide sialyl Lewisx (sLex) is the natural binding epitope common 
to all selectin ligands, and consequently served as a lead compound in 
selectin antagonist research. As observed for many carbohydrate-protein 
interactions, the affinity of sLex towards the selectins is in the low millimolar 
range. Its bio-active conformation has been determined by trNOE-NMR 
experiments and X-ray crystallography in complex with the selectins. Because 
binding of the selectins to their ligands occurs under shear stress conditions, 
the stabilization of the pharmacophores in sLex mimetics in the bio-active 
conformation is a pre-requisite for binding. 
 
In this PhD thesis, the importance of pre-organization of the acid orientation in 
sLex mimetics, but also the correct orientation of the core were studied. 
 
The stabilization of the acid orientation was studied by a non-covalent 
approach, using (R)- and (S)-adamantyllactic acid as replacements for the N-
acetyl neuraminic acid in sLex (chapter 2.1). Then, a ‘click chemistry’ library, 
directed towards the exploration of additional enthalpic contributions to 
binding, based on a pre-organized triazololactate was investigated (chapter 
2.2). The results obtained from these studies finally led to the project where 
the acid orientation is covalently locked in the bio-active orientation (chapter 
2.3). 
 
The core conformation of sLex and mimetics thereof was studied and found to 
be stabilized via a lipophilic interresidue interaction between fucose and 
galactose (chapter 2.4). 
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Abbreviations 
 
[α]D20 optical rotary power 
Ac acetyl 
Ad adamantyl 
AD asymmetric dihydroxylation 
AE asymmetric epoxidation 
AIBN azo-bis-isobutyronitrile 
All allyl 
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Ar aryl 
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Asn asparagine 
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d.r. diastereomeric ratio 
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GlyCAM-1 glycosylation dependent cell adhesion molecule-1 
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HMBC heteronuclear multiple bond correlation 
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IL-1 interleukin-1 
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IR infrared 
IUPAC International Union of Pure and Applied Chemistry 
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kon rate constant of association 
Lac lactate 
LAD-2 leukocyte adhesion deficiency type 2 
LAM-1 lymphocyte adhesion molecule-1 
Lea Lewisa 
LECAM-1 leukocyte endothelial cell adhesion molecule-1 
LECAM-2 leukocyte endothelial cell adhesion molecule-2 
Lex Lewisx 
LG leaving group 
LPS lipopolysaccharide 
Lys lysine 
m multiplet (NMR) 
m medium (IR) 
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MAdCAM-1 mucosal addressin cell adhesion molecule-1 
MBP-A mannose binding protein A 
MC Monte Carlo 
mCPBA meta-chloroperbenzoic acid 
MD molecular dynamics 
Me methyl 
Met methionine 
mol. sieves molecular sieves 
MS mass spectrometry 
NeuNAc N-acetyl neuraminic acid 
NIS N-iodo succinimide 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NSAID non-steroidal anti-inflammatory drugs 
ORTEP Oak ridge thermal ellipsoid plot 
PDC pyridinium dichromate 
PE petrol ether 
PG protecting group 
Ph phenyl 
Pr propyl 
Pro proline 
PSGL-1 P-selectin glycoprotein ligand 1 
py pyridine 
r.t. room temperature 
Rf retention factor 
rIC50 relative IC50 
ROE rotating frame Overhauser enhancement 
ROESY ROE spectroscopy 
rt room temperature 
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s strong (IR) 
sc side chain 
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sLea sialyl Lewisa 
sLex sialyl Lewisx 
STD saturation transfer difference 
SUMM systematic unbounded multiple minimum 
t triplet 
TBAF tetrabutylammonium fluoride 
TBAI tetrabutylammonium iodide 
tBu tert. butyl 
TCP tetrachlorophthal- 
TEA triethylamine 
TEMPO 2,2,6,6-tetramethylpiperidine-1-oxyl 
tert. tertiary 
Tf triflyl 
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TMS trimethylsilyl 
TNF-α tumor necrosis factor α 
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TOF time-of-flight 
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UV ultraviolet 
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1. Introduction 
 
Acute or chronic inflammatory diseases have a strong negative impact on the 
patient’s quality of life but also on the budget of the public health system. 
Among those diseases are allergies, stroke, organ transplant rejection, 
psoriasis, rheumatoid arthritis and others of large socio-economical impact. 
 
Many diseases have a significant inflammatory component and non-steroidal 
anti-inflammatory drugs (NSAID, e.g. cyclooxygenase inhibitors) as well as 
steroid-based drugs (e.g. cortisol) are widely used therapeutics. Usually, the 
treatment is not curing the patient but has a palliative character. The side 
effects of those drugs are well documented. Consequently, biologics for the 
treatment of inflammatory diseases have entered the market. Major 
pharmaceutical companies, e.g. Abbott Labs (HUMIRA) or Wyeth (Enbrel or 
etanercept), offer antibody treatment against chronic inflammatory diseases. 
However, the high costs of the treatment of patients with these novel biologics 
is only covered by the public health system when severe side effects with 
traditional medicine is observed. 
 
Therefore, the research at the Institute of Molecular Pharmacy (IMP) at the 
University of Basel is focusing on the discovery of small molecules that 
interfere with the inflammatory cascade at an early stage without having the 
side effects and cost burden of the established treatment of inflammation. The 
selectins are a class of cell adhesion molecules involved in the early stage of 
the inflammatory cascade. The initial tethering and rolling step of the 
leukocytes mediated by the selectins is an essential mechanism of the host 
immune defense. Therefore, the blocking of the selectin – leukocyte 
interaction in case of excessive influx of leukocytes into adjacent tissue is the 
goal of our research and the topic of this PhD thesis. 
Chapter 1.1 
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1.1 Structure and prevalence of the selectins 
 
The selectins form a family of calcium binding C-type lectins. Lectins are 
carbohydrate recognizing proteins, involved in cellular recognition.1 The family 
of E-, P- and L-selectin share common structural motifs (figure 1). They 
possess an N-terminal carbohydrate recognition domain (CRD), followed by 
an epidermal growth factor like domain (EGF), a varying number of short 
consensus repeats or complement regulatory-like (CR) domains, one 
transmembrane region and a C-terminal cytosolic tail.2 The major difference 
between the selectins is the number of the CR domains. The overall 
homology of the selectins is approx. 50%. The highest level of homology is 
found in their N-terminal CRD and EGF domains. The CRD domain hosts the 
carbohydrate ligand in the recognition process via a structural Ca2+ ion 
required for conformational stabilization. The EGF domain is required for 
binding, although its role is not fully understood. It may directly interact with 
the ligands or serve as chaperone for the correct fold of the CRD domain.3,4 
 
The CR domains are thought to act as spacers between the membranes of 
the two interacting cells.5 With the transmembrane domain the selectins are 
incorporated into the cell membrane, whereas the short C-terminal tail is 
believed to be involved in signal transduction.6 
 
 
 
Figure 1: The domain organization of the selectins (adapted from 7) 
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The names of the selectins were given according to the site of their first 
identification. 
 
• E-selectin (CD62E, ELAM-1 or LECAM-2) was discovered in the late 
1980’s by Bevilacqua and co-workers8,9 and has first been identified on 
endothelial cells. Its sequence consists of 589 amino acids and it has a 
calculated weight of 64 kDa. Because of its 5 potential N-glycosylation 
sites, the protein is highly glycosylated and the observed molecular 
weight is increased to 115 kDa.10,11 
 
• L-selectin (CD62L, LAM-1 or LECAM-1) was first discovered on 
lymphocytes, and was described as lymphocyte homing receptor.12 It 
was also found on neutrophil granulocytes and monocytes, and its role 
in leukocyte migration into inflamed tissue was reported.13,14 Its 
sequence consists of 372 amino acids and has a calculated weight of 
42 kDa. L-selectin is highly glycosylated and the observed molecular 
weight is increased to 90 kDa.15,16 
 
• P-selectin (GMP-140) was discovered on platelets by McEver17 and 
Furie18 in 1984. The sequence consists of 789 amino acids and has a 
calculated weight of 86 kDa. P-selectin is also highly glycosylated and 
the observed molecular weight is increased to 
140 kDa.19,20  
 
1.2 Ligands to the selectins 
 
The natural ligands to the selectins are glycoproteins which usually bear 
sialylated and fucosylated terminal glycan epitopes.21-23 The isomeric 
trisaccharides Lewisx (1, Lex, figure 2) and Lewisa (2, Lea), as well as their 
sialylated tetrasaccharide analogs sialyl Lewisx (3, sLex) and sialyl Lewisa (4, 
sLea) are generally considered to be the common terminal epitopes. 
Derivatives of sialyl Lewisx with sulfation of the 6-positions of N-acetyl 
glucosamine or galactose were also shown to bind to the selectins. 
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E-selectin ligand 1 (ESL-1) was identified as a non-sulfated 150 kDa N-linked 
glycoprotein ligand to E-selectin.24,25 Although it bears sLex motifs, it does not 
bind to P-selectin because of the lack of sulfation. The sequence of ESL-1 
contains 5 possible N-glycosylation sites.26 
 
GlyCAM-1,27 MAdCAM-1,28,29 CD34,30 podocalyxin-like protein,31 endo-
mucin,32 endoglycan33 and PSGL-134 have been identified as ligands to L-
selectin. GlyCAM-1, a sialo-mucin, is the best characterized L-selectin ligand. 
It is stored in the cytoplasmic granula of human endothelial venules in lymph 
node tissue.27,35-39 The secretory glycoprotein GlyCAM-1 is believed to be a 
regulatory protein for the recruitment of lymphocytes into peripheral 
lymphnodes.40,41 
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Figure 2: Carbohydrate epitopes in selectin ligands 
 
The best characterized and major natural P-selectin ligand is the P-selectin 
glycoprotein ligand 1 (PSGL-1) which has been discovered in 1993.42 The  
125 kDa protein forms dimers via a cysteine disulfide bridge. PSGL-1 
possesses terminal sLex structures in its sialomucin type glycans. This 
glycoprotein is also a ligand to E- and L-selectin, but for P-selectin binding, 
additional sulfation at two of the three N-terminal tyrosine residues (Tyr46, 
Tyr48 and Tyr51) is required.43-45 
 
An overview on the selectins and their ligands was published by Vestweber 
and Blanks40 and is shown in figure 3. 
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Figure 3: The selectins and their natural glycoprotein ligands.40 
 
1.2.1 The role of the selectins in the inflammatory cascade 
 
The inflammatory cascade is an important step of the defense mechanism of 
the immune system. In healthy humans, an invasion of pathogens or an injury 
triggers this complex cascade, ultimately leading to neutralization of the 
pathogen and healing of the injury. This process can be described by six 
directly linked steps (see figure 4). 
 
First, an inflammatory stimulus causes an immune response in the host. 
Inflammatory mediators, such as cytokines (e.g. TNF-α or IL-1) or LPS, 
stimulate endothelial cells to display E- and P-selectin on their cell surface. P-
selectin is transiently expressed and usually stored in α-granulocytes in 
platelets and in Weibel-Palade bodies in endothelial cells.46,47 Upon histamine 
or thrombin stimulation P-selectin is rapidly translocated to the cell surface 
within minutes. In contrast to the rapid exposure of P-selectin, E-selectin is 
expressed de novo by TNF-α, IL-1 or LPS mediated stimulation of 
transcription.48,49 The peak level of expression is observed 3-4 h after 
stimulation.50 
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Figure 4: The inflammatory cascade51 
 
As a second step, the initially freely flowing leukocytes interact via their 
surface glycoproteins (e.g. PSGL-1 and ESL-1) with the exposed E- and P-
selectins on the endothelial cell surface. This fast association, fast 
dissociation contact leads to the observed tethering and rolling process of the 
leukocytes along the blood vessel (see also figure 5).52,53 In fact, observations 
of this process and the following extravasation of leukocytes have been 
reported already at the end of the 19th century.54-56 
 
 
 
Figure 5: Leukocyte rolling (left) on endothelial cells  
and migration into tissue (right)57 
 
L-selectin is constitutively expressed at the surfaces of leukocytes and can 
interact via its own glycan structures with E-selectin.58 The pool of leukocytes 
attracted to the site of inflammation is further expanded via leukocyte-
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leukocyte interactions of PSGL-1 on already tethered leukocytes with L-
selectin on new leukocytes.59,60 
 
In a third step, chemokines from the endothelial cells are responsible for the 
secondary activation of the leukocytes. As a result, integrins, a second class 
of cell adhesion molecules located on leukocytes are activated,61,62 and can 
then interact with their ligands on endothelial cells initiating the firm adhesion 
in the fourth step of the inflammatory cascade. This firm adhesion mediated 
by the integrin interaction with their ligands, e.g. VCAM-1, ICAM-1 and also 
MAdCAM-161,62 is necessary for the subsequent step of extravasation of 
leukocytes from the blood stream into the inflamed tissue (see also figure 5). 
Finally, the leukocytes are attracted to the site of inflammation where they 
fight the inflammatory stimulus with cytokines, oxidative agents and 
proteases. 
 
1.2.2. Physiological and pathophysiological importance of the selectins 
 
In many acute or chronic inflammatory diseases excessive recruitment of 
leukocytes into tissue is a principal element. The disruption of the selectin-
leukocyte interaction was shown to have a severe effect on the course of 
these diseases.63-65  
 
Selectin-deficient mice showed impaired inflammatory responses.66,67 But 
also the application of selectin directed antibodies led to a severe decrease in 
the host’s response.68-70 
 
Further evidence for the importance of the selectins was reported in 1992. In 
a rare disease called leukocyte adhesion deficiency type-2 (LAD-2), the 
patient’s inflammatory response is impaired.71,72 In those patients, a mutation 
in a GDP-fucose transporter gene leads to a dramatic effect on the glycans 
expressed.73,74 These patients lack fucosylation in their glycoconjugates and 
as a result, rolling of leukocytes is reduced.  
 
Selectins play major roles in a variety of inflammatory diseases like ischemia 
and reperfusion injury,75,76 asthma,77-80 and rheumatoid arthritis.81-84 An 
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overview on these pathological functions would exceed the frame of this 
thesis and it is therefore recommended to the interested reader to go into the 
references cited. 
 
Carbohydrate epitopes which bind to the selectins were also reported as 
tumor-associated antigens.85 Carcinoma cell metastasis is believed to 
progress via the interaction of their sialylated and fucosylated mucin surface 
proteins with the selectins.86 Recently, Varki and Varki reported on the 
association between cancer metastasis and P-selectin.87 
 
1.3 Sialyl Lewisx as lead 
 
Sialyl Lewisx is the minimal epitope recognized by all three selectins21,22,88 and 
served therefore as a lead structure for selectin antagonist research.89-92 
Sialyl Lewisx was chosen for this purpose although it only has, similar to most 
carbohydrate - receptor interactions, a modest affinity in the millimolar range. 
Soluble sLex was shown to have beneficial effects in in vitro and in vivo 
models.93-96 
 
1.3.1 The assay format 
 
The binding kinetics of the selectins to their in vivo ligands show fast 
association - fast dissociation kinetics with kon values typically in the range of 
104 M-1s-1 and koff values in the range of 1 s-1.97-99 Sialyl Lewisx shows also 
similar binding kinetics to a sLex specific antibody GSLA-2.100,101 This 
behavior of the ligand is essential to overcome the shear forces under flow 
conditions. Interestingly, the overall affinity of sLex is rather low and results 
from only a few, mostly electrostatic interactions.99 To have a significant read-
out of a cell-free assay, the reference ligand is therefore displayed in an oligo-
valent fashion.102,103 
 
sLex has been reported with various affinities to the selectins as a result of the 
wide variety of target-based assays applied in this field. This is a significant 
drawback when comparing different compounds that have been evaluated by 
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different groups, i.e. with different assays. Therefore, the affinities reported in 
this work will always be relative to sLex or to one of its well studied mimetics 
(CGP69669A,69 vide infra). In addition, false positives were reported due to 
the presence of trace amounts of polyanionic ion exchange resins especially 
for P-selectin which requires additional sulfation for binding.104 
 
Under static cell-free conditions, various ELISA-based assays are reported in 
the literature. Either sLex is grafted on microtiter plates via sLex-glycolipids 
and an antibody directed against the glycan with a secondary read-out motif is 
displaced by the testing compounds105-108 or the inverse process is used 
where selectin is immobilized and a polymeric sLea with a secondary signal is 
displaced by the compound of interest.102,109,110 Also HL-60 cells displaying 
sLex on their surface have been used to determine affinities of compounds of 
interest using selectin-IgG constructs and myeloperoxidase activity after cell 
lysis as read-out.111,112 
 
Since in vivo the binding process occurs under shear stress conditions, more 
sophisticated dynamic assay formats were developed. Because of their low 
throughput, however, they are only used as secondary assays. Rolling of 
neutrophils on a stimulated HUVEC cell monolayer can be observed in the 
flow-assay reported by the Novartis team.113 Intravital microscopy was 
developed as a convenient in vivo characterization method.69,114-119 The 
tethering, rolling and extravasation process in a blood vessel can directly be 
observed by this format. 
 
1.3.2 Essential pharmacophores 
 
Systematic studies towards the replacement of all functional groups in sLex 
gave a good picture of the essential pharmacophores. These are: 
 
a,  the 3- and 4-hydroxyl groups of fucose120,121 
b,  the 4- and 6-hydroxyl groups of galactose122,123 
c,  the carboxylic acid of neuraminic acid (and additionally, 4-OH 
and hydrophobic contributions for P-selectin)120,124-12 
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From several studies, it became evident that GlcNAc is not directly involved in 
the binding process: it does not bear essential pharmacophores for selectin 
binding.127-129 
 
1.3.3 Conformation of the tetrasaccharide motif 
 
Oligosaccharides were regarded for a long time as conformationally flexible 
when compared to other classes of biopolymers, e.g. polypeptides. However, 
intrinsic properties of saccharides lead to a stabilization, respectively a 
conformational preference across glycosidic linkages. The exo-anomeric 
effect130,131 is a main reason for this preference, but also inter-residue 
hydrogen bonds and other effects, e.g. steric constraints, contribute to a 
preferred population of the possible conformations of saccharides. 
 
Sialyl Lewisx has attracted the attention of many researchers in the field of 
medicinal chemistry. Consequently, there is a large number of reports on 
conformational issues of sLex in solution but also bound to the selectins. An 
overview on this topic was given by Porro.132 
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Figure 6: Simultaneous NOEs between Gal-H3 and NeuNAc-H3ax and H8 
prove the existence of at least two conformations of sLex in solution 
 
In solution, sLex populates three conformational clusters resulting from 
different interglycosidic dihedral angles. However, the degree of population of 
the individual clusters is still debated. Results have been obtained from 
computational studies and NMR experiments of the ligand alone.133-140 There 
is a general agreement on the conformational stability of the Lewisx core of 
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sLex. However, a certain flexibility around the glycosidic linkage of sialic acid 
with galactose is topic of discussion. Especially the presence of NOEs 
between sialic acid H3134,137,140 and H8138,139 with the galactose H3 proton 
supports the co-existence of two conformations in solution (figure 6).  
 
 
 
Figure 7: The bioactive conformation of sLex from trNOE NMR experiments141,142 
 
Finally, structural analysis in presence of the protein revealed the bioactive 
conformation with the help of transferred-NOE experiments (figure 7).141,142 
Saturation transfer difference (STD) spectroscopy could show the epitopes of 
sLex which are in close contact with the protein in the bound state.143 
 
Later, in the year 2000, this bioactive conformation was confirmed by X-ray 
crystallography of sLex in complex with all three selectins as reported by 
Camphausen and co-workers,126 based on the crystal structure of the apo-
protein published in 1994.144 
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Figure 8: Contacts of the pharmacophores in sLex with E-selectin  
(adapted from 126) 
 
 
 
Figure 9: Top-view on sLex bound to E-selectin as determined by X-
ray126: The essential pharmacophores are oriented in a plane 
complementary to the receptor, whereas GlcNAc and NeuNAc, with 
exception of its carboxylic acid, are not in contact with the protein (yellow 
sphere: Ca2+ ion, dotted spheres: H2O molecules) 
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An information already obtained from the X-ray structure of the highly 
homologous mannose binding protein (MBP-A)145 in complex with its glycan 
ligand proved true also in the case of the complex of sLex with the selectins: 
the fucose (mannose in MBP-A) residue is involved in inner-sphere 
complexation of the protein bound Ca2+ ion. The interactions of the remaining 
pharmacophores of sLex with E-selectin are depicted in figure 8. The essential 
carboxylate of neuraminic acid is involved in a tyrosine supported salt-bridge 
with Arg97, whereas the remaining functional groups of this residue are not in 
contact with the protein. From this structure, it also becomes evident that the 
GlcNAc moiety just serves as a spacer to keep the fucose and the galactose 
residues in their appropriate positions, as GlcNAc itself has no contacts with 
the protein surface (figure 9). 
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1.4 Selectin antagonists 
 
One major drawback in the development of sLex antagonists were the testing 
conditions. Because of this wide variety of assays, it is difficult to compare the 
non-standardized affinities measured by different groups. Furthermore, false-
positives as a result of ion-exchange resin contamination should always be 
taken into account when comparing reported data (vide supra).104 
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Figure 10: Recently reported selectin binding molecules 
 
The numerous small molecule mimetics of sialyl Lewisx based on 
replacements of single saccharide subunits, but also de novo design of E-
selectin antagonists were summarized by Wong and co-workers92 in 1998 and 
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in a more recent review by Ernst, Kolb and Schwardt.57 Here, I want to 
mention the latest research results which are not included in those two review 
articles. 
 
Schön further analyzed efomycine M (5, figure 10), a natural product which is 
supposed to bind to the selectins.146 This molecule has been mentioned 
before in a patent by Bayer AG, Germany, as a potential treatment for 
psoriasis.147 However, when tested by an independent group at Schering AG, 
Germany, these results could not be confirmed.148 
 
A team led by Aydt at Revotar, Germany, published a series of patents149-154 
and one paper155 on various de novo designed pan-selectin antagonists (e.g. 
6 and 7, figure 10). These molecules do not resemble sLex because of the 
total loss of any carbohydrate motif. In a competitive binding assay, IC50 
values were reported to be in the micromolar range. 
 
Ulbrich and co-workers156 synthesized and tested selectin antagonists based 
on long C10-alky chains and carboxylic acids (8, figure 10), that resemble 
detergents. The IC50s reported are thus not expected to result from functional 
selectin inhibition. 
 
Kaila157 and co-workers at Wyeth reported on quinic acid derivatives as 
selectin binding molecules (10, figure 10). Quinic acid was chosen since it has 
the same relative orientation of the hydroxyl groups as in fucose. The affinities 
towards P-selectin were in the millimolar range, and crystals of selectin could 
be soaked with solutions of these small molecules to give insight in their 
binding properties. Independently, Girard et al. published the synthesis of 
quinic acid derivatives and their evaluation in an HL-60 cell based assay (9, 
figure 10).158 The IC50s were reported to be greater than 50 mM. 
 
In 2007, Kaila and co-workers published two papers on the optimization of 
quinolone derivatives as P-selectin antagonists (figure 10).159 These 
molecules moved on to clinical trials this year at Wyeth, although they display 
IC50s in the micromolar range.160 
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1.4.1 Locked Conformations 
 
It is a well known concept in medicinal chemistry, that a conformational pre-
organization of the pharmacophores in their bioactive spatial arrangement 
ultimately leads to a higher binding affinity. This results from decreased 
entropy costs upon binding when compared to a flexible analog. This 
phenomenon has been shown in various fields of supramolecular assembly161 
and medicinal chemistry (vide infra). In 1993, Carver was discussing the idea 
of reducing conformational freedom of molecules in solution to obtain 
oligosaccharides with higher binding affinity towards their receptors.162 
 
A beautiful example of this approach, where the affinity benefits largely from 
the locked conformation, was the introduction of cyclic ureas as HIV protease 
inhibitors in 1994.163 Bundle recently reported on the stabilization of the 
bioactive conformation of a trisaccharide, mimicking the LPS of Shigella 
flexneri for antibody binding.164,165 They could reduce the entropic cost of 
binding (TΔS) by 1.2 kcal mol-1 via a locked bioactive conformation. 
 
 
 
Figure 11: Internal coordinates of sLex: the core conformation indicates 
the relative spatial arrangement of the fucose and galactose residues, 
the acid orientation defines the tilting angle of the C1-C2 bond vector of 
sialic acid relative to the core 
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Entropic contributions are much more important for binding under shear 
stress conditions, as they are present in the selectin-mediated inflammatory 
cascade, than in cases where binding occurs under static conditions. It is 
therefore the philosophy of our research group that only small molecules with 
pre-organized pharmacophores will be functional selectin blockers.166  
 
This working hypothesis has evolved from two reports by Kolb and Ernst in 
1997, where biological affinities of selectin ligands were predicted as function 
of their conformational preference in silico.167,168 For better visualization of the 
internal conformation of sLex in the bound conformation, two internal 
coordinates were defined. These are  
 
• the core conformation, i.e. the relative spatial 
arrangement of fucose and galactose and 
 
• the acid orientation which defines the tilting 
angle of the C1-C2 bond vector of sialic acid 
with the core (figure 11). 
 
The bioactive conformation of sLex142 and the prediction of the conformational 
preference of sLex in solution as a function of these two coordinates are 
shown in figure 12 as 2-dimensional plot. 
 
 
 
Figure 12: The bioactive conformation of sLex as a function of acid/core 
dihedrals (left) and the computationally predicted behavior in solution 
(right)167,168 
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This concept of conformational restriction is the basis of the present thesis: 
 
• The pre-organization of the core as a result of 
lipophilic inter-residual stabilization was studied 
(chapter 2.4).  
 
• The major part of this thesis however, deals 
with the flexibility of the neuraminic acid, the 
impact of this flexibility on binding and how the 
conformation can be pre-stabilized in the 
correct orientation (chapter 2.1, 2.2, 2.3). 
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1.4.2 Replacements for NeuNAc in sLex mimetics: importance of pre-
organization 
 
The literature regarding replacements of NeuNAc as well as the importance of 
the above mentioned pre-organization was summarized in a review for 
CHIMIA. 
 
Titz, A.; Ernst, B. CHIMIA 2007, 61, 194. 
 
Copyright  Swiss Chemical Society: CHIMIA 61, 194-197, 2006. 
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1.5 Status of low molecular weight compounds in clinical and 
pre-clinical development 
 
Various low molecular weight selectin antagonists have entered preclinical 
and clinical trials. In 2003, Schön169 and Ulbrich170 summarized the 
compounds in clinical development. Here, an updated version is given (figure 
13). 
 
Several molecules entered clinical trials, which however were stopped due to 
inefficacy. Bristol-Meyers-Squibb was active in the field with BMS-190394, a 
sulfatide analog (12, figure 13).171 Cytel Corp. launched its P-selectin sulfatide 
sLex analogous antagonist CY-1503172 and went into clinical trials.173 Nippon 
Organon was studying OJ-R9188 (13, figure 13) in 2001, a pan-selectin 
inhibitor in allergic dermatitis without any further reporting until now.174 
Another selectin-inhibitor, OC-229648 (14, figure 13) from Ontogen 
Corporation, was developed as a non-carbohydrate derived selectin 
antagonist but was not further pursued.175,176 As mentioned above, Wyeth is 
now entering preclinical development with its quinolinone inhibitors (11, figure 
10).160 
 
Bimosiamose (15, TBC1269, figure 13), a selectin directed dimeric sLex 
mimicking compound based on mannose as fucose replacement has been 
developed by Revotar (Berlin, Germany) in asthma and psoriasis. Its current 
status for both indications is clinical phase II.177 However, in 2005 Norman 
could show that bimosiamose does not inhibit rolling of leukocytes in vivo and 
is thus not a functional selectin antagonist.178 
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Figure 13: Selectin antagonizing low molecular weight 
compounds in clinical and pre-clinical development 
 
In collaboration together with the Institute of Molecular Pharmacy at the 
University of Basel, GlycoMimetics Inc., Maryland, is continuing to develop 
the Ciba-Geigy compound CGP69669A69 (16, figure 13). Various doctoral 
theses, including the present one, were dedicated to gain further insight into 
the blocking of the selectins with molecules derived from sLex.7,132,179-181 
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2. Results and Discussion 
 
2.1 Pre-organization of the acid as a result of non-covalent 
restrictions 
 
The concept of pre-organiztion of the carboxylic acid in sLex mimetics of Kolb 
and Ernst167,168 was further studied by substitution of NeuNAc with 
adamantyllactic acids of both absolute configurations (R) and (S). 
 
This part was published in Bioorganic and Medicinal Chemistry: 
 
Titz, A.; Patton, J.; Alker, A.M.; Porro, M.; Schwardt, O.; Hennig, M.; 
Francotte, E.; Magnani, J.; Ernst, B. Bioorg. Med. Chem. 2008, 16, 1046. 
 
Copyright  Elsevier B.V.: Bioorg. Med. Chem. 16, 1046-1056, 2008 
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2.2 Targeting the protein surface for additional enthalpic 
interactions 
 
To screen for sLex mimetics with increased binding affinity via additional 
enthalpic interactions in proximity to the carboxylic acid, a library was 
designed that permits fast and selective diversification in the last step. A set 
of molecules was synthesized and tested for their biological affinity. 
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1. Introduction 
 
The selectins play a key role in the early inflammatory cascade. The 
recruitment and extravasation of leukocytes into inflamed tissue mediated by 
E-, P- and L-selectin, a family of closely related cell adhesion molecules, is an 
essential mechanism of the immune defense. The selectin-leukocyte 
interaction leads to the characteristic tethering and rolling process of 
leukocytes on the vascular endothelium. Upon secondary activation, firm 
adhesion and migration through the endothelial cell monolayer takes place.1,2 
However, excessive influx of leukocytes into the surrounding tissue can cause 
acute or chronic reactions as observed in reperfusion injury, stroke or 
rheumatoid arthritis.3,4 As a result, the antagonism of the selectins is 
considered to be a valuable approach for the treatment of inflammatory 
diseases. 
 
Since the physiological ligands of the selectins bear the terminal 
tetrasaccharide epitope sialyl Lewisx (1, sLex, figure 1),5,6 this motif served as 
lead structure in the search for selectin antagonists.7-9 Numerous publications 
determined the essential pharmacophores of sLex for binding to E-selectin, 
i.e. four hydroxyl groups (fucose 3- and 4-OH, galactose 4- and 6-OH) and 
the carboxylic acid of neuraminic acid.9,10 The bioactive conformation (figure 
1) of sLex was determined by trNOE NMR experiments11,12 and was 
subsequently confirmed by X-ray crystallography13 of E-, P- and L-selectin co-
crystallized with sLex. Carbohydrate-protein interactions are usually of low 
affinity9 (e.g. sLex has an IC50 of 1 mM, rIC50 = 1.0). However, a reduction of 
the entropy costs upon binding by stabilizing the bioactive conformation of 
sLex and mimics thereof, proved to be a valuable approach to increase 
binding affinity.14-17 
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Figure 1: The minimal binding epitope of all three selectins: sialyl Lewisx 
(1, sLex, essential pharmacophores in bold face) and its bioactive 
conformation as determined by trNOE NMR experiments11,12 
 
Numerous modifications of the Lex core have been studied.9 Only a few 
reports, however, are dealing with modifications at the neuraminic acid part of 
sLex.17 Most of them simply replace NeuNAc by an anionic moiety (e.g. 
sulphate or phosphate) or are focusing on the stabilization of the acid 
orientation in the bioactive conformation.16,17 Targeting the receptor surface 
for additional enthalpic contributions to binding was largely neglected, since 
only one patent by Kolb is addressing this issue.18  
 
To date, there is no crystal structure of a complex of E-selectin with the 
optimized lead compound CGP69669A19 available and a docking model 
suggests that this mimic adopts a similar binding mode to E-selectin as sLex 
itself.20 Consequently, the protein surface adjacent to the binding region of the 
carboxylic acid could be suitable for accommodation of additional 
pharmacophores (figure 2).  
 
In the patent of Kolb,18 a series of isoserine derived ligands was synthesized 
and biologically evaluated (figure 3). Isoserine was used as a neuraminic acid 
replacement and this motif was diversified via amine, amide or sulfonamide 
linkages. The substituents analyzed varied largely (e.g. aryl sulfonamides, 
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fatty acid amides or polyhydroxylated alkyl chains), but excluded heterocyclic 
fragments. 
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Figure 2: Potential interactions of lactic acid derivatives (R) with amino 
acids in the E-selectin binding sites (sc: interactions of the side chain, bb: 
interactions of the backbone) 
 
Biological data reported for these compounds show binding to E-selectin, 
albeit with rather low affinities. Almost all secondary amines and amides show 
rIC50s in the range of 0.6 to 2.0. When sulfonamides were introduced, the 
inhibition potency increases to rIC50s of 0.12-0.26. For the N-alkylated amides 
and tertiary amines, the rIC50 values lie within a range of 0.2-0.6. However, 
none of the analyzed isoserine derivatives was a better ligand to E-selectin 
than the cyclohexyllactate derivative CGP69669A14,15 (rIC50 = 0.08). 
 
Speculatively interpreted, at least part of these results might originate from 
the linking functionality. In case of amines, a zwitter ionic species is present at 
physiological pH, and thus may influence the strength of the crucial salt bridge 
with the guanidinium of Arg97 in E-selectin (figure 2). In case of the amides, 
the H-bond donating character might influence the conformation of the ligand 
upon binding to the protein, and therefore alter the optimal conformation for 
salt-bridge formation, leading to reduced affinity. This would also explain why 
the N-alkylated amides lacking an H-bond donor display better binding when 
compared to the amides with a free nitrogen bound proton. 
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Figure 3: E-selectin ligands with neuraminic acid replacements to 
target the receptor for additional enthalpic contributions to binding18 
 
To address this issue, we report the design, synthesis and biological 
evaluation of a library of E-selectin antagonists with a diversification as the 
last step, taking both, the introduction of heterocyclic fragments for receptor 
targeting, as well as a non-charged and a non-hydrogen bond donating 
functional group for diversification into account. 
 
2. Results and discussion 
 
For the selective and quantitative diversification as last step of the synthesis, 
but also for a linking functionality that meets the desired criteria, a click 
chemistry21,22 approach seemed to be the most straight forward. For this 
purpose, there are various ‘spring-loaded’ reactions available, e.g. the 
copper-(I) catalyzed Huisgen23 1,3-dipolar cycloaddition of azides and 
alkynes. Here, we introduced an azide functionality into a mimic of sLex 
bearing all necessary pharmacophores (5, scheme 1). This tetrasaccharide 
mimetic could then easily be used to obtain selectively derivatized ligands (6, 
scheme 1) using an array of commercial terminal alkynes. 
 
Before synthesizing the library, we were carefully analyzing if a ligand bearing 
an unsubstituted triazol (6a, R = H, scheme 1) in the 3-position of the (S)-
lactate derivative would still adopt the bioactive arrangement of the essential 
pharmacophores in solution using the Monte-Carlo-(jumping-between-
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wells)/stochastic dynamics (MC(JBW)/SD) protocol.14 The in silico results 
(data not shown) nicely demonstrate that antagonist (S)-6a is well pre-
organized in the bioactive window and therefore a suitable candidate as basis 
for the library.  
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Scheme 1: E-selectin ligand synthesis via click chemistry to target  
the receptor surface adjacent to the binding site of the carboxylate 
 
For the synthesis of the library precursor 5, the tin acetal mediated alkylation 
of the trisaccharide core using a lactate electrophile was chosen. In the 
present case, the lactate electrophile is derived from (R)-isoserine which was 
obtained from the chiral pool. The hydroxyl group and the 1-carboxylate of 
(R)-malic acid (7, scheme 2) were protected as cyclohexyl-dioxolane 8 in 98% 
yield to render the terminal carboxyl group available for selective 
transformation. Its acyl chloride was obtained by refluxing in thionylchloride. 
Transformation of the acyl chloride into an acyl azide by treatment with 
sodium azide gave the precursor for the Curtius rearrangement. In the 
following rearrangement, an isocyanate is formed which upon acidic 
hydrolysis intramolecularly reacts with the 2-OH group to form a carbamate. 
This could be observed by 1H-NMR as a doublet of doublets at 5.00 ppm for 
H-2, being a downfield shift of 0.8 ppm compared to isoserine hydrochloride. 
Complete hydrolysis gave (R)-isoserine hydrochloride (9) in 51% yield over 4 
steps. 
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Scheme 2: (i) Cyclohexanone, BF3•Et2O, Et2O, 0 °C-r.t., 1 d, 98%; (ii) 
SOCl2, reflux, 30 min; (iii) NaN3, H2O, acetone, -20 °C, 1 h; (iv) PhMe 
reflux, 30 min; (v) 6M HCl reflux, 6 h, 51% (4 steps); (vi) SOCl2, MeOH, 
reflux, 3.5 h, quant.; (vii) BnBr, NEt3, DMF, r.t., 36 h, 85%; (viii) Tf2O, 2,6-
tBu2-py, CH2Cl2, -20 °C, 5 h (16: 68%, 18: 48%, 21: 88%); (ix) Cbz-Cl, 
NaHCO3, THF/H2O, 0 °C, 3 h, 69%; (x) TCP-anhydride, DIPEA, 
PhMe/DMF, reflux, 5 h, 31%; (xi) TfN3, CuSO4, NaHCO3, PhMe/H2O/ 
MeOH, r.t., 24 h (17: 58%); (xii) BnBr, NEt3, DMF, r.t., 1 d, 63% over 2 
steps; 
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Scheme 3: (i) Bu2SnO, MeOH, mol. sieves 3Å, reflux, 15 h; (ii) 21, CsF, 
DME, r.t., 6 d; (iii) Pd(OH)2/C, H2, THF, H2O, 4 bar, r.t., 72 h; (iv) TfN3, 
CuSO4, NaHCO3, PhMe/H2O/MeOH, r.t., 22 h; (v) 1. alkyne, Cu, CuSO4, 
EtOH/H2O, 24 h; 2. 1 eq NaOH; yields (over 3 steps from 23): 6b 35%, 
6c 35%, 6d 15%, 6e 34%, 6f 33%; for 6a: TMS-acetylene, DIPEA, CuCl, 
MeCN/H2O, 9 d; (vi) for 6a: 1. TBAF, HOAc/THF, r.t., 30 min; 2. 1 eq 
NaOH, 7% (over 4 steps from 23); 
 
Because the tin-acetal mediated alkylation with lactate triflates usually gives 
low to moderate yields, we studied several protecting groups for the amine as 
well as for the carboxylic acid. For this SN2-type alkylation reaction, small 
protecting groups are expected to give higher yields because of a better 
accessibility of the electrophilic carbon. Therefore, the carboxylate was 
protected as methyl ester (10) by refluxing (R)-isoserine hydrochloride (9) in 
methanol in the presence of thionylchloride. For the amine protection, a series 
of standard amine protecting groups was tested (scheme 2). Dibenzylation of 
the amino group in 10 yielded the dibenzylamino product 11 in quantitative 
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yield. However, when the secondary hydroxyl group was transformed into a 
leaving group by treatment with triflic anhydride, the tertiary amine underwent 
an intramolecular cyclization with loss of triflate to form the aziridinium 
compound 12. Similar observations have been made recently by Couturier 
and co-workers by transforming the hydroxyl group of isomeric methyl N,N-
dibenzyl serinate into a mesylate.24 
 
To reduce the nucleophilicity of the nitrogen, the amine was protected as 
electron withdrawing O-benzyl carbamate 13. However, upon treatment of 13 
with triflic anhydride cyclization occurred to give the oxazoline 14. Finally, 
protection of the amine as tetrachlorophthalimide rendered 15 in moderate 
yield, which could be transformed into the corresponding stable triflate 16. 
Additionally, an azide was installed as protecting group by CH2Cl2-free diazo 
transfer.25 The resulting azido lactate 17 was then transformed into the 
corresponding triflate 18. As alternative protecting group for the carboxylic 
acid, a benzyl ester (20) was installed after introduction of the azide protecting 
group in 19. The corresponding electrophile was obtained by transformation 
of the hydroxyl group into a leaving group (21). 
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Scheme 4: (i) 1-benzotriazolyl-prop-2-yne, Cu, MeOH/H2O, 48 h; 
(ii) 1. Pd(OH)2/C, H2, dioxane/H2O, 4 bar, r.t., 24 h; 2. 1 eq NaOH; 
 
Tin-acetal mediated alkylation of the 3-position of galactoside 2216 (scheme 3) 
with the obtained electrophiles 16, 18 and 21 was in our hands only 
successful for 21. In case of the TCP protected amine 16, steric hindrance 
may have been the primary cause of failure. For the sterically least 
demanding azido methyl ester 18, the water sensitive alkylation probably 
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failed due to insufficient drying of the volatile triflate. Finally, alkylation with the 
less volatile benzyl derivative 21 proved successful, although with moderate 
yield (scheme 3).26,27 
 
Hydrogenolytic deprotection of tetrasaccharide mimetic 23 gave the amino 
compound 24. The azide needed for click chemistry mediated diversification 
was reinstalled with the CH2Cl2-free diazo transfer (5, scheme 3). Finally, a 
small library of putative E-selectin antagonists (6a-f, table 1) was obtained by 
copper-(I) catalyzed Huisgen 1,3-dipolar cycloaddition with the corresponding 
alkynes. The tetrahydro-benzotriazolyl compound 6g was obtained by 
inverting the reaction sequence, i.e. the fully protected azide 23 was first 
reacted with benzotriazolylpropyne to give 25, followed by hydrogenolytic 
cleavage of the benzyl groups and partial hydrogenation of the benzotriazol 
moiety (scheme 4). 
 
The obtained sLex mimetics were tested in a static cell-free in vitro assay for 
their binding to E-selectin.28 The results obtained for the azido lactate derived 
library showed that all molecules were binding to the protein (6e as one 
exception). However, the rIC50s vary widely. When additional fragments are 
attached to the triazol linker, the binding was not increased, yet it is in the 
range of sLex. Interestingly, the unsubstituted triazol is the best binder in this 
series with an rIC50 of 0.48. Finally, the molecule tested with the lowest rIC50 
of 0.29 proved to be the unsubstituted azide 5. 
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Table 1: Relative IC50s (rIC50) of the E-selectin antagonists 5 and 6a-g. IC50s were 
measured using CGP69669 (rIC50 = 0.08) as reference compound and are scaled on 
sLex (rIC50 = 1). 
 
Entry Compound R = rIC50 
1 5 - 0.29 
2 6a H 0.48 
3 6b 
 
1.03 
4 6c S
 
0.88 
5 6d 
N  
3.13 
6 6e 
F3C
 
n.a. 
7 6f N
N
N
 
1.18 
8 6g N
N
N
 
1.22 
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3. Conclusion 
 
In the present manuscript, we show the design, synthesis and biological 
evaluation of a small library of E-selectin ligands with neuraminic acid 
replacements. In these ligands, pharmacophore fragments were introduced to 
target the receptor for additional enthalpic contributions to binding. A related 
set of molecules by Kolb18 based on amine and amide linkers did not improve 
binding affinity to the receptor. This may have originated from a negative 
influence on the necessary salt bridge between the ligand carboxylate and 
Arg97 by the zwitterionic character in the amine series or by additional 
hydrogen bonding possibilities in the amide series. Therefore, the library 
molecules in this study were obtained from the azido-lactate mimic 5 of sLex, 
which was used in copper-(I) catalyzed click chemistry with various alkynes to 
introduce diversity in the last step of the synthesis. The trans-triazol 
generated by this chemistry was chosen as a linker because of its facile 
introduction as well as the lack of positive charge or hydrogen-bond donating 
properties, which might have a negative influence on binding. The obtained 
ligands were tested in an in vitro assay and showed binding to E-selectin (with 
one exception (6e)). However, when pharmacophore fragments were added 
to the triazol (6b-g), the observed inhibitory potency dropped when compared 
to the unsubstituted triazol 6a or even the azido compound 5. These data 
together with the reported affinities of the Kolb library let us conclude that 
pharmacophores attached in vicinity to the essential carboxylate might have 
additional enthalpic interactions with the protein but will then alter the acid 
orientation, which was shown to be essential for binding. This would lead to a 
weakening of the salt bridge with the protein and consequently result in 
decreased affinity. Since this interpretation is based on a computational 
model on the binding mode of sLex mimics, solid experimental structural data 
(i.e. X-ray crystallography or NMR spectroscopy) of such a mimetic in 
complex with E-selectin is needed for further understanding and optimization 
of the binding potency. Studies addressing these issues are in progress. 
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4. Experimental 
 
General Methods 
 
Nuclear magnetic resonance spectroscopy was performed on a Bruker 
Avance 500 UltraShield spectrometer at 500.13 MHz (1H) or 125.76 MHz 
(13C). Chemical shifts are given in ppm using residual solvent peaks29 or 
tetramethyl silane as references. Multiplicities were specified as s (singlet), m 
(multiplet) or interpreted according to 1st order30 and higher order where 
possible. 
 
The signals were assigned with the help of DEPT-135, 1H,1H-COSY/TOCSY 
and 1H,13C-HSQC/HMBC experiments. Assignments are indicated according 
to IUPAC nomenclature. For complex molecules, the following prefixes for 
substructures are used: Cy (cyclohexyl), Fuc (fucose), Gal (galactose), Lac 
(lactate), and Bt (benzotriazol). Ci indicates the ipso substituted carbons of 
aromatic systems. 
 
IR spectra were recorded on a Perkin Elmer Spectrum One as KBr pellets or 
as films on NaCl plates. Bands are given in cm-1 and characterized as s 
(strong), m (medium) or w (weak). Optical rotations were measured on a 
Perkin Elmer 341 polarimeter in the indicated solvents in p.a. quality. ESI 
mass spectra were recorded on a Waters micromass ZQ instrument. High 
resolution mass spectra were obtained on a ESI Bruker Daltonics micrOTOF 
spectrometer equipped with a TOF hexapole detector. 
 
TLC was performed using silica gel 60 coated glass plates containing 
fluorescence indicator (Merck KGaA, Darmstadt, Germany) and visualized by 
using UV light (254 nm) and/or by charring either in aqueous KMnO4 solution 
or in a molybdate solution (a 0.02 M solution of ammonium cerium sulfate 
dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4) 
with heating to 140 °C for 5 min. Column chromatography was performed 
using silica gel 60 (0.040-0.063 mm, Fluka). Hydrogenation reactions were 
performed in a shaking apparatus (Parr Instruments Company, Moline, 
Illinois, USA) in 250 mL or 500 mL bottles with 4 bar H2 pressure. Solvents 
were purchased from Fluka and dried prior to use. CH2Cl2 was dried by 
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filtration through basic aluminum oxide (Fluka). Dioxane, DME, Et2O and 
PhMe were dried by distillation from sodium/benzophenone. DMF was dried 
over activated molecular sieves and MeOH by distillation from sodium 
methoxide. 
 
Biological data were obtained using the published ELISA procedure with (S)-6 
as reference compound.28 
 
(5R)-(2,2-Cyclohexylidene-4-oxo-1,3-dioxolan-5-yl) acetic acid (8). 
Compound 8 was prepared in analogy to Hanessian et al.31 To a suspension 
of 7 (4.00 g, 29.8 mmol) in dry Et2O (100 mL) was added cyclohexanone 
(3.09 mL, 29.8 mmol) at 0 °C followed by BF3*Et2O (5.62 mL, 44.8 mmol) via 
syringe. The mixture was stirred at 0 °C for 1 h and turned into a light red 
solution. After stirring for another 18 h at r.t., Et2O (100 mL) was added, and 
the organic phase was washed with aqueous sodium acetate (3 x 10 mL, 10% 
w/v). The combined aqueous phases were extracted with Et2O (2 x 50 mL). 
The combined organic layers were dried over Na2SO4 and the solvent 
evaporated in vacuo affording spectroscopically pure 8 (6.25 g; 98%) as 
slightly red colored crystals. 
 
1H-NMR (500.1 MHz, CDCl3): δ 10.60 (br s, RCO2H), 4.72 (X of ABX, 3J = 3.9, 
6.5 Hz, 1H, H-2), 3.00 (A of ABX, 2J = 17.2, 3J = 3.9 Hz, 1H, H-3a), 2.85 (B of 
ABX, 2J = 17.2, 3J = 6.5 Hz, 1H, H-3b), 1.90-1.81 (m, 2H, -C5H10-), 1.80-1.60 
(m, 6H, -C5H10-), 1.55-1.35 (m, 2H, -C5H10-); 
 
13C-NMR (125.8 MHz, CDCl3): δ 175.1, 172.0 (2 C=O), 112.2 (C-ketal), 70.0 
(C-2), 36.2 (2C, C5H10), 35.3 (C-3), 24.4 (1C, C5H10), 23.4 (2C, C5H10); 
 
ESI-MS calcd. for C10H13O5 [M-H]-: 213.1; found: 213.0; 
 
IR (KBr): 3208 (m), 2939 (m), 1802 (s), 1733 (s), 1375 (m), 1291 (m), 1197 
(s), 932 (m); 
 
[α]20D = -2.9 (c 1.0, CHCl3); 
 
This analytical data matched with the reported NMR spectra.32 
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(R)-3-Amino-2-hydroxy-propionic acid hydrochloride (9). Compound 8 
(6.25 g, 29.2 mmol) was dissolved in SOCl2 (48 mL) in a round bottom flask 
with strong gas evolution. The solution was heated to reflux and the gas 
evolution ceased after 15 min. After refluxing the dark solution for 1 h, the 
solvent was evaporated and the residue dried under high vacuum over night. 
The remaining brownish oil was then dissolved in acetone (56 mL) and cooled 
to -20 °C. A solution of sodium azide (2.56 g, 39.4 mmol) in water (16 mL) 
was added dropwise to the solution via syringe and the mixture was stirred for 
1.5 h. After removal of the acetone in vacuo at 0 °C, water (150 mL) was 
added and the aqueous phase was extracted with PhMe (3 x 200 mL). The 
combined organic layers were dried (Na2SO4) and concentrated to a final 
volume of ca. 75 mL. The remaining solution was slowly heated to reflux for   
1 h, then the solvent was removed and aqueous HCl (6M, 35 mL) was added. 
The mixture was refluxed for 7 h. The solvent was removed in vacuo, the 
residue was taken up in water (100 mL) and washed with CH2Cl2 (1 x 100 mL, 
2 x 50 mL). The combined organic phases were extracted with aqueous HCl 
(3N, 2 x 50 mL). The aqueous phases were pooled and the water removed by 
evaporation to give a brownish oil (3.05 g). Precipitation from 
PhMe/EtOAc/MeOH gave 9 as off-white solid (2.1 g, 51%). 
 
Rf (n-BuOH/HOAc/H2O/py, 4:1:2:1) = 0.10; 
 
1H-NMR (500.1 MHz, D2O): δ 4.52 (X of ABX, 3J = 4.1, 3J = 8.4 Hz, 1H, H-2), 
3.45 (A of ABX, 2J = 13.3, 3J = 4.0 Hz, 1H, H-3a), 3.23 (B of ABX, 2J = 13.3, 
3J = 8.4 Hz, 1H, H-3b);  
 
13C-NMR (125.8 MHz, DMSO-d6): δ 172.6 (C-1), 67.0 (C-2), 41.7 (C-3); 
 
ESI-MS calcd. for C3H8NO5 [M-Cl]+: 106.1; found: 106.0; 
 
IR (film): 3422 (s), 1735 (s), 1623 (m), 1234 (m), 1150 (m), 1079 (m); 
 
[α]20D = +9.9 (c 0.48, H2O); 
 
Methyl (R)-3-amino-2-hydroxy-propanoate hydrochloride (10) was 
synthesized according to a procedure by Lall et al.33 Isoserine 
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hydrochloride (1.29 g, 9.11 mmol) was dissolved in MeOH (15 mL), cooled 
to 0 °C and SOCl2 (1.78 mL, 18.2 mmol) was added dropwise via syringe. 
The solution was then heated to reflux for 1 h. Subsequently, the solvent was 
evaporated and MeOH (15 mL) was added. At 0 °C, SOCl2 (1.78 mL,        
18.2 mmol) was added and the mixture refluxed for 2.5 h. Removal of the 
solvent yielded the title compound (1.42 g, quant.) as a brown 
spectroscopically pure solid, which was used without further purification. 
 
1H-NMR (500.1 MHz, CDCl3): δ 8.22 (br s, 3H, NH3+), 4.39 (X of ABX, 3J = 
8.5, 3J = 3.1 Hz, 1H, H-2), 3.67 (s, 3H, MeO), 3.08-3.07 (m, 1H, H-3a), 2.90-
2.88 (m, 1H, H-3b);  
 
13C-NMR (125.8 MHz, CDCl3): δ 171.5 (C-1), 66.9 (C-2), 52.1 (MeO), 41.5 (C-
3); 
 
ESI-MS calcd. for C4H10NO3 [M-Cl]+: 120.1; found: 120.0; 
 
IR (KBr): 3502 (s), 3044 (s), 1743 (s), 1513 (m), 1243 (s), 1146 (s);  
 
[α]D20 = +16.3 (c 0.60, H2O); 
 
This analytical data matched with the reported optical rotation and IR 
spectra.34 
 
Methyl (R)-3-N,N-dibenzylamino-2-hydroxy-propanoate (11). To a 
solution of amino-ester 10 (121 mg, 0.78 mmol) in MeOH (10 mL), benzyl 
bromide (0.28 mL, 2.34 mmol) and NaHCO3 (350 mg, 4.17 mmol) were 
added. The mixture was heated to reflux for 2 h. Volatiles were removed by 
evaporation. The residue was taken up in water (5 mL) and extracted with 
EtOAc (3 x 25 mL). The combined organic phases were washed with brine (3 
x 20 mL) and dried over Na2SO4. After removal of the solvent the residue was 
purified by column chromatography (petrol ether/EtOAc, gradient of 6/1 to 4/1) 
to give 11 (232 mg, quant.) as a white solid.  
 
Rf (petrol ether/EtOAc, 2:1) = 0.75;  
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1H-NMR (500.1 MHz, CDCl3): δ 7.34-7.24 (m, 10H, Ar-H), 4.25 (M of ABM, 3J 
= 4.3, 3J = 6.4 Hz, 1H, H-2), 3.78 (A’ of A’B’, 2J = 13.5 Hz, 2H, PhCH2), 3.67 
(s, 3H, MeO), 3.52 (B’ of A’B’, 2J = 13.5 Hz, 2H, PhCH2), 2.90 (A of ABM, 2J = 
13.4, 3J = 4.2 Hz, 1H, H-3a), 2.86 (B of ABM, 2J = 13.4, 3J = 6.8 Hz, 1H, H-
3b);  
 
13C-NMR (125.8 MHz, CDCl3): δ 173.9 (C-1), 138.5 (2C, Ar-Ci), 129.1, 128.4, 
127.3 (10C, Ar-CH), 69.4 (C-2), 59.0 (2C, PhCH2), 56.1 (C-3), 52.3 (MeO); 
 
ESI-MS calcd. for C18H22NO3 [M+H]+: 300.2; found: 300.2; 
 
[α]D20 = +32.7 (c 0.79, CHCl3); 
 
Methyl (R)-N-benzyloxycarbonyl-3-amino-2-hydroxy-propanoate (13). To 
a solution 10 (200 mg, 1.28 mmol) and sodium carbonate (213 mg,           
2.00 mmol) in THF/H2O (15 mL, 3:1) was added benzyl chloroformate       
(241 mg, 1.41 mmol) in THF (5 mL) at 0 °C. The reaction was stirred for 3 h. 
After extraction with EtOAc (3 x 40 mL), the combined organic phases were 
washed with brine (3 x 15 mL), dried over Na2SO4 and the solvent was 
removed in vacuo. The crude product was purified by column chromatography 
(petrol ether/EtOAc, 2:1) to give 13 (209 mg, 69%) as white solid.  
 
Rf (petrol ether/EtOAc, 2:1) = 0.18; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.37-7.26 (m, 5H, Ar-H), 5.18 (br s, 1H, NH), 
5.07 (s, 2H, CH2-Ph), 4.27 (t, 3J = 4.4 Hz, 1H, H-2), 3.75 (s, 3H, OMe), 3.60-
3.46 (m, 2H, H-3); 
 
IR (KBr): 3362 (m), 1724 (s, ester + carbamate), 1258 (s); 
 
This analytical data matched with the reported 1H-NMR spectra of the known 
(S)-enantiomer.35  
 
Methyl (R)-3-tetrachlorophtalimido-2-hydroxy-propanoate (15). To a 
solution of 10 (200 mg, 1.28 mmol) and tetrachlorophtalic anhydride (404 mg, 
1.41 mmol) in PhMe/DMF (5:1, 12 mL) was added DIPEA (438 µL,            
2.56 mmol). The reaction mixture was connected to a Dean Stark water trap 
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and heated to reflux for 5 h. The solvents were removed in vacuo, and the 
crude product was purified by column chromatography (petrol ether/EtOAc, 
4:1) to yield 15 (154 mg, 31%) as white crystalline needles. 
 
Rf (petrol ether/EtOAc, 2:1) = 0.60; 
 
1H-NMR (500.1 MHz, CDCl3): δ 4.47 (X of ABX, 3J = 5.2 Hz, 1H, H-2), 4.05 (A 
of ABX, 3J = 5.1, 2J = 14.0 Hz, 1H, H-3a), 3.95 (B of ABX, 3J = 6.8, 2J = 14.0 
Hz, 1H, H-3b), 3. 83 (s, 3H, OMe);  
 
13C-NMR (125.8 MHz, CDCl3): δ 172.9 (C-1), 163.6 (2C, imid-CO), 140.6, 
130.1, 127.6 (6C, Ar-C), 68.1 (C-2), 53.5 (OMe), 41.7 (C-3); 
 
HR-MS calcd. for C12H7Cl4NO5Na [M+Na]+: 407.8976; found: 407.8991; 
 
IR (KBr): 1713 (s, imide and ester), 1361 (s), 736 (s, ν(C-Cl)); 
 
[α]D20 = +4.9 (c 0.50, CHCl3); 
 
Methyl (R)-3-tetrachlorophtalimido-2-trifluoromethanesulfonyloxy-
propanoate (16). To a solution of 15 (154 mg, 0.40 mmol) in dry CH2Cl2       
(6 mL) was added 2,6-di-tert.-butylpyridine (117 µL, 0.52 mmol) at -20 °C 
under argon. Tf2O (89 µL, 0.53 mmol) was added dropwise via syringe and 
the mixture was stirred for 3 h at –20 °C. Then a second portion of Tf2O      
(13 µL, 0.08 mmol) and 2,6-di-tert.-butylpyridine (18 µL, 0.08 mmol) were 
added. After 1 h the reaction mixture was diluted with CH2Cl2 (14 mL) and 
extracted with aqueous KH2PO4 solution (1 M, 30 mL). The phases were 
separated, and the aqueous phase was extracted with CH2Cl2 (2 x 20 mL). 
The combined organic phases were dried over Na2SO4 and the solvent was 
removed in vacuo. Purification of the crude product by column 
chromatography (petrol ether/EtOAc, gradient of 6:1 to 4:1) gave 16 (142 mg, 
68%) as a white crystalline solid.  
 
Rf (petrol ether/EtOAc, 4:1) = 0.30; 
 
1H-NMR (500.1 MHz, CDCl3): δ 5.39 (t, 3J = 5.9 Hz, 1H, H-2), 4.29 (d, 3J = 5.9 
Hz, 2H, H-3), 3.86 (s, 3H, OMe);  
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13C-NMR (125.8 MHz, CDCl3): δ 165.1 (C-1), 162.8 (2C, imid-CO), 140.8, 
130.2, 127.0 (6C, Ar-C), 118.0 (q, 1J = 320 Hz, CF3), 78.6 (C-2), 54.2 (OMe), 
39.2 (C-3); 
 
ESI-MS calcd. for C13H6Cl4F3NO7SNa [M+Na]+: 541.8; found: 541.9; 
 
IR (KBr): 1717 (s, imide and ester), 1417 (m), 1137 (m), 737 (m, ν(C-Cl)); 
 
Methyl (R)-3-azido-2-hydroxy-propanoate (17). Compound 10 (385 mg, 
2.47 mmol) and CuSO4•5H2O (6 mg, 25 µmol) were dissolved in water      
(6.5 mL). MeOH (22 mL) and NaHCO3 (622 mg, 7.40 mmol) were added 
subsequently at r.t.. A solution of TfN325 (7.4 mmol in 6.25 mL PhMe) was 
added dropwise to this solution, and the mixture was stirred vigorously at r.t. 
for 24 h. After quenching the reaction with benzyl amine (808 µL, 7.41 mmol), 
the solvents were removed in vacuo. The crude product was purified by 
column chromatography (CH2Cl2/MeOH, 20:1) to give the title compound   
(208 mg, 58%) as an oil.  
 
Rf (CH2Cl2/MeOH, 9:1) = 0.70; 
 
1H-NMR (500.1 MHz, CDCl3): δ 4.36 (X of ABMX, 3J = 3.7, 3J = 4.5 Hz, 1H, H-
2), 3.82 (s, 3H, OMe), 3.63 (A of ABX, 2J = 12.8, 3J = 3.3 Hz, 1H, H-3a), 3.48 
(B of ABX, 2J = 12.8, 3J = 4.2 Hz, 1H, H-3b), 3.15 (M of AM, 3J = 5.1 Hz, 1H, 
OH);  
 
13C-NMR (125.8 MHz, CDCl3): δ 172.8 (C-1), 70.6 (C-2), 53.9 (C-3), 53.2 
(OMe); 
 
This analytical data matched with the reported 1H-NMR spectrum.36 
 
Methyl (R)-3-azido-2-trifluoromethanesulfonyloxy-propanoate (18). To a 
solution of 17 (34 mg, 0.23 mmol) in dry CH2Cl2 under argon was added 2,6-
di-tert.-butylpyridine (69 µL, 0.30 mmol) at -20 °C. After dropwise addition of 
Tf2O (53 µL, 0.31 mmol), the reaction was stirred for 3 h at -20 °C. After 
dilution with CH2Cl2 (20 mL) the mixture was washed with aqueous KH2PO4 
solution (1 M, 7.5 mL) and the aqueous phase was extracted with CH2Cl2 (2 x 
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15 mL). The combined organic layers were dried over Na2SO4 and the solvent 
was evaporated in vacuo. Purification by column chromatography (petrol 
ether/EtOAc, 15:1) yielded 18 (31.2 mg, 48%) as colorless oil.  
 
Rf (petrol ether/EtOAc, 8:1) = 0.37; 
 
1H-NMR (500.1 MHz, CDCl3): δ 5.21 (X of ABX, 3J = 3.6, 3J = 5.9 Hz, 1H, H-
2), 3.87 (s, 3H OMe), 3.84-3.80 (m, 2H, H-3);  
 
13C-NMR (125.8 MHz, CDCl3): δ 165.2 (C-1), 118.6 (q, 1J = 320 Hz, CF3), 
81.2 (C-2), 54.0 (OMe), 51.7 (C-3); 
 
(R)-3-Azido-2-hydroxy propanoic acid (19). To a solution of 9 (363 mg, 
2.56 mmol), NaHCO3 (893 mg, 10.6 mmol) and CuSO4•5H2O (24 mg,       
0.10 mmol) in water (2 mL) were added TfN3 in PhMe (1 M, 3.1 mL) and 
MeOH (12 mL). After stirring for 21 h, the organic solvents were removed, and 
the residue was taken up in water (20 mL). The olive green mixture (pH 8) 
was washed with CH2Cl2 (20 mL) and acidified with 6 N HCl. The resulting 
light red mixture was extracted with EtOAc (3 x 80 mL). The combined ester 
phases were dried over Na2SO4, filtered and the solvent was removed in 
vacuo to give 635 mg of a 1:1.1 mixture of the 19 (83%) and TfNH2. The 
material was used in the next step without further purification. 
 
Rf (n-BuOH/HOAc/H2O/pyridine, 4:1:2:1) = 0.60; 
 
1H-NMR (500.1 MHz, DMSO-d6): δ 4.22 (X of ABX, 3J = 3.6, 3J = 5.8 Hz, 1H, 
H-2), 3.47 (A of ABX, 2J = 12.8, 3J = 3.5, 1H, H-3a), 3.40 (B of ABX, 2J = 12.8, 
3J = 5.9, 1H, H-3b);  
 
13C-NMR (125.8 MHz, DMSO-d6): δ 173.2 (C-1), 69.8 (C-2), 53.5 (C-3); 
 
ESI-MS calcd. for C3H4N3O3 [M-H]-: 130.0; found: 129.9; 
 
IR (KBr): 2117 (s, N3), 1733 (s, CO); 
 
This analytical data matched with the reported 1H-NMR spectrum.37 
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Benzyl (R)-3-azido-2-hydroxy propanoate (20). To a solution of crude 19 
(3.97 g) in DMF (30 mL) was added benzyl bromide (13 mL, 110 mmol) 
followed by dropwise addition of NEt3 (19 mL, 137 mmol) at r.t.. Upon addition 
of the base, the exothermic reaction needed to be cooled with a water bath at 
r.t.. After stirring for 1 d, the mixture was concentrated, diluted with water    
(100 mL) and extracted with CH2Cl2 (3 x 100 mL). The combined organic 
phases were dried over Na2SO4, filtered and the solvents removed in vacuo. 
The crude product was purified by column chromatography (petrol 
ether/EtOAc, 4:1). The product (1.92 g, 63% from 9) was obtained as white 
solid. 
 
Rf (petrol ether/EtOAc, 4:1) = 0.55; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.41-7.39 (m, 5H, Ar-H), 5.26 (s, 2H, PhCH2), 
4.40 (m, 1H, H-2), 3.64 (A of ABX, 2J = 12.8, 3J = 3.3 Hz, 1H, H-3a), 3.50 (B 
of ABX, 2J = 12.8, 3J = 4.3 Hz, 1H, H-3b);  
 
13C-NMR (125.8 MHz, CDCl3): δ 172.3 (C-1), 134.9 (Ar-Ci), 129.02, 128.96, 
128.67 (5C, Ar-C), 70.4 (C-2), 68.3 (PhCH2), 54.0 (C-3); 
 
ESI-MS calcd. for C10H11N3O3Na [M+Na]+: 244.1; found: 243.9; 
 
IR (KBr): 3392 (m), 2110 (s, N3), 1739 (s, CO), 1199 (s); 
 
[α]D20 = +82.9 (c 1.04, CHCl3); 
 
This analytical data matched with the reported 1H-NMR spectrum.18 
 
Benzyl (R)-3-azido-2-O-trifluoromethanesulfonyl-propanoate (21). To a 
solution of 20 (1.00 g, 4.52 mmol) in dry CH2Cl2 (30 mL) under argon was 
added 2,6-di-tert.-butylpyridine (1.73 mL, 7.69 mmol) at -20 °C. After dropwise 
addition of Tf2O (1.29 mL, 7.69 mmol), the reaction was stirred for 3 h at         
-20 °C. Then, the reaction was allowed to come to 0 °C. After stirring for 1 h, 
additional 2,6-di-tert.-butylpyridine (1.73 mL, 7.69 mmol) and Tf2O (1.29 mL,     
7.69 mmol) were added at 0 °C. After stirring for 3 h, the reaction mixture was 
diluted with CH2Cl2 (100 mL), washed with ice-cold aqueous KH2PO4 solution 
(1 M, 50 mL) and the aqueous phase was extracted with CH2Cl2 (2 x 100 mL). 
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The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated in vacuo. Purification by column chromatography (petrol 
ether/EtOAc, 10:1) yielded 21 (1.40 g, 88%) as colorless oil. 
 
Rf (petrol ether/EtOAc, 8:1) = 0.37; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.35-7.41 (m, 5H, ArH), 5.31, 5.28 (A, B of 
AB, 2J = 12.0 Hz, 2H, PhCH2), 5.23 (X of A’B’X, 3J = 3.6, 3J = 6.0 Hz, 1H, H-
2), 3.84 (A’ of A’B’X, 2J = 13.9, 3J = 3.6 Hz, 1H, H-3a), 3.81 (B’ of A’B’X, 2J = 
13.9, 3J = 6.0 Hz, 1H, H-3b);  
 
13C-NMR (125.8 MHz, CDCl3): δ 164.4 (C-1), 133.9 (Ar-Ci), 129.1, 128.8, 
128.6 (5C, Ar-C), 118.4 (q, 1J = 320 Hz, CF3), 81.0 (C-2), 69.0 (PhCH2), 51.5 
(C-3); 
 
ESI-MS calcd. for C11H10F3N3O5SNa [M+Na]+: 376.0; found: 376.0; 
 
This analytical data matched with the reported 1H- and 13C-NMR spectrum.18 
 
Benzyl (2S)-3-azido-2-O-{1-O-[(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fuco-
pyranosyl)-cyclohexyl] 6-O-benzyl-β-D-galactopyranos-3-yl} propionate 
(23). Trisaccharide mimetic 2216 (667 mg, 0.85 mmol) and Bu2SnO (235 mg, 
0.94 mmol) were dried in high vacuum for 1 h and subsequently dissolved in 
dry MeOH (50 mL) under argon with warming. Activated molecular sieves 
(3Å, 2.00 g) were added to the solution, which was then refluxed under argon 
for 15 h. Filtration of the suspension over celite, evaporation of the solvent, 
co-evaporation with dry PhMe and drying for 8 h in high vacuum gave a 
yellow oily substance (880 mg). This residue was dissolved in dry DME       
(10 mL) under argon and a solution of dry triflate 21 (384 mg, 1.09 mmol) in 
dry DME (4 mL) was added. When extensively dried CsF (168 mg,            
1.11 mmol) was added, the solution turned slightly turbid. After stirring for 6 d 
at r.t., TLC indicated a ratio of acceptor to product of ca. 1:1, but no triflate. A 
solution of KF (10%) in aqueous KH2PO4 (1N, 50 mL) was added and after 
stirring for 1 h, the reaction was extracted with CH2Cl2 (3 x 50 mL). The 
combined organic phases were dried over Na2SO4 and the solvents were 
removed in vacuo. Purification of the residue by column chromatography 
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(CH2Cl2/iPrOH, gradient 0 to 4%) yielded 23 (329 mg, 39%) as a white solid. 
 
Rf (PhMe/EtOAc, 3/1) = 0.55; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.37-7.23 (m, 25 H, Ar-H), 5.23, 5.15 (A, B of 
AB, 2J = 12.1 Hz, 2H, PhCH2OCO-), 4.96-4.94 (m, unresolved A’ of A’B’, 2H, 
Fuc-H1, 1H of PhCH2), 4.80 (A’’ of A’’B’’, 2J = 11.6 Hz, 1H, PhCH2), 4.74 (A’’’ 
of A’’’B’’’, 2J = 11.9 Hz, 1H, PhCH2), 4.68 (B’’ of A’’B’’, B’’’ of A’’’B’’’, 2J = 11.7 
Hz, 2H, PhCH2), 4.60 (B’ of A’B’, 2J = 11.0 Hz, 1H, PhCH2), 4.57 (M of ABM, 
3J = 2.2, 3J = 5.2 Hz, 1H, Lac-H2), 4.52, 4.48 (A’’’’ and B’’’’ of A’’’’B’’’’, 2J = 
12.0 Hz, 1H, PhCH2), 4.38 (q, 3J = 7.8 Hz, 1H, Fuc-H5), 4.30 (d, 3J = 7.7 Hz, 
1H, Gal-H1), 4.02-3.97 (m, 3H, Fuc-H2, -H3, Gal-H4), 3.80 (t, 3J = 8.3 Hz, 1H, 
Gal-H2), 3.76-3.74 (m, 2H, 1H of Cy-CH, Gal-H6a), 3.67 (br s, 1H, Fuc-H4), 
3.65-3.50 (m, 5H, 1H of Cy-CH, Gal-H5, -H6b, Lac-H3a/b), 3.43 (dd, 3J = 2.1, 
3J = 9.3 Hz 1H, Gal-H3), 2.02-1.81 (m, 2H, Cy-CH2), 1.67-1.60 (m, 2H, Cy-
CH2), 1.39-1.12 (m, 4H, Cy-CH2), 1.10 (d, 3J = 6.3 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, CDCl3): δ 170.5 (Lac-C1), 139.2, 138.9, 138.8, 138.0, 
134.8 (5C, Ar-Ci), 128.8-127.2 (25C, Ar-CH), 100.2 (Gal-C1), 94.6 (Fuc-C1), 
82.8 (Gal-C3), 79.7 (CH), 79.0 (Lac-C2), 78.2 (Fuc-C4), 77.2 (Gal-C2), 76.3 
(Cy-CH), 76.1 (CH), 74.9, 73.7 (2C, PhCH2), 73.2 (CH), 73.01, 72.97 (2C, 
PhCH2), 71.1 (CH), 68.9 (Gal-C6), 67.6 (Ph-CH2-O-CO-), 67.3 (CH), 66.3 
(Fuc-C5), 52.8 (Lac-C3), 30.1, 29.7, 29.2, 23.3 (4C, Cy-CH2), 16.6 (Fuc-C6);  
 
ESI-MS calcd. for C56H65N3O13Na [M+Na]+: 1010.4; found: 1010.5; 
 
IR (KBr): 2923 (s), 2106 (s, N3), 1742 (s, CO), 1453 (m); 
 
This analytical data matched with the reported 1H-NMR spectrum.18 
 
(2S)-3-Amino-2-O-{1-O-[(1R,2R)-2-O-(α-L-fucopyranosyl)-cyclohexyl]-β-
D-galactopyranos-3-yl} propanoic acid (24). To a solution of protected 
azide 23 (293 mg, 297 µmol) in THF/water (5 mL; 4:1) was added Pd(OH)2/C 
(50 mg) and the reaction mixture was hydrogenated at 4 bar for 72 h at r.t.. 
Additional Pd(OH)2/C (100 mg) was added and the mixture hydrogenated at  
4 bar for another 48 h. After dilution with MeOH/water (1:1, 20 mL), the 
Chapter 2.2 
- 79 - 
mixture was filtered and the solvents were removed to give crude 24         
(144 mg), which was used without further purification. 
 
1H-NMR (500.1 MHz, D2O): δ 4.99 (d, 3J = 3.9 Hz, 1H, Fuc-H1), 4.63 (q, 3J = 
6.6 Hz, 1H, Fuc-H5), 4.52 (d, 3J = 7.8 Hz, 1H, Gal-H1), 4.29 (dd, 3J = 8.2, 3J = 
3.9 Hz, 1H, Lac-H2), 4.04 (d, 3J = 2.8 Hz, 1H, Gal-H4), 3.91 (dd, 3J = 10.4, 3J 
= 6.6 Hz, 1H, Fuc-H3), 3.79 (dd, 3J = 9.3, 3J = 3.0 Hz, 1H, Fuc-H2), 3.77-3.71 
(m, 4H, Fuc-H4, Gal-H5, -H6a, 1H of Cy-CH), 3.65-3.60 (m, 2H, Gal-H2,         
-H6b), 3.55 (dd, 3J = 9.6, 3J = 3.2 Hz, 1H, Gal-H3), 3.53-3.49 (m, 1H, 1H of 
Cy-CH), 3.41 (dd, 2J = 13.8, 3J = 3.9 Hz, 1H, Lac-H3a), 3.22 (dd, 2J = 13.4, 3J 
= 8.3 Hz, 1H, Lac-H3b), 2.14-2.04 (m, 2H, Cy-CH2), 1.69 (br s, 2H, Cy-CH2), 
1.33-1.21 (m, 4H, Cy-CH2), 1.19 (d, 3J = 6.8 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, D2O): δ 171.0 (Lac-C1), 100.1 (Gal-C1), 95.9 (Fuc-C1), 
82.9 (Gal-C3), 79.0 (Cy-CH), 77.6 (2C, Lac-C2 and Cy-CH), 74.7, 72.4, 70.8 
(Fuc-C4, Gal-C2, -C5), 69.9 (Fuc-C3), 68.2 (Fuc-C2), 66.9 (Gal-C4), 66.8 
(Fuc-C5), 61.8 (Gal-C6), 42.2 (Lac-C3), 29.9, 29.6, 29.5, 23.5 (4C, Cy-CH2), 
15.6 (Fuc-C6);  
 
HR-MS calcd. for C21H36NO13 [M-H]-: 510.2192; found: 510.2197; 
 
Sodium (2S)-3-azido-2-O-{1-O-[(1R,2R)-2-O-(α-L-fucopyranosyl)-cyclo-
hexyl]-β-D-galactopyranos-3-yl} propionate (5). To a solution of crude 24 
(126 mg) in MeOH/water (3 mL; 7.5:1) was added a solution of TfN325 in 
PhMe (0.91 mL, 0.36 M). After stirring for 22 h at r.t., the reaction mixture was 
concentrated and purified by column chromatography (CH2Cl2/MeOH/water, 
10/4/0.8) to give 5 (79 mg, contaminated with silica gel). This product was 
used for the 1,3-dipolar cycloaddition reactions without further purification. For 
analysis and biological testing, a small sample (6.6 mg) was purified by 
preparative HPLC to give pure 5 (4.7 mg, 35%, two steps) as free acid. The 
sodium salt was obtained by addition of an equimolar amount of aqueous 
NaOH (1 M, 87 µL) to an aqueous solution of the acid. Spectral data for the 
free acid: 
 
Rf (CH2Cl2/MeOH/water, 10:4:0.8) = 0.26; 
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1H-NMR (500.1 MHz, CD3OD): δ 4.85 (d, 3J = 3.8 Hz, 1H, Fuc-H1), 4.62 (q, 3J 
= 6.5 Hz, 1H, Fuc-H5), 4.51 (dd, 3J = 5.4, 3J = 3.5 Hz, 1H, Lac-H2), 4.30 (d, 3J 
= 7.7 Hz, 1H, Gal-H1), 4.00 (d, 3J = 2.7 Hz, 1H, Gal-H4), 3.87 (dd, 3J = 9.9, 3J 
= 3.4 Hz, 1H, Fuc-H3), 3.78-3.74 (m, 2H, Lac-H3a, Gal-H6a), 3.73-3.63 (m, 
5H, Fuc-H2, -H4, Gal-H2, -H6b, 1H of Cy-CH), 3.57-3.51 (m, 2H, 1H of Cy-
CH, Lac-H3b), 3.45-3.41 (m, 2H, Gal-H3, -H5), 2.05-2.03 (m, 2H, Cy-CH2), 
1.71 (br s, 2H, Cy-CH2), 1.41-1.22 (m, 4H, Cy-CH2), 1.18 (d, 3J = 6.4 Hz, 3H, 
Fuc-H6);  
 
13C-NMR (125.8 MHz, CD3OD): δ 175.1 (Lac-C1), 102.8 (Gal-C1), 97.5 (Fuc-
C1), 84.8 (Gal-C3), 80.5 (Lac-C2), 79.4 (CH), 77.5 (Cy-CH), 76.2 (Gal-C5), 
74.0 (CH), 72.4 (Gal-C2), 71.7 (Fuc-C3), 70.2 (CH), 68.6 (Gal-C4), 67.6 (Fuc-
C5), 62.9 (Gal-C6), 54.3 (Lac-C3), 31.1, 30.2, 24.6 (4C, Cy-CH2), 16.7 (Fuc-
C6);  
 
HR-MS calcd. for C21H34N3O13 [M-H]-: 536.2097; found: 536.2091; 
 
IR (KBr, Na-form of 5): 3412 (s), 2111 (s, N3), 1606 (s, CO), 1447 (m); 
 
[α]20D = -112.1 (c 0.24, MeOH);  
 
Sodium (2S)-3-N-(1,2,3-triazol-1-yl)-2-O-{1-O-[(1R,2R)-2-O-(α-L-fuco-
pyranosyl)-cyclohexyl]-β-D-galactopyranos-3-yl} propionate (6a). A 
solution of crude 5 (14 mg) and DIPEA (13.7 µL, 80 µmol) in MeCN/water  
(1.5 mL, 2:1) was thoroughly degassed by bubbling through argon. 
Subsequently, TMS-acetylene (7.4 µL, 54 µmol) and CuCl (5.3 mg, 80 µmol) 
were added and the mixture was stirred under argon. After 4 d, additional 
CuCl (5.3 mg, 80 µmol) and TMS-acetylene (15 µL, 110 µmol) were added 
and the reaction was stirred for another 5 d. The solvents were removed in 
vacuo, the residue was taken up in MeOH, filtered (0.2 µm) and evaporated. 
After drying the residue for 2 h in high vacuum, it was taken up in TBAF in 
THF (1 M, 1 mL) and HOAc was added (0.2 mL). The reaction was stirred for 
30 min at r.t.. Evaporation of the solvent and purification of the residue by 
preparative HPLC, followed by ion-exchange chromatography (Dowex-50, 
Na-form) and a second preparative HPLC gave 2.0 mg (7%, 4 steps) of pure 
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6a as the free acid. The sodium salt was obtained by addition of equimolar 
amounts of aqueous NaOH to an aqueous solution of the acid. Spectral data 
for the free acid: 
 
1H-NMR (500.1 MHz, D2O): δ 8.08 (s, 1H, triazol-H), 7.78 (s, 1H, triazol-H), 
4.95 (d, 3J = 3.5 Hz, 1H, Fuc-H1), 4.90 (dd, 2J = 14.1, 3J = 3.4 Hz 1H, Lac-
H3a), 4.80-4.73 (m, 1H, Lac-H3b), 4.63-4.57 (m, 2H, Fuc-H5, Lac-H2), 4.41 
(d, 3J = 7.0 Hz, 1H, Gal-H1), 4.01 (d, 3J = 1.7 Hz, 1H, Gal-H4), 3.87 (dd, 3J = 
10.4, 3J = 3.4 Hz, 1H, Fuc-H3), 3.77-3.65 (m, 5H, Fuc-H2, -H4, Gal-H6a/b, 1H 
of Cy-CH), 3.54 (dd, 3J = 7.4, 3J = 4.2 Hz, 1H, Gal-H5), 3.50-3.43 (m, 3H, Gal-
H2, -H3, 1H of Cy-CH), 2.09-2.02 (m, 2H, Cy-CH2), 1.69-1.63 (m, 2H, Cy-
CH2), 1.27-1.17 (m, 4H, Cy-CH2), 1.15 (d, 3J = 6.9 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, D2O, HCO2H std.): δ 174.9 (Lac-C1), 99.7 (Gal-C1), 
95.5 (Fuc-C1), 82.1 (Gal-C3), 78.3 (CH), 78.1 (CH), 77.2 (Lac-C2), 74.3 (CH), 
72.0 (Gal-C5), 70.2 (Fuc-C3), 69.5 (Fuc-C2), 67.9 (Gal-C4), 67.6 (Fuc-C5), 
66.4 (2C, CH), 61.3 (Gal-C6), 52.0 (Lac-C3), 29.6, 29.1, 23.1 (4C, Cy-CH2), 
15.2 (Fuc-C6);  
 
HR-MS calcd. for C23H37N3O13Na [M+H]+: 586.2224; found: 586.2214; 
 
Sodium (2S)-3-N-[4-benzyl-1,2,3-triazol-1-yl]-2-O-{1-O-[(1R,2R)-2-O-(α-L-
fucopyranosyl)-cyclohexyl]-β-D-galactopyranos-3-yl} propionate (6b). 
Compound 5 (7.1 mg, 13 µmol) was dissolved in a solution of 1-phenyl-prop-
2-yne (16.4 µL, 132 µmol) in EtOH/water (1 mL, 3:2). Copper powder (1.0 mg, 
15.7 µmol) and CuSO4•5H2O (3.5 mg, 14 µmol) were added, and the reaction 
was vigorously stirred for 24 h at r.t.. Filtration through cotton, evaporation of 
the solvents, and microfiltration (0.2 µm) of a solution of the residue in 
MeOH/water (1:1) gave the crude product which was purified by preparative 
HPLC. Pure 6b was obtained as free acid (5.4 mg, 35% over 3 steps) and 
was subsequently transformed in to the sodium salt by addition of equimolar 
amounts of NaOH. Spectral data for the free acid: 
 
Rf (CH2Cl2/MeOH/water, 10:4:0.8) = 0.34;  
 
1H-NMR (500.1 MHz, CD3OD): δ 8.00 (s, 1H, triazol-H), 7.30-7.22 (m, 4H, Ar-
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H), 7.20-7.17 (m, 1H, p-Ar-H), 4.88-4.84 (m, 2H, Fuc-H1, Lac-H3a), 4.74-4.68 
(m, 1H, Lac-H3b), 4.62-4.56 (m, 2H, Fuc-H5, Lac-H2), 4.26 (d, 3J = 7.7 Hz, 
1H, Gal-H1), 4.03 (br s, 2H, PhCH2), 3.93 (br s, 1H, Gal-H4), 3.86 (dd, 3J = 
10.0, 3J = 3.3 Hz, 1H, Fuc-H3), 3.77-3.64 (m, 5H, Fuc-H2, -H4, Gal-H6a/b, 1H 
of Cy-CH), 3.61-3.52 (m, 2H, Gal-H2, 1H of Cy-CH), 3.41 (m, 1H, Gal-H5), 
3.55-3.31 (m, 1H, Gal-H3), 2.07-2.01 (m, 2H, Cy-CH2), 1.73-1.67 (m, 2H, Cy-
CH2), 1.40-1.22 (m, 4H, Cy-CH2), 1.18 (d, 3J = 6.5 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, CD3OD): δ 174.5 (Lac-C1), 140.7 (triazol-Ci), 131.4 
(Ar-Ci), 129.8, 129.7 (4 Ar-CH), 127.6 (2C, triazol-CH, Ar-CH), 102.8 (Gal-
C1), 97.4 (Fuc-C1), 84.9 (Gal-C3), 79.5 (Lac-C2), 77.5 (Cy-CH), 76.1 (Cy-
CH), 74.0 (Gal-C5), 72.1 (Fuc-C4), 71.7 (Gal-C2), 70.5 (Fuc-C3), 68.0 (Fuc-
C2), 67.6 (2C, Fuc-C5, Gal-C4), 63.0 (Gal-C6), 53.7 (Lac-C3), 32.7 (PhCH2), 
31.1, 30.9, 24.6 (4C, Cy-CH2), 16.8 (Fuc-C6);  
 
HR-MS calcd. for C30H43N3O13Na [M+H]+: 676.2694; found: 676.2696; 
 
[α]20D = -67.7 (c 0.27, MeOH);  
 
Sodium (2S)-3-N-[4-(3-thiophenyl)-1,2,3-triazol-1-yl]-2-O-{1-O-[(1R,2R)-2-
O-(α-L-fucopyranosyl)-cyclohexyl]-β-D-galactopyranos-3-yl} propionate 
(6c). In analogy to 6b, compound 6c was prepared from 5 (7.1 mg, 13 µmol)  
and 3-ethynyl-thiophene (12.7 µL, 129 µmol). After HPLC, 5.3 mg (35% over 
3 steps) of the free acid were obtained, which was transformed into the 
sodium salt as described above. Spectral data for the free acid: 
 
Rf (CH2Cl2/MeOH/water, 10:4:0.8) = 0.27; 
 
1H-NMR (500.1 MHz, CD3OD): δ 8.54 (s, 1H, triazol-H), 7.75-7.74 (m, 1H, Ar-
H), 7.50-7.48 (m, 2H, Ar-H), 4.98 (dd, 2J = 14.3, 3J = 2.9 Hz, 1H, Lac-H3a), 
4.84  (d, 3J = 3.9 Hz, 1H, Fuc-H1), 4.77 (dd, 2J = 14.2, 3J = 6.8 Hz, 1H, Lac-
H3b), 4.64 (dd, 3J = 6.7, 3J = 2.9 Hz, 1H, Lac-H2), 4.58 (q, 3J = 6.6 Hz, 1H, 
Fuc-H5), 4.28 (d, 3J = 7.7 Hz, 1H, Gal-H1), 3.97 (d, 3J = 2.7 Hz, 1H, Gal-H4), 
3.86 (dd, 3J = 10.1, 3J = 3.4 Hz, 1H, Fuc-H3), 3.75 (dd, 2J = 11.4, 3J = 6.9 Hz, 
1H, Gal-H6a), 3.72-3.62 (m, 5H, Fuc-H2, -H4, Gal-H2, Gal-H6b, 1H of Cy-
CH), 3.54 (dt, 3J = 9.4, 3J = 4.5 Hz, 1H, 1H of Cy-CH), 3.44-3.38 (m, 2H, Gal-
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H3, -H5), 2.07-2.01 (m, 2H, Cy-CH2), 1.74-1.66 (m, 2H, Cy-CH2), 1.43-1.22 
(m, 4H, Cy-CH2), 1.15 (d, 3J = 6.7 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, CD3OD): δ 145.1 (triazol-Ci), 133.2 (Ar-Ci), 127.6, 
127.0 (2C, Ar-C), 124.2 (triazol-CH), 122.2 (Ar-C), 102.7 (Gal-C1), 97.4 (Fuc-
C1), 85.0 (Gal-C3), 79.5 (CH), 77.5 (Cy-CH), 76.0 (Gal-C5), 74.0 (CH), 72.0 
(Gal-C2), 71.7 (Fuc-C3), 70.2 (CH), 67.9 (Gal-C4), 67.6 (Fuc-C5), 63.0 (Gal-
C6), 54.1 (Lac-C3), 31.1, 30.2, 24.6 (4C, Cy-CH2), 16.8 (Fuc-C6);  
 
HR-MS calcd. for C27H39N3O13SNa [M+H]+: 668.2101; found: 668.2100; 
 
[α]20D = -60.8 (c 0.27, MeOH, free acid);  
 
Sodium (2S)-3-N-[4-(3-pyridyl)-1,2,3-triazolyl]-2-O-{1-O-[(1R,2R)-2-O-(α-L-
fucopyranosyl)-cyclohexyl]-β-D-galactopyranos-3-yl} propionate (6d). In 
analogy to 6b, compound 6d was prepared from 5 (7.1 mg, 13 µmol)  and 3-
ethynyl-pyridine (15 mg, 145 µmol). After HPLC, 2.2 mg (15% over 3 steps) of 
the free acid were obtained, which was transformed into the sodium salt as 
described above. Spectral data for the free acid: 
 
Rf (CH2Cl2/MeOH/water, 10:4:0.8) = 0.22; 
 
1H-NMR (500.1 MHz, CD3OD): δ 9.04 (br s, 1H, Ar-H), 8.78 (s, 1H, triazol-H), 
8.52 (br s, 1H, Ar-H), 8.30 (d, 3J = 7.6 Hz, 1H, Ar-H), 7.55-7.51 (m, 1H, Ar-H), 
5.02 (dd, 2J = 14.5, 3J = 2.8 Hz, 1H, Lac-H3a), 4.83 (d, 3J = 3.5 Hz, 1H, Fuc-
H1), 4.79 (dd, 2J = 14.2, 3J = 7.1 Hz, 1H, Lac-H3b), 4.72 (dd, 3J = 7.0, 3J = 2.7 
Hz, 1H, Lac-H2), 4.59 (q, 3J = 6.7 Hz, 1H, Fuc-H5), 4.27 (d, 3J = 7.2 Hz, 1H, 
Gal-H1), 3.98 (d, 3J = 2.3 Hz, 1H, Gal-H4), 3.85 (dd, 3J = 9.8, 3J = 3.1 Hz, 1H, 
Fuc-H3), 3.75 (dd, 2J = 11.7, 3J = 7.2 Hz, 1H, Gal-H6a), 3.71-3.65 (m, 4H, 
Fuc-H2, -H4, Gal-H6b, 1H of Cy-CH), 3.62 (t, 3J = 8.0 Hz, 1H, Gal-H2), 3.52 
(dt, 3J = 9.4, 3J = 4.4 Hz, 1H, 1H of Cy-CH), 3.44-3.38 (m, 2H, Gal-H3, -H5), 
2.07-2.00 (m, 2H, Cy-CH2), 1.72-1.65 (m, 2H, Cy-CH2), 1.41-1.19 (m, 4H, Cy-
CH2), 1.13 (d, 3J = 6.5 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, CD3OD, selected resonances from 1H,13C-HSQC): δ 
147.2, 135.1, 126.1, 124.8 (4C, Ar-CH), 102.3 (Gal-C1), 97.0 (Fuc-C1), 84.3 
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(Gal-C3), 78.6 (Lac-C2), 77.0 (CH), 75.9 (CH), 73.1 (CH), 71.9 (CH), 71.3 
(Fuc-C3), 71.2 (CH), 67.5 (Gal-C4), 66.7 (Fuc-C5), 62.8 (Gal-C6), 54.1 (Lac-
C3), 31.1, 30.2, 24.6 (4C, Cy-CH2), 16.8 (Fuc-C6);  
 
HR-MS calcd. for C28H40N4O13Na [M+H]+: 663.2490; found: 663.2490; 
 
[α]20D = -44.7 (c 0.11, MeOH, free acid);  
 
Sodium (2S)-3-N-[4-(3-trifluoromethyl-phenyl)-1,2,3-triazol-1-yl]-2-O-{1-O-
[(1R,2R)-2-O-(α-L-fucopyranosyl)-cyclohexyl]-β-D-galactopyranos-3-yl} 
propionate (6e). In analogy to 6b, compound 6e was prepared from 5       
(7.1 mg, 13 µmol)  and 3-ethynyl-trifluoromethylbenzene (18.7 µL, 130 µmol). 
After HPLC, 5.9 mg (34% over 3 steps) of the free acid were obtained, which 
was transformed into the sodium salt as described above. Spectral data for 
the free acid: 
 
Rf (CH2Cl2/MeOH/water, 10:4:0.8) = 0.35; 
 
1H-NMR (500.1 MHz, CD3OD): δ 8.75 (s, 1H, triazol-H), 8.16 (s, 1H, Ar-H), 
8.10-8.09 (m, 1H, Ar-H), 7.65-7.61 (m, 2H, Ar-H), 5.01 (dd, 2J = 13.7, 3J = 2.3 
Hz, 1H, Lac-H3a), 4.83 (d, 3J = 3.6 Hz, 1H, Fuc-H1), 4.82-4.76 (m, 2H, Lac-
H2, -H3b), 4.59 (q, 3J = 6.7 Hz, 1H, Fuc-H5), 4.27 (d, 3J = 7.6 Hz, 1H, Gal-
H1), 3.99 (d, 3J = 2.5 Hz, 1H, Gal-H4), 3.85 (dd, 3J = 10.1, 3J = 3.3 Hz, 1H, 
Fuc-H3), 3.75 (dd, 2J = 11.4, 3J = 6.9 Hz, 1H, Gal-H6a), 3.72-3.64 (m, 4H, 
Fuc-H2, -H4, Gal-H6b, 1H of Cy-CH), 3.64-3.61 (m, 1H, Gal-H2), 3.52 (dt, 3J = 
9.4, 3J = 4.3 Hz, 1H, 1H of Cy-CH), 3.41-3.41 (m, 2H, Gal-H3, -H5), 2.04-1.99 
(m, 2H, Cy-CH2), 1.68 (br s, 2H, Cy-CH2), 1.41-1.21 (m, 4H, Cy-CH2), 1.13 (d, 
3J = 6.6 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, CD3OD): δ 174.5 (Lac-C1), 147.4 (triazol-Ci), 133.2 
(Ar-Ci), 131.0, 130.4 (2C, Ar-CH), 125.8 (triazol-CH), 125.0, 123.4 (2C, Ar-C), 
102.8 (Gal-C1), 97.5 (Fuc-C1), 84.7 (Gal-C3), 79.6 (Lac-C2), 79.0 (Cy-CH), 
77.6 (Cy-CH), 76.1 (Gal-C5), 74.0 (Fuc-C4), 72.2 (Gal-C2), 71.7 (Fuc-C3), 
70.2 (Fuc-C2), 68.2 (Gal-C4), 67.5 (Fuc-C5), 62.9 (Gal-C6), 53.8 (Lac-C3), 
31.1, 30.3, 24.6 (4C, Cy-CH2), 16.7 (Fuc-C6);  
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HR-MS calcd. for C30H40F3N3O13Na [M+H]+: 730.2411; found: 730.2419; 
 
[α]20D = -52.9 (c 0.27, MeOH, free acid);  
 
Sodium (2S)-3-N-[4-(benzotriazolylmethyl)-1,2,3-triazol-1-yl]-2-O-{1-O-
[(1R,2R)-2-O-(α-L-fucopyranosyl)-cyclohexyl]-β-D-galactopyranos-3-yl} 
propionate (6f). In analogy to 6b, compound 6f was prepared from 5 (7.1 mg, 
13 µmol)  and 1-N-benzotriazolyl-prop-2-yne (20.7 mg, 132 µmol). After 
HPLC, 5.4 mg (33% over 3 steps) of the free acid were obtained, which was 
transformed into the sodium salt as described above. Spectral data for the 
free acid: 
 
Rf (CH2Cl2/MeOH/water, 10:4:0.8) = 0.30; 
 
1H-NMR (500.1 MHz, CD3OD): δ 8.37 (br s, 1H, triazol-Ar-H), 7.98 (A of 
ABCD, 3J = 7.5 Hz, 1H, Bt-H), 7.81 (D of ABCD, 3J = 7.5 Hz, 1H, Bt-H), 7.55 
(C of ABCD, 3J = 7.5 Hz, 1H, Bt-H), 7.43 (C of ABCD, 3J = 7.5 Hz, 1H, Bt-H), 
6.03 (br s, 2H, Bt-CH2-triazol), 4.92-4.86  (m, 2H, Fuc-H1, Lac-H3a), 4.74 (dd, 
3J = 13.5, 3J = 6.5 Hz, 1H, Lac-H3b), 4.63-4.61 (m, 1H, Lac-H2), 4.59 (q, 3J = 
6.4 Hz, 1H, Fuc-H5), 4.24 (d, 3J = 7.8 Hz, 1H, Gal-H1), 3.93 (br s, 1H, Gal-
H4), 3.87 (dd, 3J = 10.0, 3J = 3.5 Hz, 1H, Fuc-H3), 3.77-3.65 (m, 5H, Fuc-H2, -
H4, Gal-H6a/b, 1H of Cy-CH), 3.61-3.53 (m, 2H, Gal-H2, 1H of Cy-CH), 3.41-
3.38 (m, 1H, Gal-H5), 3.33-3.31 (m, 1H, Gal-H3), 2.08-2.01 (m, 2H, Cy-CH2), 
1.71 (br s, 2H, Cy-CH2), 1.42-1.22 (m, 4H, Cy-CH2), 1.18 (d, 3J = 6.7 Hz, 3H, 
Fuc-H6);  
 
13C-NMR (125.8 MHz, CD3OD): δ 176.8 (Lac-C1), 147.2 (Bt-Ci), 142.9 (triazol-
Ci), 134.4 (Bt-Ci), 139.1 (Bt-CH), 127.4 (triazol-CH), 125.9 (Bt-CH), 120.1 (Bt-
CH), 112.0 (Bt-CH), 102.7 (Gal-C1), 97.4 (Fuc-C1), 85.1 (Gal-C3), 79.5 (Cy-
CH), 78.7 (Lac-C2), 77.4 (Cy-CH), 76.0 (Gal-C5), 74.0 (Fuc-C4), 72.8 (Gal-
C2), 71.7 (Fuc-C3), 70.2 (Fuc-C2), 67.9 (Gal-C4), 67.6 (Fuc-C5), 63.0 (Gal-
C6), 53.8 (Lac-C3), 44.6 (Bt-CH2), 30.8, 24.4 (4C, Cy-CH2), 16.8 (Fuc-C6);  
 
HR-MS calcd. for C30H42N6O13Na [M+Na]+: 717.2708; found: 717.2705; 
 
[α]20D = -53.7 (c 0.27, MeOH);  
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Benzyl (2S)-3-N-[4-(benzotriazolylmethyl)-1,2,3-triazol-1-yl]-2-O-{1-O-
[(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl] 6-O-
benzyl-β-D-galactopyranos-3-yl} propionate (25). 3-Benzotriazolyl propyne 
(95 mg, 60.7 µmol) was dissolved in MeOH/water (1 mL; 9:1) and copper 
powder (1 mg) was suspended in this solution. A solution of azide 23 (10 mg, 
10.1 µmol) in MeOH/water (1 mL, 9:1) was added and the reaction mixture 
was stirred for 24 h at r.t.. Additional copper powder (5 mg) was added and 
stirring continued for further 24 h before the solvent was removed in vacuo. 
Purification by column chromatography (PhMe/EtOAc 1:1) yielded 25 (10 mg; 
86%) as a white solid. 
 
Rf (PhMe/EtOAc, 1:1) = 0.35; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.97-7.92 (m, 1H, Bt-H), 7.85 (br s, 1H, 
triazol-H), 7.62-7.57 (m, 1H, Bt-H), 7.38 (m, 1H, Bt-H), 7.32-7.13 (m, 26H, 25 
Ar-H, 1 Bt-H), 5.80 (br s, 2H, Bt-CH2-triazol), 5.13, 5.06 (A, B of AB, 2J = 11.9 
Hz, 2H, PhCH2OCO-), 4.88-4.86 (m, 2H, Fuc-H1, 1H of PhCH2), 4.74-4.70 
(m, 2H, 1H of PhCH2, Lac-H3a), 4.66 (A’’’ of A’’’B’’’, 2J = 12.0 Hz, 1H, PhCH2), 
4.61 (B’’ of A’’B’’, B’’’ of A’’’B’’’, 2J = 11.7 Hz, 2H, PhCH2), 4.53 (B’ of A’B’, 2J = 
11.5 Hz, 1H, PhCH2), 4.50-4.46 (m, 2H, Lac-H2, -H3b), 4.42, 4.38 (A’’’’ and 
B’’’’ of A’’’’B’’’’, 2J = 12.0 Hz, 1H, PhCH2), 4.31 (q, 3J = 6.3 Hz, 1H, Fuc-H5), 
4.07 (d, 3J = 7.7 Hz, 1H, Gal-H1), 3.94 (dd, 3J = 10.1, 3J = 3.5 Hz, 1H, Fuc-
H2), 3.89 (dd, 3J = 10.1, 3J = 2.7 Hz, 1H, Fuc-H3), 3.77 (d, 3J = 2.5 Hz, 1H, 
Gal-H4), 3.66-3.60 (m, 3H, Fuc-H4, Gal-H6a, 1H of Cy-CH), 3.57-3.51 (m, 
3H, Gal-H2, -H6b, 1H of Cy-CH,), 3.31 (t, 3J = 6.0 Hz, 1H, Gal-H5), 3.39 (dd, 
3J = 2.7, 3J = 9.3 Hz, 1H, Gal-H3), 1.97-1.87 (m, 2H, Cy-CH2), 1.66-1.56 (m, 
2H, Cy-CH2), 1.35-1.13 (m, 4H, Cy-CH2), 1.01 (d, 3J = 6.5 Hz, 3H, Fuc-H6);  
 
13C-NMR (125.8 MHz, CDCl3): δ 170.2 (Lac-C1), 139.4, 139.1, 139.0, 138.2, 
134.5 (5C, Ar-Ci), 129.1-127.5 (Ar-C), 124.4, 120.0, 110.4 (3C, Bt-Ar-C), 
100.7 (Gal-C1), 95.0 (Fuc-C1), 83.6 (Gal-C3), 79.9 (Fuc-C3), 78.4 (Fuc-C4), 
77.9 (Cy-CH), 77.4 (Lac-C2), 76.6 (Fuc-C2), 76.3 (Cy-CH), 75.1, 73.8, 73.2 
(4C, PhCH2), 73.0 (Gal-C5), 70.6 (Gal-C2), 69.0 (Gal-C6), 68.4 (PhCH2-O-
CO-), 66.7 (Gal-C4), 66.4 (Fuc-C5), 52.3 (Lac-C3), 44.0 (Bt-CH2-triazol), 30.2, 
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29.9, 29.4, 23.4 (4C, Cy-CH2), 16.9 (Fuc-C6);  
 
ESI-MS calcd. for C65H72N6O13Na [M+Na]+: 1167.5; found: 1167.7; 
 
Sodium (2S)-3-N-[4-(tetrahydrobenzotriazolylmethyl)-1,2,3-triazol-1-yl]-2-
O-{1-O-[(1R,2R)-2-O-(α-L-fucopyranosyl)-cyclohexyl]-β-D-galacto-
pyranos-3-yl} propionate (6g). To a solution of 25 (10 mg, 8.7 µmol) in 
dioxane/water (3 mL, 4:1) was added Pd(OH)2/C (18 mg) and the reaction 
mixture was hydrogenated at 4 bar for 48 h at r.t.. After filtration and removal 
of the solvents, the crude product was purified by preparative HPLC to give 
the free acid of 6g (2.4 mg, 39%). The sodium salt was obtained as a white 
powder by addition of stoichiometric amounts of dilute NaOH (1 N, 30 µL) to 
an aqueous solution of 6g followed by lyophilization. Spectral data for the free 
acid: 
 
1H-NMR (500.1 MHz, CD3OD): δ 8.27 (br s, 1H, triazol-Ar-H), 5.57 (br s, 2H, 
4H-Bt-CH2-triazol), 4.93-4.84 (m, 2H, Fuc-H1, Lac-H3a), 4.75 (dd, 3J = 14.6, 
3J = 5.9 Hz, 1H, Lac-H3b), 4.64-4.60 (m, 1H, Lac-H2), 4.59 (q, 3J = 6.8 Hz, 
1H, Fuc-H5), 4.27 (d, 3J = 8.0 Hz, 1H, Gal-H1), 3.94 (br s, 1H, Gal-H4), 3.86 
(dd, 3J = 9.9, 3J = 3.6 Hz, 1H, Fuc-H3), 3.77-3.65 (m, 5H, Fuc-H2, -H4, Gal-
H6a/b, 1H of Cy-CH), 3.61-3.52 (m, 2H, Gal-H2, 1H of Cy-CH), 3.41 (t, 3J = 
5.6 Hz, 1H, Gal-H5), 3.35-3.34 (m, 1H, Gal-H3), 2.70-2.64 (m, 4H, 4H-Bt-H), 
2.07-2.02 (m, 2H, Cy-CH2), 1.87-1.77 (m, 4H, 4H-Bt-H), 1.73-1.68 (m, 2H, Cy-
CH2), 1.41-1.22 (m, 4H, Cy-CH2), 1.18 (d, 3J = 6.6 Hz, 3H, Fuc-H6);  
 
HR-MS calcd. for C30H46N6O13Na [M+Na]+: 721.3021; found: 721.3021; 
 
[α]20D = -40.8 (c 0.12, MeOH);  
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2.2b A safe and convenient method for the preparation of triflyl azide, 
and its use in diazo transfer reactions to primary amines 
 
In the course of the studies for the synthesis of the library precursor (vide 
supra, chapter 2.2), an improved methodology for the transformation of 
primary amines into azides via the copper-catalyzed diazo transfer was found. 
 
This part was published in Tetrahedron Letters: 
 
Titz, A.; Radic, Z.; Schwardt, O.; Ernst, B. A safe and convenient method for 
the preparation of triflyl azide, and its use in diazo transfer reactions to 
primary amines Tetrahedron Lett. 2006, 47, 2383 - 2385. 
 
Copyright  Elsevier B.V.: Tetrahedron Lett. 47, 2383 - 2385, 2008 
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2.3 Pre-organization of the carboxylic acid by covalent means 
 
The insufficient biological results of the library directed towards additional 
enthalpic interactions prompted me to tackle the problem of pre-organization 
first and then screen for additional pharmacophores. Inspired by the work of 
Wong182 and Thoma183, a covalently pre-organized carboxylic acid should 
allow optimal salt-bridge formation with Arg97 supported by Tyr48. Secondly, 
this scaffold could then be exploited for the attachment of additional 
pharmacophores without disturbing the geometry of the acid orientation. 
 
Thoma’s approach (21, chapter 1.4.2) led to a covalent orientation of the 
carboxylic acid, although outside the bioactive conformation and, therefore, 
was not successful as selectin ligand. In the Wong group ((S)-23, (R)-23, 
chapter 1.4.2), the carboxylic acid was introduced into a galactoside derived 
disaccharyl ketone using D- and L-cysteine, respectively. The angle of the 
carboxylic acid was covalently fixed through a thiazine ring. However, the 
results published by Wong’s group show that both diastereomers, obtained 
from D- and L-cysteine, exhibit similar biological activities towards the 
selectins. They claim that the orientation of the carboxylic acid is not of 
special importance. Furthermore, it is reported that the main contribution to 
the increased affinity of the spirocyclic antagonists originates from the 
lipophilicity of the sulphur in both diastereomers, when compared to the 
acyclic carboxymethyl analog (22184,185, chapter 1.4.2). 
 
The two spirocyclic diastereomers synthesized by Wong and co-workers 
additionally showed different behavior in chemical stability. Whereas the L-
cysteine derived compound (R)-23 (chapter 1.4.2), with the acid oriented in 
the ‘wrong’ orientation, was reported to be a moderately stable molecule, the 
D-cysteine analog (S)-23 with the ‘correct’ orientation of the acid was not. 
Rapid isomerization via inversion of the orientation of the spirocyclic thiazine 
ring was reported. 
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This isomerization, or even hydrolysis of the labile thiazine ring is not 
surprising. The stability of cysteine derived thiazines was extensively studied 
by Riemschneider,186,187 Belikov188 and Butvin189. Unsubstituted thiazines 
derived from formaldehyde, 2-monosubstituted thiazines from other 
aldehydes and 2,2-disubstituted thiazines from ketones were analyzed for 
their solubility and stability in different solvents. Although formaldehyde 
derived thiazines were stable, 2,2-disubstituted analogs obtained from 
ketones were very labile especially in polar solvents like water or methanol.186 
Belikov reported an immediate hydrolysis of the 2,2-dimethyl thiazine from L-
cysteine upon contact with water.188 
 
The approach of the Wong group to fix the acid orientation via a spirocyclic 
ring was a very valuable idea, although the exact nature of the thiazine 
compounds tested remains obscure. When taking the literature on thiazine 
stability in aqueous solvents into account, it can be assumed that the similar 
biological activity of the two diastereomeric thiazines might be a result of 
hydrolysis rather than similar intrinsic activity of the pure individual 
compounds. 
 
Consequently, the idea of a spirocyclic ring for the locking of the acid 
orientation was continued, however, by using a stable 5-membered ring as 
locking-motif. For this purpose the spiro-tetrahydrofuranyl galactoside 
derivative 17 (scheme 1) was chosen as target structure. 
 
The retrosynthetic analysis (scheme 1) of 17 leads via a retro-Williamson 
disconnection to the acyclic precursor 18. The leaving group necessary for 
ring closure should be introduced from acrylate 19, which leads to the 3C-allyl 
galactoside motif 20 by retro-Grubbs olefin metathesis. This carbon-linked 
allyl derivative 20 gives the ketone 21 by retro-Grignard disconnection, which 
leads via a series of protecting group transformations to the known building 
block 24190 as available starting material. 
 
To study the transformations at the galactose residue of 24, a simpler and 
commercially available starting material was chosen. Galactoside 25 (scheme 
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2) was first selectively O-allylated in the 3-position with the help of a tin-acetal 
intermediate using a modified procedure of Pieters191 and co-workers. 
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Scheme 1: Retrosynthetic analysis of the desired spiro target structure 17 
 
Subsequently, the remaining hydroxyl groups in 26 were protected as 
benzoates to give 27 in quantitative yield. Removal of the allyl ether by 
palladium mediated allyl transfer to methanol gave the free alcohol 28. 
Chromium-VI mediated oxidation of the secondary alcohol gave the desired 
ketone 29 in 86% yield. The carbon-linked allyl group was introduced in 30 by 
a Barbier-type reaction using an allyl-zinc reagent. This reaction proceeded 
smoothly with a diastereomeric excess of more than 98%.  
 
To confirm the desired axial substitution, ROESY NMR spectroscopy was 
performed. Unfortunately, ROE’s between Gal-H1/H5 and the allylic protons 
were not detected, as observed by Hindsgaul192 and co-workers for similar 
galactose derivatives. Because the epimer of 30 was not accessible via this 
route due to a high degree of stereoselectivity, a control to unambiguously 
determine the stereochemistry in 30 was not available. Consequently, 30 was 
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Scheme 2: Synthesis of the acrylate precursor in the benzoate test 
series: (i) DBTO, MeCN, PhMe, µW, 7 min., 150 °C; (ii) AllBr, TBAI, 10 d, 
r.t.; (iii) BzCl, C5H5N, 18 h, 0 °C – r.t.; (iv) cat. PdCl2, MeOH, 22 h, 40 °C; 
(v) PDC, HOAc, mol. sieves, CH2Cl2, 3 h, 0 °C – r.t.; (vi) Zn (powder), 
AllBr, cat. I2, dry THF, 4 h, r.t.; (vii) methyl acrylate, Grubbs 2nd gen., 
CH2Cl2, reflux, 2 h; 
 
crystallized and the structure of gulo-derivative 30 could be confirmed by X-
ray crystallography (figure 14, table 1). Although the configuration of 30 was 
the gulo- and not the desired galacto-epimer, it was transformed into acrylate 
31 for further synthetic studies using Grubbs olefin cross-metathesis in very 
good yield (scheme 2). 
 
An epoxide introduced via asymmetric epoxidation (AE)193 could serve as 
leaving group in the subsequent cyclization to form the 5-membered ring in 17 
(scheme 1) and give rise to a free hydroxyl group as attachment handle for 
further derivatization in a library derived from 17. AE of acrylates using the 
novel electron-deficient fructose-derived Shi auxiliary194 promised to be a 
valuable approach to stereoselectively introduce an epoxide. Therefore, the 
auxiliary was synthesized according to the acidic195 acylation conditions used 
by Vidal-Ferran196 in four steps from fructose. However, when 31 was 
exposed to epoxidation conditions with the fructose-derived auxiliary, epoxide 
product could not be detected neither using the Shi194 conditions at pH 8-10, 
nor under Vidal-Ferran196 conditions in a buffered system at pH 6. Other 
mostly nucleophilic epoxidation conditions (e.g. H2O2/NaOH,197 mCPBA, 
mCPBA/base, NaOCl/C5H5N or tBuOOH/base) were applied to 31, but did 
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either not react or led to complex mixtures because of the labile benzoate 
protecting groups. 
 
 
 
Figure 14: ORTEP plot of the X-ray structure of 30 proving the gulo stereochemistry 
 
Alternatively, an asymmetric dihydroxylation (AD) using Sharpless conditions 
with AD-mix beta should lead to a diastereomerically pure diol.198 Since the 
pKa of the α-hydroxyl group is much more acidic then the one of the 
remaining hydroxyl groups, it could be transformed selectively into a leaving 
group suitable for cyclization.199 When the AD reaction was performed with 
31, no product was formed. Since AD and AE failed on 31, but were 
successful on methyl cinnamate in control experiments, it can be concluded 
that the double bond in 31 is not accessible by the catalysts and can therefore 
not be oxidized using these methods. Dihydroxylation of 31 without a chiral 
catalyst was possible and the corresponding mixture of syn-diols could be 
obtained (61%, d.r. 1:1.7, data not shown). Cyclization of the diol to the 
desired THF ring was studied under a variety of conditions (CeCl3,200 
Tf2O/2,6-tBu2-C5H3N/THF, Tf2O/2,6-tBu2C5H3N/CH2Cl2), but did not react or 
led to complex mixtures of unidentified products. 
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Table 1: Crystallographic data of gulose derivative 30 
Compound 30 
CCDC number not deposited 
Empirical formula C31H30O9 
Formula weight 546.55 
Temperature (K) 100 
Wavelength (Å) 1.5418 
Crystal system Monoclinic 
Space group P21 
Cell dimensions  
a (Å) 8.26620(10) 
b (Å) 11.1738(2) 
c (Å) 14.5223(2) 
α (°) 90 
β (°) 92.2730 
γ (°) 90 
Volume (Å3) 1340.29(3) 
Z 2 
Density calculated (kg/dm3) 1.354 
F000 576 
θ range for data collection (°) 3.05-58.93 
Reflections collected 5729 
Independent reflections 3138 
Data/restraints/parameters 3138/1/304 
Goodness of fit on F2 1.121 
Final R indices [I > 2σ(I)] R1 = 0.0830, wR2 = 0.2073 
R indices (all data) R1 = 0.0910, wR2 = 0.2184 
Largest diff. peak and hole (e Å3) 0.624 and -0.644 
 
 
Because of the undesired gulo stereochemistry in 30 and the difficulties with 
the oxidation of the double bond in 31, protecting groups were changed from 
benzoates to benzyl ethers. This allowed both, zinc mediated Barbier-type 
allylation and a more reactive Grignard allylation to extend the galactose 
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moiety. Furthermore, a reduction of the acrylate to an allylic alcohol for 
Sharpless epoxidation was now possible with these protecting groups. 
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Scheme 3: Synthesis of the epoxide precursor in the benzyl test series: (i) 
DBTO, MeCN, PhMe, µW, 7 min., 150 °C; (ii) AllBr, TBAI, 3 d, 60 °C; (iii) 
BnBr, NaH, DMF, 4 h, 0 °C – r.t.; (iv) cat. PdCl2, MeOH, 3.5 h, 40 °C; (v) 
(CO)2Cl2, DMSO, NEt3, CH2Cl2, 5 h, -78 °C – r.t.; (vi) Zn (powder), AllBr, 
cat. I2, dry THF, 4 h, r.t.; (vii) methyl acrylate, Grubbs 2nd gen., CH2Cl2, 
reflux, 2 h; (viii) DIBAl-H, PhMe, -78 °C, 1 h; (ix) (-)-DET, Ti(OiPr)4, 
tBuOOH, mol. sieves, -20 °C - r.t., 2 h; 
 
Again, methyl galactoside 25 served as the starting material for studying the 
reaction sequence. Selectively protected galactoside 32 (scheme 3) was 
obtained after 3-O allylation as performed for 26 (scheme 2), but with 
increased temperature (60 °C) during the allylation. This led to a shortened 
reaction time of 3 days and an increased yield after benzylation of the 
remaining hydroxyl groups. Deallylation of 32 using Pd(II) and methanol gave 
the free alcohol 33, which was used for oxidation to the ketone 34 under 
Swern conditions. Barbier-type allylation of 34 gave an inseparable mixture of 
diastereomers of 35 (d.r. 4.3:1) which was exposed to olefin metathesis 
conditions to give 36 in 90% yield over 2 steps.  
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Scheme 4: (i) NaOMe, MeOH, r.t., 12 h, r.t. (ii) H2, Pd/C, MeOH, 12 h, r.t. 
 
To verify the stereochemistry in 35, Overhauser effects were analyzed by 
ROESY NMR and could only be observed between Gal-H1/H5 and the allylic 
protons of the side chain for the minor diastereomer. These results indicate 
again a preference of the zinc reagent for the gulo type product over the 
desired galacto type product. To verify these assignments, both benzoate 
protected 30 and the mixture of benzyl protected 35 were transformed into 3-
C propyl derivative 43 (scheme 4). Because the major diastereomer of the 
product 43 obtained from 35 showed the same NMR data as the one obtained 
from diastereomerically pure 30, a gulo preference could be unambiguously 
assigned for the Barbier type allylation to obtain 35. 
 
Acrylate 36 could now be reduced to give the allylic alcohol 37, which was 
diastereoselectively epoxidized under Sharpless conditions to give epoxide 38 
(scheme 3). Upon exposure of 38 to camphor sulfonic acid in methylene 
chloride, the expected cyclization to give the spiro isomer 39 could not be 
observed (scheme 5). An unexpected benzyl group migration from 2-O to the 
primary terminal hydroxyl group took place, followed by a nucleophilic attack 
of the less sterically hindered 2-OH to the epoxide to give an annulated THF 
ring in 41 in 23% yield as the only observed product. Similar selective sulfonic 
acid mediated cleavage of more labile 2-O p-methoxybenzyl groups in 
galactosides has rarely been reported in the literature.201,202 The two hydroxyl 
groups in 41 were subsequently derivatized with 3,5-dinitrobenzoyl chloride to 
give the diester 42. 
 
Careful NMR analysis of 41 and its derivative 42 further confirmed the 
proposed structure (figure 15). In 41, the absence of a HMBC signal between 
C-2 and benzylic protons indicated loss of the 2-O-benzyl group, and 
additionally the large coupling constants (10.4 and 12.7 Hz) of Hax of the 
methylene group  adjacent  to C-3 originate from the gemial coupling with Heq 
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Scheme 5: Cyclization of epoxide 38 and derivatization for 
structure assignment: (i) CSA, CH2Cl2, r.t., 12 h; (ii) 3,5-
(NO2)2BzCl, DMAP, CH2Cl2, r.t., 4 h; 
 
and a trans-oriented vicinal proton. This 3J trans coupling is only present in 
the 5-membered ring of 41, in a possible isomeric 6-membered ring the two 
methylene protons would both have a gauche orientation to the neighboring 
proton and thus show a 3J coupling constant in the low single digit Hertz range 
(1-3 Hz) as derived from the Karplus equation. In 42, the chemical shift of C-3 
has moved downfield by 11.5 ppm in the carbon-13 NMR when compared to 
its chemical shift in 41. This is in accordance with the difference of the 
chemical shifts of the quaternary carbons in tert.-BuOH and tert.-butyl acetate 
(+ 11.6 ppm).203 Furthermore, the methine proton adjacent to the ester 
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function in the side chain of 42 has shifted downfield by 0.95 ppm, when 
compared with its chemical shift in 41. 
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Figure 15: Assignment of the structure of 41 and its derivative 42 by NMR 
 
With the lessons learnt from these test reactions on monosaccharide 25 
(schemes 2-5), the synthesis of 17 was now started from the core moiety 
44190 (scheme 6). Selective O-allylation of the 3-position of the galactose 
moiety in 44 gave 45 in good yield. Subsequently, the free hydroxyls were 
protected as benzyl ethers in 46 and then, the free 3-OH group in 47 was 
obtained by palladium-(II) mediated deallylation. Swern oxidation of 47 gave 
the ketone 48 in very good yield. The allylation under Grignard conditions 
could be optimized to give an almost equimolar ratio (1.2:1) of the undesired 
but mechanistically preferred gulo-49 to the desired galacto-49 epimer in 77% 
yield by adding 48 dropwise at 0 °C to a large excess (40 equiv.) of the allyl 
Grignard reagent in Et2O. Galacto-49 was subsequently transformed into 
acrylate 50 in 91% yield via olefin metathesis using only 5 mol-% of the 
Grubbs  2nd  generation  catalyst.  The reduction of 50 to allylic alcohol 51 with  
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Scheme 6: Synthesis of the epoxide precursor 52: (i) DBTO, MeCN, 
PhMe, µW, 7 min., 150 °C; (ii) AllBr, TBAI, 12 h, 75 °C; (iii) BnBr, NaH, 
DMF, 7 h, r.t.; (iv) cat. PdCl2, MeOH, 2 h, 50 °C; (v) (CO)2Cl2, DMSO, 
NEt3, CH2Cl2, 10 h, -78 °C – r.t.; (vi) Mg (turnings), AllBr, cat. I2, dry Et2O, 
3.5 h, 0 °C; (vii) methyl acrylate, Grubbs 2nd gen., CH2Cl2, reflux, 1 h; (viii) 
DIBAl-H, PhMe, -78 °C, 1 h; (ix) (-)-DET, Ti(OiPr)4, tBuOOH, mol. sieves,   
-20 °C – +10 °C, 2 h; 
 
DIBAl-H was performed in 76% yield, but also DIBAl-H mediated 
debenzylation of the galactose-2-O-benzyl group was observed as reported 
for benzylated carbohydrates by Lecourt et al..204 In the following Sharpless 
epoxidation of 51, epoxide 52 was obtained almost as a 1:1 mixture of 
diastereomers. This probably results from a mismatch situation of the 
substrate 51 with the (-)-diethyl tartarate complex of titanium-(IV), because 
homo-allylic alcohols, as also present in 51, have been reported to be suitable 
substrates for asymmetric epoxidation via the Sharpless route. Match and 
mismatch in the Sharpless epoxidation of similar allylic – homoallylic systems 
have been studied in detail by Takano and co-workers and can lead to either 
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complete selectivity for one diastereomer, or in case of mis-match to 
equimolar diastereomeric mixtures of products.205 Furthermore, partial Lewis 
acid mediated 2-O debenzylation occurred during the epoxidation and was 
responsible for the low yield (44%) in the synthesis of 52. 
 
Because acidic conditions led to 2-O debenzylation as observed for the 
monosaccharide 38, but also for 51 and 52 when exposed to Lewis acids, 
basic conditions were chosen to test the cyclization of the mixture of epoxides 
52. The diastereomeric mixture 52 was exposed to sodium hydride in dry 
DMF at room temperature and a mixture of isomeric products with correct 
molecular mass (as observed from mass spectrometry) was obtained 
(scheme 7). Cyclization was successful and the spiro-THF compound 53 
derived from the undesired epoxide (S,S)-52 was obtained in 21% yield. The 
second product obtained from this base-catalyzed cyclization was a mixture of 
oxetanes 54 resulting from the desired epoxide (R,R)-52 and partially from its 
diastereomer (S,S)-52. In fact, base-catalyzed isomerization of 4-hydroxy-1,2-
epoxybutanes to the corresponding oxetanes has been described in a few 
reports in the literature, usually for systems where the 5-membered ring 
product would not be accessible because of high steric hindrance or ring 
strain of other rings in the molecules.206-215 The structure of THF 53 and the 
oxetane mixture 54 was determined by derivatization as bis-dinitrobenzoates 
55 and 56, respectively and analysis of the downfield shifts of the protons 
adjacent to the ester groups when compared to their precursors 53 and 54. 
The stereochemistry of the spiro-THF compounds 53 and 55 was determined 
with the help of ROEs observed between THF-H4syn to Gal-H1 and THF-H4anti 
to Gal-H5. The peaks of THF-H4syn and THF-H4anti were assigned due to their 
characteristic difference in 3J-coupling with THF-H3. THF-H4syn does not have 
a significant coupling to THF-H3, whereas THF-H4anti has a 3J coupling of 5.5-
6.5 Hz in 53 and 55. 
 
In accordance with Murphy’s law, epoxide (S,S)-52 cyclized to the desired 
spiro compound, however, with the wrong stereochemistry at the THF ring 
(53). Probably an unfavored transition state in the course of the ring-closure 
leads to the 4-membered ring in 54 for epoxide (R,R)-52. Since (S,S)-52 gives 
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both 5-membered and 4-membered ring products 53 and 54, a prolonged 
reaction time was estimated to lead to an isomerization215 of the oxetanes to 
the corresponding more stable spiro-THF products. Unfortunately, this 
attempt only resulted in a lower yield of 53 and hydrolysis of the oxetanes, 
probably due to the presence of NaOH in the NaH used. Interestingly, in a 
test reaction (10 mg scale) where NaHCO3 was used instead of NaH for the 
cyclization, no oxetanes were observed by TLC but an additional spot 
appeared on the TLC plate together with a the spot running at the same Rf 
value as 53. 
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Scheme 7: Cyclization of epoxides 52 and derivatization of the 
products for structure assignment: (i) NaH, DMF, r.t., 12 h; (ii) 3,5-
(NO2)2BzCl, DMAP, CH2Cl2, r.t., 3-12 h; 
 
Selective oxidation of the primary alcohol in 53 with TEMPO/NaOCl216 and 
final deprotection are expected to proceed smoothly to give the derivative of 
17 with the undesired stereochemistry. Further studies on the improvement of 
both, epoxidation and cyclization and on the completion of the synthesis of 
the derivative of 17 with the undesired stereochemistry could not be 
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performed due to a lack of time and material. Nevertheless, the proof of 
principle for the synthesis of a spiro-THF sLex analog was given. 
 
 
Experimental 
 
General experimental information is given in the publications of the preceding 
sections (2.1, 2.2 and 2.4) and this also applies to chapter 2.3. 
 
Methyl 3-O-allyl-β-D-galactoside (26). Five batches according to the 
following procedure were prepared: methyl β-D-galactoside (25, 500 mg,  
2.57 mmol) and dibutyltin oxide (705 mg, 2.83 mmol) were suspended in a 
mixture of MeCN/PhMe (6 mL, 1/5 v/v) in a microwave vial. The sealed vial 
was then exposed to microwave irradiation at a controlled temperature of   
150 °C for 7 min. The obtained homogeneous solutions of the five batches 
were transferred to one round bottom flask. TBAI (13.8 g, 35.4 mmol) and allyl 
bromide (5.55 mL, 64.4 mmol) were added to the solution, which was 
protected from light and flushed with argon. After stirring for 10 days at r.t., 
the solvents were removed in vacuo and the residue was purified by column 
chromatography (SiO2, CH2Cl2/MeOH, gradient of 4-10%). The selectively    
3-O allylated product 26 (2.81 g) was obtained as a colorless oil containing  
16.6 mol-% TBAI (as judged by NMR, this corresponds to a yield of 70%) and 
was used for the next step without further purification. The NMR spectra of 
the product corresponded to those reported in the literature.217 
 
Methyl 3-O-allyl-2,4,6-tri-O-benzoyl-β-D-galactoside (27). After compound 
26 (2.05 g, 8.75 mmol) was dissolved in pyridine (45 mL) under argon, 
benzoyl chloride (6.09 mL, 52.5 mmol) was added dropwise at 0 °C. DMAP 
(53 mg, 0.44 mmol) was added and the reaction stirred for 3 h at 0 °C and 
then 2.5 days at r.t.. After the solvent was evaporated, the residue was co-
evaporated with PhMe and then dried under vacuum. Resuspension of the 
residue in EtOAc (300 mL) and washing with aqueous HCl (0.5 N, 100 mL), 
saturated aqueous NaHCO3 (100 mL) and brine (50 mL) gave the crude 
product after drying over Na2SO4 and removal of the solvent. Purification by 
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column chromatography (SiO2, petrol ether/EtOAc, 5/1) gave pure 27 (4.72 g, 
99%) as white foam. 
 
Rf (petrol ether/EtOAc, 2/1) = 0.47; 
 
The NMR spectra of the product corresponded to those reported in the 
literature.218 
 
Methyl-2,4,6-tri-O-benzoyl-β-D-galactoside (28). Compound 27 (4.57 g, 
8.36 mmol) was dissolved in dry MeOH (70 mL) and upon addition of PdCl2 
(74 mg, 0.42 mmol), the solution became a heterogeneous black mixture. 
After stirring for 19 h at 45 °C, the solvent was removed and the black residue 
was taken up in EtOAc (350 mL) and filtered through a celite plug. The EtOAc 
solution was washed with saturated aqueous sodium NaHCO3 (60 mL), 
aqueous HCl (0.5 N, 60 mL) and brine (60 mL). Drying over Na2SO4 and 
evaporation of the solvent gave the crude product as white foam (4.36 g), 
which was purified by column chromatography (SiO2, petrol ether/EtOAc, 2/1). 
Pure 28 (3.44 g, 81%) was obtained as white foam. 
 
Rf (petrol ether/EtOAc, 2/1) = 0.32; 
 
The NMR spectra of the product corresponded to those reported in the 
literature.219 
 
Methyl-2,4,6-tri-O-benzoyl-β-D-xylo-hex-3-ulopyranoside (29). Compound 
28 (2.84 g, 5.60 mmol) was dissolved in dry CH2Cl2 (50 mL) and activated 
powdered molecular sieves were added under argon. The mixture was then 
cooled to 0 °C and 1 drop glacial acetic acid was added. After stirring for      
10 min, PDC (2.32 g, 6.16 mmol) was added and the reaction was allowed to 
warm to r.t. during 3 h. After stirring for further 21 h at r.t., the reaction was 
filtered through a plug of celite, the volatiles were removed in vacuo and the 
residue was taken up in EtOAc (300 mL). The organic phase was washed 
with half saturated aqueous NaHCO3 (100 mL) and water (80 mL). The 
combined aqueous layers were extracted with CH2Cl2 (2 x 100 mL) and then, 
the combined organic layers were dried over Na2SO4, filtered and the volatiles 
were removed in vacuo. The residue was purified by column chromatography 
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(SiO2, petrol ether/EtOAc, gradient of 25-33%) to give pure 29 (2.41 g, 86%, 
its hydrate was also detected by ESI-MS, the presence of additional peaks in 
the NMR and by decreased percentage of carbon and increased percentage 
of hydrogen in the microanalysis) as white foam. 
 
Rf (petrol ether/EtOAc, 2/1) = 0.38; 
 
1H-NMR (500.1 MHz, CDCl3): δ 8.15-8.02 (m, 6H, Ar-H), 7.64-7.56 (m, 3H, Ar-
H), 7.50-7.43 (m, 6H, Ar-H), 5.75 (d, 3J = 7.7 Hz, 1H, H-2), 5.66 (d, 3J = 1.6 
Hz, 1H, H-4), 4.87 (d, 3J = 7.7 Hz, 1H, H-1), 4.77 (dd, 2J = 11.4, 3J = 6.4 Hz, 
1H, H-6a), 4.59 (dd, 2J = 11.4, 3J = 6.6 Hz, 1H, H-6b), 4.29 (td, 3J = 6.5, 3J = 
1.6 Hz, 1H, H-5), 3.65 (s, 3H, MeO-);  
 
13C-NMR (125.8 MHz, CDCl3): δ 194.6 (C-3), 165.9, 164.9, 164.8 (3C, Ar-
COOR), 134.0, 133.6, 133.4 (3C, Ar-Ci), 130.2, 130.0, 129.7, 128.7, 128.5, 
128.4 (15C, Ar-CH), 103.3 (C-1), 77.0 (C-2), 74.7 (C-4), 72.3 (C-5), 61.6 (C-
6), 57.4 (MeO); 
 
elemental analysis calcd. for C28H24O9 (504.49): C 66.66, H 4.79;  
found: C 66.16, H 4.87; 
 
ESI-MS calcd. for C28H24O9Na [M+Na]+: 527.1; found: 527.0; 
 
[α]20D = -11.1 (c 0.50, CHCl3);  
 
Methyl-3-C-allyl-2,4,6-tri-O-benzoyl-β-D-guloside (30). To a suspension of 
Zn powder (1.19 g, 18.1 mmol) in dry THF (13.2 mL) one I2 crystal was added 
under argon, followed by dropwise addition of allyl bromide (0.69 mL,        
7.97 mmol). After completion of the addition, the mixture was stirred for        
30 min at r.t.. Then, the remaining Zn was allowed to settle and a first part of 
the supernatant (4.00 mL) was added to a solution of compound 29 (1.00 g, 
1.99 mmol) in dry THF (13.2 mL) under stirring. After stirring for 1 h, a second 
fraction of Zn-allyl solution (4.00 mL) was added, and after stirring for another 
2 h, a third addition of Zn-allyl solution (4.00 mL) led to completion of the 
reaction after 4 h in total. The reaction was quenched with saturated aqueous 
NH4Cl (44.0 mL), and after stirring for 10 min, the aqueous phase was 
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extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were dried 
over Na2SO4, filtered and the volatiles were removed in vacuo. The residue 
was purified by column chromatography (SiO2, petrol ether/EtOAc, gradient of 
10-50%) to give diastereomerically pure 30 (885 mg, 81%) as white foam. A 
small sample of 30 was recrystallized from CH2Cl2/heptane by evaporation for 
X-ray analysis. 
 
Rf (petrol ether/EtOAc, 4/1) = 0.55; 
 
1H-NMR (500.1 MHz, CDCl3): δ 8.18-8.07 (m, 6H, Ar-H), 7.66-7.44 (m, 9H, Ar-
H), 5.88-5.80 (m, 1H, allyl-CH), 5.45 (d, 3J = 8.0 Hz, 1H, H-2), 5.39 (br s, 1H, 
H-4), 5.18-5.03 (m, 2H, allyl-CH2), 5.00 (d, 3J = 8.0 Hz, 1H, H-1), 4.70-4.66 
(m, 1H, H-5), 4.52 (dd, 2J = 11.4, 3J = 7.0 Hz, 1H, H-6a), 4.43 (dd, 2J = 11.4, 
3J = 5.8 Hz, 1H, H-6b), 3.55 (s, 3H, MeO-), 2.48 (dd, 2J = 14.4, 3J = 6.8 Hz, 
1H, 1H of allyl-CH2), 2.31 (dd, 2J = 14.4, 3J = 8.2 Hz, 1H, 1H of allyl-CH2);  
 
13C-NMR (125.8 MHz, CDCl3): δ 166.2, 165.6, 165.2 (3C, Ar-COOR), 133.6, 
133.3, 132.9 (3C, Ar-Ci), 130.7 (allyl-CH), 130.7-128.3 (15C, Ar-CH), 121.4 
(allyl-CH2), 100.4 (C-1), 74.2 (C-3), 73.1 (C-2), 71.6 (C-4), 70.6 (C-5), 63.4 (C-
6), 57.4 (MeO), 39.3 (allyl-CH2); 
 
ESI-MS calcd. for C31H30O9Na [M+Na]+: 569.2; found: 569.2; 
 
elemental analysis calcd. for C31H30O9 (546.57): C 68.12, H 5.53;  
found: C 68.00, H 5.60; 
 
[α]20D = +20.3 (c 0.50, CHCl3); 
 
Methyl-3-C-(E-1-methoxycarbonyl-prop-1-en-3-yl)-2,4,6-tri-O-benzoyl-β-
D-guloside (31). A round bottom flask equipped with a reflux condenser was 
charged with a solution of compound 30 (184 mg, 0.34 mmol) in dry CH2Cl2       
(4 mL). Grubbs catalyst 2nd generation (28.6 mg, 0.03 mmol) was added, 
immediately followed by addition of methyl acrylate (303 µL, 3.37 mmol). After 
heating the reaction to reflux under argon and stirring for 2 h, the volatiles 
were removed in vacuo. The residue was purified by column chromatography 
(SiO2, petrol ether/EtOAc, gradient of 20-33%) to give 31 (179 mg, 88%) as 
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white foam. 
 
Rf (petrol ether/EtOAc, 3/1) = 0.25; 
 
1H-NMR (500.1 MHz, CDCl3): δ 8.15-8.06 (m, 6H, Ar-H), 7.64-7.33 (m, 9H, Ar-
H), 6.95-6.88 (m, 1H, propenyl-H2), 5.67 (d, 3J = 15.6 Hz, 1H, propenyl-H1), 
5.44 (d, 3J = 8.0 Hz, 1H, H-2), 5.42 (br s, 1H, H-4), 4.95 (d, 3J = 8.0 Hz, 1H, 
H-1), 4.68-4.64 (m, 1H, H-5), 4.55 (dd, 2J = 11.5, 3J = 7.0 Hz, 1H, H-6a), 4.38 
(dd, 2J = 11.5, 3J = 5.8 Hz, 1H, H-6b), 3.52, 3.49 (2 s, 6H, 2 MeO-), 2.55 (dd, 
2J = 14.8, 3J = 7.1 Hz, 1H, 1H of allyl-CH2), 2.45 (dd, 2J = 14.9, 3J = 8.3 Hz, 
1H, 1H of allyl-CH2);  
 
13C-NMR (125.8 MHz, CDCl3): δ 166.1, 165.8, 165.3, 165.2 (4C, -COOR), 
140.9 (propenyl-CH), 133.8, 133.6, 133.1 (3C, Ar-Ci), 130.2-128.4 (15C, Ar-
CH), 125.3 (propenyl-CH), 100.4 (C-1), 75.0 (C-3), 73.1 (C-2), 71.7 (C-4), 
70.6 (C-5), 62.7 (C-6), 57.1, 51.4 (2C, 2 MeO), 38.6 (propenyl-CH2); 
 
HR-MS calcd. for C33H32O11Na [M+Na]+: 627.1837; found: 627.1861; 
 
elemental analysis calcd. for C33H32O11 (604.60): C 65.56, H 5.33;  
found: C 65.31, H 5.42; 
 
[α]20D = + 27.1 (c 0.50, CHCl3);  
 
Methyl 3-O-allyl-2,4,6-tri-O-benzyl-β-D-galactoside (32). Galactoside 25    
(1.80 g, 9.25 mmol) was 3-O-allylated as described above, with two 
modifications. Less TBAI (3.20 g, 8.68 mmol) was used and the allylation step 
was run at 60 °C for 3 d. The crude material was purified by column 
chromatography and gave the TBAI rich product 26. This material was 
dissolved in dry DMF (10.0 mL), cooled to 0 °C and NaH (4.44 g, 92.6 mmol,      
w = 50%) was added portionwise under argon. Benzyl bromide (6.60 mL,       
55.8 mmol) was added dropwise over 10 min at 0 °C. The reaction was 
allowed to warm slowly to r.t. and was stirred for 4 h at r.t.. Then, the reaction 
was quenched with H2O (75.0 mL) and extracted with CH2Cl2 (4 x 50 mL). 
The combined organic layers were dried over Na2SO4, filtered and the 
volatiles removed in vacuo. Purification of the residue by column 
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chromatography (SiO2, petrol ether/EtOAc, gradient of 5-50%) gave pure 32 
(3.65 g, 78%, 2 steps) as white foam. 
 
Rf (petrol ether/EtOAc, 6/1) = 0.30; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.39-7.26 (m, 15H, Ar-H), 5.97-5.90 (m, 1H, 
allyl-CH), 5.34-5.16 (m, 2H, allyl-CH2), 4.93 (A of AB, 2J = 11.7 Hz, 1H, 1H of 
PhCH2), 4.87 (A’ of A’B’, 2J = 11.0 Hz, 1H, 1H of PhCH2), 4.75 (B’ of A’B’, 2J = 
11.3 Hz, 1H, 1H of PhCH2), 4.61 (B of AB, 2J = 11.6 Hz, 1H, 1H of PhCH2), 
4.45, 4.41 (A’’, B’’ of A’’B’’, 2J = 11.7 Hz, 2H, 2H of PhCH2), 4.26 (d, 3J = 7.7 
Hz, 1H, H-1), 4.22-4.17 (m, 2H, 2H of allyl-CH2), 3.86 (d, 3J = 2.4 Hz, 1H, H-
4), 3.74 (dd, 3J = 7.7, 3J = 9.7 Hz, 1H, H-2), 3.60 (dd, 2J = 6.3, 3J = 1.9 Hz, 
1H, H-6a), 3.55-3.51 (m, 5H, H-5, H-6b, MeO), 3.42 (dd, 3J = 9.8, 3J = 2.9 Hz, 
1H, H-3);  
 
13C-NMR (125.8 MHz, CDCl3): δ 138.8, 138.6, 137.9 (3C, Ar-Ci), 134.9 (allyl-
CH), 128.4-127.5 (15C, Ar-CH), 116.6 (allyl-CH2), 104.9 (C-1), 81.7 (C-3), 
79.5 (C-2), 75.1, 74.3, 73.5 (3C, PhCH2), 73.3 (C-5), 73.2 (C-4), 71.9 (allyl-
CH2), 68.8 (C-6), 57.0 (MeO); 
 
ESI-MS calcd. for C31H36O6Na [M+Na]+: 527.2; found: 527.1; 
 
Methyl-2,4,6-tri-O-benzyl-β-D-galactoside (33). Compound 32 (3.34 g,        
6.62 mmol) was deallylated at 40 °C for 3.5 h as described for 28. Pure 32 
(2.30 g, 75%) was obtained as white foam. 
 
Rf (petrol ether/EtOAc, 3/1) = 0.20; 
 
ESI-MS calcd. for C28H32O6Na [M+Na]+: 487.2; found: 487.1; 
 
The NMR spectra of the product corresponded to those reported in the 
literature.217 
 
Methyl-2,4,6-tri-O-benzyl-β-D-xylo-hex-3-ulopyranoside (34). To a solution 
of oxalyl chloride (1.90 mL, 21.8 mmol) in dry CH2Cl2 (100 mL) at -78 °C was 
added DMSO (3.80 mL, 54.0 mmol) dropwise under strong gas evolution. 
After stirring for 10 min at -78 °C, a solution of compound 33 (2.30 g,         
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4.95 mmol) in dry CH2Cl2 (50 mL) was added dropwise. After stirring for 2 h at 
-78 °C, TEA (5.5 mL, 40.0 mmol) was added dropwise and the color of the 
reaction changed from light red to colorless. The mixture was allowed to warm 
to r.t. during 3 h and was finally poured into aqueous saturated NaHCO3   
(200 mL). The phases were separated and the aqueous layer was extracted 
with CH2Cl2 (2 x 100 mL). The combined organic layers were dried over 
Na2SO4, filtered and the volatiles removed in vacuo. The residue was purified 
by column chromatography (SiO2, petrol ether/EtOAc, gradient of 10-45%) to 
give pure 34 (1.80 g, 80%) as white foam. 
 
Rf (petrol ether/EtOAc, 2/1) = 0.40; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.40-7.14 (m, 15H, Ar-H), 4.70, 4.66 (A, B of 
AB, 2J = 11.8 Hz, 2H, 2H of PhCH2), 4.54, 4.47 (A’, B’ of A’B’, 2J = 11.9 Hz, 
2H, 2H of PhCH2), 4.41 (d, 3J = 7.6 Hz, 1H, H-1), 4.39-4.36 (m, 2H, H-2, 1H of 
PhCH2), 4.29 (B’’ of A’’B’’, 2J = 11.8 Hz, 1H, 1H of PhCH2), 3.88 (d, 3J = 1.3 
Hz, 1H, H-4), 3.76-3.70 (m, 3H, H-5, H-6a, H-6b), 3.57 (s, 3H, MeO-);  
 
13C-NMR (125.8 MHz, CDCl3): δ 204.0 (C-3), 137.8, 137.3, 136.5 (3C, Ar-Ci), 
128.5-127.7 (15C, Ar-CH), 105.1 (C-1), 82.2 (C-2), 80.8 (C-4), 73.7 (C-5), 
73.6, 73.5, 72.3 (3C, PhCH2), 67.7 (C-6), 57.3 (MeO); 
 
elemental analysis calcd. for C28H30O6 (462.54): C 72.71, H 6.54;  
found: C 72.55, H 6.63; 
 
HR-MS calcd. for C28H30O6Na [M+Na]+: 485.1940; found: 485.1938; 
 
[α]20D = -82.5 (c 2.50, CHCl3);  
 
Methyl-3-C-(E-1-methoxycarbonyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-
guloside (gulo-36) and methyl-3-C-(E-1-methoxycarbonyl-prop-1-en-3-
yl)-2,4,6-tri-O-benzyl-β-D-galactoside (galacto-36). Ketone 34 (213 mg,            
0.46 mmol) was allylated using the Zn-allyl method as described for 30. 
 
HR-MS calcd. for C31H36O6Na [M+Na]+: 527.2410; found: 527.2422; 
 
The crude product was directly used in the subsequent olefin metathesis as 
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described for 31. Purification by column chromatography (SiO2, petrol 
ether/EtOAc, gradient of 20-33%) gave the inseparable title compounds 36 
(233 mg, 90%, 2 steps, d.r. 4.3:1) as white foam. 
 
Rf (petrol ether/EtOAc, 2/1) = 0.40; 
 
HR-MS calcd. for C33H38O8Na [M+Na]+: 585.2464; found: 585.2465; 
 
Methyl-3-C-(E-1-methoxycarbonyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-
guloside (gulo-36): 
1H-NMR (500.1 MHz, CDCl3): δ 7.29-7.11 (m, 15H, Ar-H), 7.04-6.92 (m, 1H, 
propenyl-H2), 4.85 (A of AB, 2J = 11.1 Hz, 1H, PhCH2), 4.62-4.38 (m, 6H, H-
1, 5H of PhCH2), 4.16 (t, 3J = 6.9 Hz, 1H, H-5), 3.63-3.33 (m, 6H, H-4, H-6a,b, 
MeO), 3.27 (d, 3J = 7.7 Hz, 1H, H-2), 2.55 (dd, 2J = 15.3, 3J = 6.1 Hz, 1H, 
propenyl-CH2a), 2.41 (dd, 2J = 15.3 Hz, 3J = 8.3 Hz, 1H, propenyl-CH2b); 
 
13C-NMR (125.8 MHz, CDCl3): δ 166.3 (COOR), 144.7 (propenyl-CH), 138.4, 
137.8, 137.5 (3C, Ar-Ci), 128.3-127.4 (15C, Ar-CH), 123.5 (propenyl-CH), 
103.0 (C-1), 78.6 (C-2), 77.3 (C-4), 76.3 (C-3), 74.8, 74.7, 73.3 (3C, PhCH2), 
71.7 (C-5), 68.3 (C-6), 56.9, 51.4 (2C, OMe), 37.8 (propenyl-C3); 
 
Methyl-3-C-(E-1-methoxycarbonyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-
galactoside (galacto-36): 
1H-NMR (500.1 MHz, CDCl3): δ 7.29-7.11 (m, 15H, Ar-H), 7.04-6.92 (m, 1H, 
propenyl-H2), 4.75 (A of AB, 2J = 11.5 Hz, 1H, PhCH2), 4.62-4.38 (m, 5H, 5H 
of PhCH2), 4.27 (d, 3J = 7.8 Hz, 1H, H-1), 3.71 (t, 3J = 6.4 Hz, 1H, H-5), 3.63-
3.33 (m, 7H, H-2, H-4, H-6a,b, MeO), 2.83 (dd, 2J = 15.3, 3J = 4.9 Hz, 1H, 
propenyl-CH2a), 2.22 (dd, 2J = 15.4, 3J = 9.5 Hz, 1H, propenyl-CH2b); 
 
13C-NMR (125.8 MHz, CDCl3): δ 166.3 (COOR), 144.4 (propenyl-CH), 138.4, 
137.8, 137.5 (3C, Ar-Ci), 128.3-127.4 (15C, Ar-CH), 123.6 (propenyl-CH), 
103.0 (C-1), 81.9 (C-2), 78.0 (C-4), 75.7 (C-3), 75.5, 75.1, 73.3 (3C, PhCH2), 
71.6 (C-5), 68.6 (C-6), 56.9, 51.4 (2C, OMe), 34.7 (propenyl-C3); 
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Methyl-3-C-(E-1-hydroxymethyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-
guloside (gulo-37) and Methyl-3-C-(E-1-hydroxymethyl-prop-1-en-3-yl)-
2,4,6-tri-O-benzyl-β-D-galactoside (galacto-37). A solution of compound 36 
(209 mg, 0.37 mmol) in PhMe (20 mL) was cooled to -78 °C under argon and 
subsequently treated dropwise with DIBAl-H in cyclohexane (2.00 mL,         
2.0 mmol, 1 M). After 1 h at -78 °C, saturated aqueous NH4Cl (1 mL) was 
added dropwise. Then, the mixture was diluted with CH2Cl2, dried (Na2SO4), 
filtered and concentrated. Purification of the residue by column 
chromatography (SiO2, petrol ether/EtOAc, gradient of 10-30%) gave the 
diastereomeric mixture of allylic alcohols 37 (166 mg, 84%, d.r. approx. 5:1, 
gulo:galacto). 
 
Methyl-3-C-(E-1-hydroxymethyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-
guloside (gulo-37): 
1H-NMR (500.1 MHz, CDCl3): δ 7.33-7.14 (m, 15H, Ar-H), 5.64-5.48 (m, 2H, 
propenyl-CH), 4.89 (A of AB, 2J = 11.0 Hz, 1H, PhCH2), 4.57-4.46 (m, 6H, H-
1, 5H of PhCH2), 4.31 (t, 3J = 6.9 Hz, 1H, H-5), 3.92 (d, 3J = 5.6 Hz, 2H, 
CH2OH), 3.61-3.55 (m, 2H, H-6a,b), 3.48 (s, 3H, OMe), 3.42 (s, 1H, H-4), 3.28 
(d, 3J = 7.8 Hz, 1H, H-2), 2.48 (dd, 2J = 14.6, 3J = 6.2 Hz, 1H, propenyl-CH2a), 
2.34 (dd, 2J = 14.7, 3J = 7.4 Hz, 1H, propenyl-CH2b); 
 
13C-NMR (125.8 MHz, CDCl3): δ 138.4, 138.3, 138.0 (3C, Ar-Ci), 133.1, 
(propenyl-CH), 128.5, 128.5, 128.4, 128.3, 128.0, 127.6, 127.1 (16C, 15 Ar-
CH, 1 propenyl-CH), 103.3 (C-1), 79.2 (C-2), 77.3 (C-4), 76.2 (C-3), 75.0, 
74.8, 73.5 (3 PhCH2), 72.0 (C-5), 68.7 (C-6), 63.4 (CH2OH), 57.1 (OMe), 37.6 
(propenyl-CH2); 
 
Methyl-3-C-(E-1-hydroxymethyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-
galactoside (galacto-37): 
1H-NMR (500.1 MHz, CDCl3): δ 7.33-7.14 (m, 15H, Ar-H), 5.72-5.55 (m, 2H, 
propenyl-CH), 4.77, 4.62 (A,B of AB, 2J = 11.5 Hz, 2H, PhCH2), 4.57-4.46 (m, 
4H, 4H of PhCH2), 4.31 (d, 3J = 7.9 Hz, 1H, H-1), 3.99 (d, 3J = 5.6 Hz, 2H, 
CH2OH), 3.75 (t, 3J = 6.6 Hz, 1H, H-5), 3.61-3.55 (m, 3H, H-4, H-6a,b), 3.46 
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(s, 3H, OMe), 3.41 (d, 3J = 7.7 Hz, 1H, H-2), 2.70 (dd, 2J = 15.2, 3J = 3.5 Hz, 
1H, propenyl-CH2a), 2.11 (dd, 2J = 15.1, 3J = 9.0 Hz, 1H, propenyl-CH2b); 
 
13C-NMR (125.8 MHz, CDCl3): δ 138.9, 138.0, 137.9 (3C, Ar-Ci), 133.0 
(propenyl-CH), 128.6, 128.3, 128.0, 127.9, 127.6, 127.1 (16C, 15 Ar-CH, 1 
propenyl-CH), 103.4 (C-1), 82.5 (C-2), 78.0 (C-4), 75.9 (C-3), 75.5, 75.3, 75.0 
(3C, PhCH2), 71.7 (C-5), 69.0 (C-6), 63.5 (CH2OH), 57.1 (OMe), 37.6 
(propenyl-CH2); 
 
ESI-MS calcd. for C32H38O7Na [M+Na]+: 557.3; found: 557.4; 
 
Methyl-3-C-(trans-1-hydroxy-2S,3S-epoxy-but-4-yl)-2,4,6-tri-O-benzyl-β-
D-guloside (38). A mixture of freshly activated molecular sieves (45 mg, 4Å, 
powder) and dry CH2Cl2 (0.8 mL) was cooled to -20 °C under argon. (-)-DET 
(4.0 µL, 23.5 µmol) and Ti(OiPr)4 (5.8 µL, 19.5 µmol) were added and the 
mixture was stirred for 25 min. Then, a solution of compound 37 (20.9 mg, 
38.1 µmol) in dry CH2Cl2 (0.4 mL) was added and the mixture was stirred for 
additional 30 min. Then, tBuOOH in decane (13.6 µL, 78.2 µmol, 5.5 M) was 
added dropwise at -20 °C and the mixture was allowed to warm to 0 °C during 
2 h. The mixture was quenched with H2O (40 µL) and after 30 min aqeous 
NaOH (10 µL, w = 30%) was added. After stirring for further 30 min at 0 °C, 
brine was added (5 mL), the phases were separated and the aqueous layer 
was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were 
dried over Na2SO4, filtered and the volatiles were removed in vacuo. The 
residue was purified by column chromatography (SiO2, petrol ether/Et2O, 
gradient of 50-100%) to give the pure gulo-38 (18.2 mg, 85%) compound as 
white foam. 
 
1H-NMR (500.1 MHz, CD2Cl2): δ 7.30-7.15 (m, 15H, Ar-H), 4.83 (A of AB, 2J = 
11.0 Hz, 1H, PhCH2), 4.57 (A’ of A’B’, 2J = 11.4 Hz, 1H, PhCH2), 4.53 (d, 3J = 
7.8 Hz, 1H, H-1), 4.51-4.43 (m, 4H, PhCH2), 4.18 (t, 3J = 6.9 Hz, 1H, H-5), 
3.62-3.55 (m, 4H, H-4, H-6a,b, 1H of CH2OH), 3.42 (s, 3H, OMe), 3.35-3.30 
(m, 1H, 1H of CH2OH), 3.14 (d, 3J = 7.7 Hz, 1H, H-2), 2.78 (ddd, 3J = 2.4, 3J = 
3.7, 3J = 7.3 Hz, 1H, butyl-H3), 2.72 (s, 1H, OH), 2.67 (dt, 3J = 2.6, 3J = 4.9 
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Hz, 1H, butyl-H2), 1.89 (dd, 2J = 15.4, 3J = 4.3 Hz, 1H, butyl-H4a), 1.76 (dd, 2J 
= 14.9, 3J = 7.5 Hz, 1H, butyl-H4b); 
 
13C-NMR (125.8 MHz, CD2Cl2): δ 139.0, 138.7, 138.6 (3C, Ar-Ci), 128.9, 
128.8, 128.7, 128.5, 128.4, 128.3, 128.2 (15C, Ar-CH), 103.6 (C-1), 79.4 (C-
2), 78.0 (C-4), 76.5 (C-3), 75.3, 75.3, 73.9 (3C, PhCH2), 72.0 (C-5), 69.1 (C-
6), 62.2 (CH2OH), 58.2 (butyl-C2), 57.1 (OMe), 52.4 (butyl-C3), 36.6 (butyl-
C4); 
 
ESI-MS calcd. for C32H38O8Na [M+Na]+: 573.2; found: 573.2; 
 
Annulated tetrahydrofuranyl guloside 41. A solution of 38 (44.4 mg,      
80.6 µmol) in CH2Cl2 (3 mL) was treated with CSA (5 mg) at r.t.. After 12 h at 
r.t. the solution was quenched with Et3N (10 µL) and concentrated. The 
residue was eluted from a column of silica gel (petrol ether/Et2O, 10-100%) to 
give pure 41 (10.4 mg, 23%). 
 
Rf (petrol ether/Et2O, 1/9) = 0.31; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.32-7.17 (m, 15H, Ar-H), 4.79 (d, 3J = 7.9 Hz, 
1H, H-1), 4.56-4.38 (m, 6H, PhCH2), 4.27 (t, 3J = 6.7 Hz, 1H, H-5), 4.17 (d, 3J 
= 7.4 Hz, 1H, H-α), 4.01 (d, 3J = 9.7 Hz, 1H, H-β), 3.70 (d, 3J = 0.8 Hz, 1H, H-
4), 3.60 (d, 3J = 6.9 Hz, 2H, H-6a,b), 3.47 (s, 3H, OMe), 3.41-3.39 (m, 2H, H-
2, 1H of CH2OH), 3.21 (‘t’, 3J = 2J = 9.2 Hz, 1H, 1H of CH2OH), 2.87 (s, 1H, 
OH), 2.15 (dd, 2J = 12.7, 3J = 10.4 Hz, 1H, H-γa), 1.70 (dd, 2J = 12.8, 3J = 2.7 
Hz, 1H, H-γb); 
 
13C-NMR (125.8 MHz, CDCl3): δ 138.4, 138.1, 137.5 (3C, Ar-Ci), 128.8, 128.6, 
128.5, 128.0, 127.9 (15C, Ar-CH), 101.3 (C-1), 79.5 (C-2), 77.69 (C-4), 77.68 
(C-3), 77.6 (C-β), 75.0 (PhCH2), 73.8 (C-5), 73.7, 73.6 (2C, PhCH2), 71.3 
(CH2OH), 71.1 (C-α), 69.1 (C-6), 56.7 (OMe), 33.7 (C-γ); 
 
ESI-MS calcd. for C32H38O8Na [M+Na]+: 573.2; found: 573.1; 
 
Bis-dinitrobenzoyl annulated tetrahydrofuranyl guloside 42. Compound 
41 (10.4 mg, 18.9 µmol) was dissolved in dry CH2Cl2 (0.6 mL) under argon. 
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3,5-Dinitrobenzoyl chloride (19.2 mg, 83 µmol) and DMAP (10.2 mg, 83 µmol) 
was added at r.t.. After stirring for 4 h, the reaction was concentrated and the 
residue was purified by column chromatography (SiO2, petrol ether/Et2O, 
gradient of 20-100%) to give 42 (10.5 mg, 59%) as white foam. 
 
Rf (petrol ether/Et2O, 3:7) = 0.60; 
 
1H-NMR (500.1 MHz, CDCl3): δ 9.17, 9.14, 8.99, 8.93 (4 s, 6H, Ar-H), 7.33-
6.99 (m, 15H, Ar-H), 5.15-5.10 (m, 1H, H-α), 4.95 (d, 3J = 8.0 Hz, 1H, H-1), 
4.62, 4.55 (A, B of AB, 2J = 11.5 Hz, 2H, PhCH2), 4.56 (s, 1H, H-4), 4.39-4.30 
(m, 5H, H-β, 4H of PhCH2), 3.89-3.86 (m, 2H, H-2, 1H of CH2OBz), 3.84-3.80 
(m, 1H, H-5), 3.68-3.63 (m, 1H, 1H of CH2OBz), 3.59 (s, 3H, OMe), 3.56-3.41 
(m, 2H, H-6a,b), 2.56 (d, 3J = 13.7, 1H, H-γa), 2.50-2.45 (m, 1H, H-γb); 
 
13C-NMR (125.8 MHz, CDCl3): δ 162.3, 161.4 (2C, COOR), 148.9, 148.8, 
137.7, 137.5, 137.0, 134.2, 133.3 (9C, Ar-Ci), 129.9-127.6 (19C, Ar-CH), 
123.1, 122.9 (2C, Ar-CH), 100.0 (C-1), 89.1 (C-3), 80.1 (C-2), 76.0 (C-α), 75.6 
(PhCH2), 75.5 (C-β), 74.0 (PhCH2), 73.6, 73.5 (2C, C-4, C-5), 73.4 (PhCH2), 
69.0 (CH2OBz), 68.7 (C-6), 56.9 (OMe), 32.2 (C-γ); 
 
HR-MS calcd. for C46H42N4O18Na [M+Na]+: 961.2392; found: 961.2389. 
 
[α]20D = +10.1 (c 0.50, CHCl3);  
 
Methyl 3-C-propyl-β-D-guloside (43). Compound 30 (55.0 mg, 0.10 mmol) 
was dissolved in dry MeOH (2 mL) under argon. NaOMe in MeOH (0.5 M,   
0.5 mL) was added and the reaction was stirred over night at r.t.. After 
neutralization with Dowex-H+, the mixture was filtered and the volatiles were 
removed in vacuo. The residue was taken up in dry MeOH (10 mL) and Pd/C 
(35 mg, w = 10%) was added. The reaction was vigorously stirred in a H2 
atmosphere (1 atm) over night. The mixture was then filtered through a celite 
plug, and the volatiles were removed in vacuo. The crude product was 
purified by preparative HPLC (C18, H2O/MeCN 5-95%) to give pure 43    
(14.2 mg, 60%, 2 steps) as colorless oil. 
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1H-NMR (500.1 MHz, CD3OD): δ 4.44 (d, 3J = 7.9 Hz, 1H, H-1), 3.96-3.94 (m, 
1H, H-5), 3.72 (dd, 2J = 11.4, 3J = 6.8 Hz, 1H, H-6a), 3.67 (dd, 2J = 11.4, 3J = 
5.2 Hz, 1H, H-6b), 3.52 (s, 1H, H-4), 3.51 (s, 3H, MeO), 3.30 (d, 3J = 7.9 Hz, 
1H, H-2), 1.77-1.71 (m, 1H, propyl-H1a), 1.67-1.61 (m, 1H, propyl-H1b), 1.48-
1.39 (m, 2H, propyl-H2), 0.94 (t, 3J = 7.3 Hz, 3H, propyl-H3); 
 
13C-NMR (125.8 MHz, CD3OD): δ 104.5 (C-1), 76.5 (C-3), 75.6 (C-5), 73.5 (C-
2), 70.8 (C-4), 63.3 (C-6), 57.2 (MeO), 37.8 (propyl-C1), 16.2 (propyl-C2), 
15.2 (propyl-C3); 
 
ESI-MS calcd. for C10H20O6Na [M+Na]+: 259.1; found: 259.0; 
 
[α]20D = -27.9 (c 0.71, MeOH);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-O-allyl-
6-O-benzyl-β-D-galactopyranoside (45). A suspension of trisaccharide 
mimetic 44190 (1.30 g, 1.66 mmol) and dibutyltin oxide (435 mg, 1.82 mmol) in 
MeCN/PhMe (13 mL, 1:5) were heated to 150 °C under microwave irradiation 
under argon for 7 min. TBAI (611 mg, 1.66 mmol) and allyl bromide (717 µL, 
8.28 mmol) were added to the clear solution, and the mixture was stirred at    
75 °C for 12 h under argon and protected from daylight. After removal of the 
solvents, the residue was purified by column chromatography (SiO2, petrol 
ether/EtOAc, gradient of 10-100%) to give pure 45 (876 mg, 64%) as white 
foam. 
 
Rf (petrol ether/EtOAc, 1/2) = 0.75; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.31-7.15 (m, 20 H, Ar-H), 5.92-5.83 (m, 1H, 
allyl-CH), 5.27-5.22 (m, 1H, 1H of allyl-CH2), 5.16-5.13 (m, 1H, 1H of allyl-
CH2), 4.88-4.85 (m, 2H, Fuc-H1, 1H of PhCH2), 4.74 (A of AB, 2J = 11.6 Hz, 
1H, 1H of PhCH2), 4.67 (A’ of A’B’, 2J = 12.0 Hz, 1H, 1H of PhCH2), 4.62-4.58 
(m, 2H, 2H of PhCH2), 4.53 (B’’ of A’’B’’, 2J = 11.6 Hz, 1H, 1H of PhCH2), 4.42 
(br s, 2H, 2H of PhCH2), 4.34 (q, 3J = 6.3 Hz, 1H, Fuc-H5), 4.25 (d, 3J = 7.7 
Hz, 1H, Gal-H1), 4.15-4.12 (m, 2H, 2H of allyl-CH2), 3.97 (br s, 1H, Gal-H4), 
3.94 (dd, 3J = 3.2, 3J = 10.2 Hz, 1H, Fuc-H2), 3.90 (dd, 3J = 2.3, 3J = 10.1 Hz, 
1H, Fuc-H3), 3.73-3.66 (m, 2H, 1H of Cy-CH, Gal-H6a), 3.62-3.57 (m, 3H, 
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Fuc-H4, Gal-H2, -H6b), 3.53-3.49 (m, 1H, 1H of Cy-CH), 3.48-3.45 (m, 1H, 
Gal-H5), 3.28 (dd, 3J = 3.2, 3J = 9.4 Hz, 1H, Gal-H3), 2.46, 2.30 (2 br s, 2H, 2 
OH), 1.99-1.88 (m, 2H, Cy-CH2), 1.63-1.56 (m, 2H, Cy-CH2), 1.36-1.10 (m, 
4H, Cy-CH2), 1.01 (d, 3J = 6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.1, 138.9, 138.7, 137.8 (4C, Ar-Ci), 134.4 
(allyl-CH), 128.3-127.2 (20C, Ar-CH), 117.7 (allyl-CH2), 100.5 (Gal-C1), 94.6 
(Fuc-C1), 79.9 (Gal-C3), 79.6 (Fuc-C3), 78.1 (Fuc-C4), 77.5 (Cy-CH), 76.3 
(Fuc-C2), 75.9 (Cy-CH), 74.8, 73.6 (2C, PhCH2), 73.0 (Gal-C5), 72.92, 72.87 
(2C, PhCH2), 71.0 (allyl-CH2), 70.6 (Gal-C2), 68.8 (Gal-C6), 66.1 (Gal-C4), 
66.1 (Fuc-C5), 29.9, 29.1, 23.2 (4C, Cy-CH2), 16.6 (Fuc-C6);  
 
HR-MS calcd. for C49H60O11Na [M+Na]+: 847.4033; found: 847.4039; 
 
[α]20D = -42.7 (c 0.76, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-O-allyl-
2,4,6-tri-O-benzyl-β-D-galactopyranoside (46). Compound 45 (4.40 g,   
5.34 mmol) was dissolved in dry DMF (75 mL) and NaH (1.00 g, 21.3 mmol,  
w = 50%) was added in three portions under argon at r.t.. The suspension 
was stirred for 2 min and then BnBr (2.52 mL, 21.3 mmol) was added 
dropwise while keeping the temperature at r.t. with a water bath. After stirring 
for 7 h, the reaction was quenched with aqueous NaHCO3 and extracted with 
CH2Cl2 (2 x 200 mL). The combined organic layers were dried over Na2SO4 
and evaporated to dryness. The residue was purified by column 
chromatography (SiO2, petrol ether/EtOAc, gradient of 0-40%) to give pure 46 
as white foam (4.84 g, 90%). 
 
Rf (petrol ether/EtOAc, 3/1) = 0.60; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.33-7.10 (m, 30 H, Ar-H), 5.91-5.83 (m, 1H, 
allyl-CH), 5.29-5.23 (m, 1H, 1H of allyl-CH2), 5.12-5.08 (m, 1H, 1H of allyl-
CH2), 4.86-4.82 (m, 2H, 2H of PhCH2), 4.77 (br s, 1H, Fuc-H1), 4.67-4.48 (m, 
7H, Fuc-H5, 6H of PhCH2), 4.42 (A of AB, 2J = 10.9 Hz, 1H, PhCH2), 4.35-
4.26 (m, 3H, Gal-H1, 2H of PhCH2), 4.16-4.11 (m, 3H, 2H of allyl-CH2, 1H of 
PhCH2), 3.85 (br s, 3H, Fuc-H2, -H3, Gal-H4), 3.63-3.47 (m, 5H, 2H of Cy-
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CH, Gal-H2, -H6a, -H6b), 3.44-3.39 (m, 1H, Gal-H5), 3.34 (dd, 3J = 2.1, 3J = 
9.6 Hz, 1H, Gal-H3), 3.26 (br s, 1H, Fuc-H4), 2.01-1.88 (m, 2H, Cy-CH2), 
1.64-1.57 (m, 2H, Cy-CH2), 1.33-1.09 (m, 4H, Cy-CH2), 0.99 (d, 3J = 6.3 Hz, 
3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.5, 139.4, 139.2, 139.0, 138.1 (6C, Ar-Ci), 
135.3 (allyl-CH), 128.7-127.4 (30C, Ar-CH), 116.6 (allyl-CH2), 101.3 (Gal-C1), 
94.7 (Fuc-C1), 82.2 (Gal-C3), 80.1 (2C, Fuc-C3, Gal-C2), 78.9 (Fuc-C4), 78.2 
(Cy-CH), 76.3 (Fuc-C2), 75.9 (Cy-CH), 75.5, 75.2 (3C, PhCH2), 74.1 (Gal-C4), 
73.7, 73.1, 72.8 (3C, PhCH2), 72.7 (Gal-C5), 72.1 (allyl-CH2), 68.5 (Gal-C6), 
66.1 (Fuc-C5), 30.3, 29.5, 23.6 (4C, Cy-CH2), 16.6 (Fuc-C6);  
 
HR-MS calcd. for C63H72O11Na [M+Na]+: 1027.4972; found: 1027.4999; 
 
[α]20D = -58.8 (c 1.05, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 2,4,6-tri-O-
benzyl-β-D-galactopyranoside (47). Compound 46 (4.84 g, 4.81 mmol) was 
dissolved in dry MeOH (100 mL) and PdCl2 (85.0 mg, 0.48 mmol) was added. 
The suspension was stirred at 50 °C under argon for 105 min. The volatiles 
were removed in vacuo and the residue was purified by column 
chromatography (SiO2, petrol ether/EtOAc, gradient of 5-50%) to give pure 47 
(4.38 g, 94%) as white foam. 
 
Rf (petrol ether/EtOAc, 2/1) = 0.45;  
 
1H-NMR (500.1 MHz, CDCl3): δ 7.31-7.12 (m, 30 H, Ar-H), 4.96 (A of AB, 2J = 
11.2 Hz, 1H, 1H of PhCH2), 4.78 (d, 3J = 2.8 Hz, 1H, Fuc-H1), 4.76 (A’ of A’B’, 
2J = 11.1 Hz, 1H, 1H of PhCH2), 4.70-4.66 (m, 3H, 3H of PhCH2), 4.58 (B’’ of 
A’’B’’, 2J = 12.1 Hz, 1H, 1H of PhCH2), 4.55-4.51 (m, 4H, Fuc-H5, 3H of 
PhCH2), 4.45 (B’ of A’B’, 2J = 11.1 Hz, 1H, 1H of PhCH2), 4.37-4.34 (m, 2H, 
Gal-H1, 1H of PhCH2), 4.28 (B’’’ of A’’’B’’’, 2J = 11.9 Hz, 1H, 1H of PhCH2), 
4.22 (B’’’’ of A’’’’B’’’’, 2J = 11.5 Hz, 1H, 1H of PhCH2), 3.87-3.85 (m, 3H, Fuc-
H2, -H3, Gal-H4), 3.66-3.62 (m, 1H, Cy-CH), 3.61-3.56 (m, 2H, Gal-H3, -
H6a), 3.55-3.48 (m, 3H, Gal-H5, -H6b, Cy-CH), 3.42 (dd, 3J = 7.6, 3J = 9.6 Hz, 
1H, Gal-H2), 3.33 (br s, 1H, Fuc-H4), 2.23 (br s, 1H, OH), 2.03-1.87 (m, 2H, 
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Cy-CH2), 1.65-1.56 (m, 2H, Cy-CH2), 1.33-1.11 (m, 4H, Cy-CH2), 1.01 (d, 3J = 
6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.2, 138.9, 138.5, 137.9 (6C, Ar-Ci), 128.5-
127.2 (30C, Ar-CH), 101.7 (Gal-C1), 94.8 (Fuc-C1), 80.1 (Gal-C2), 79.9 (Fuc-
C3), 78.7 (Fuc-C4), 78.1 (Cy-CH), 76.2 (Fuc-C2), 75.6 (Cy-CH), 75.5 (Gal-
C4), 75.3, 75.0, 74.8 (3C, PhCH2), 74.2 (Gal-C3), 73.4, 72.9 (2C, PhCH2), 
72.8 (Gal-C5), 72.7 (PhCH2), 68.2 (Gal-C6), 65.9 (Fuc-C5), 30.0, 29.3, 23.3 
(4C, Cy-CH2), 16.7 (Fuc-C6);  
 
HR-MS calcd. for C60H68O11Na [M+Na]+: 987.4659; found: 987.4696; 
 
[α]20D = -51.8 (c 1.00, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 2,4,6-tri-O-
benzyl-β-D-xylo-hex-3-ulopyranoside (48). To a solution of oxalyl chloride 
(1.66 mL, 19.3 mmol) in dry CH2Cl2 (100 mL) at -78 °C was added DMSO 
(3.42 mL, 48.2 mmol) dropwise under strong gas evolution. After stirring for 
10 min at -78 °C, a solution of compound 47 (4.65 g, 4.81 mmol) in dry 
CH2Cl2 (100 mL) was added dropwise. After stirring for 2.5 h at -78 °C, NEt3 
(4.74 mL, 33.7 mmol) was added dropwise and the color of the reaction 
changed from light yellow to colorless. The mixture was stirred another 75 min 
at -78 °C, was then allowed to warm to r.t. during 6 h and finally poured into 
aqueous saturated NaHCO3 (200 mL). The phases were separated and the 
aqueous layer was extracted with CH2Cl2 (3 x 150 mL). The combined organic 
layers were dried over Na2SO4, filtered and the volatiles removed in vacuo. 
The residue was purified by column chromatography (SiO2, petrol 
ether/EtOAc, gradient of 10-100%) to give pure 48 (4.10 g, 88%) as white 
foam. 
 
Rf (petrol ether/EtOAc, 3/1) = 0.40;  
 
1H-NMR (500.1 MHz, CDCl3): δ 7.33-6.97 (m, 30 H, Ar-H), 4.81 (d, 3J = 3.3 
Hz, 1H, Fuc-H1), 4.74-4.54 (m, 8H, 8H of PhCH2), 4.50 (d, 3J = 7.5 Hz, 1H, 
Gal-H1), 4.42 (q, 3J = 6.2 Hz, 1H, Fuc-H5), 4.37 (A of AB, 2J = 12.0 Hz, 1H, 
1H of PhCH2), 4.28, 4.26 (A’, B’ of A’B’, 2J = 12.6 Hz, 2H, 2H of PhCH2), 4.21 
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(A’’ of A’’B’’, 2J = 11.2 Hz, 1H, 1H of PhCH2), 4.17-4.15 (m, 2H, Gal-H1, 1H of 
PhCH2), 3.89 (dd, 3J = 3.4, 3J = 10.1 Hz, 1H, Fuc-H2), 3.87-3.84 (m, 2H, Fuc-
H3, Gal-H4), 3.68-3.63 (m, 2H, Gal-H6a, Cy-CH), 3.61-3.59 (m, 1H, Gal-H6b), 
3.56-3.52 (m, 2H, Gal-H5, Cy-CH), 3.34 (br s, 1H, Fuc-H4), 1.96-1.87 (m, 2H, 
Cy-CH2), 1.65-1.57 (m, 2H, Cy-CH2), 1.33-1.10 (m, 4H, Cy-CH2), 0.85 (d, 3J = 
6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 204.2 (Gal-C3), 139.1, 139.0, 138.9, 137.7, 
137.4, 136.7 (6C, Ar-Ci), 128.4-127.1 (30C, Ar-CH), 102.3 (Gal-C1), 94.5 
(Fuc-C1), 82.4 (Gal-C2), 81.0 (Gal-C4), 79.8 (Fuc-C3), 79.0 (Cy-CH), 78.3 
(Fuc-C4), 76.2 (Fuc-C2), 75.4 (Cy-CH), 74.9, 73.7, 73.3 (3C, PhCH2), 73.0 
(Gal-C5), 72.9, 72.8, 72.4 (3C, PhCH2), 67.0 (Gal-C6), 65.9 (Fuc-C5), 29.7, 
28.9, 23.1 (4C, Cy-CH2), 16.4 (Fuc-C6);  
 
HR-MS calcd. for C60H66O11Na [M+Na]+: 985.4503; found: 985.4539; 
 
[α]20D = -47.5 (c 0.15, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-C-allyl-
2,4,6-tri-O-benzyl-β-D-gulopyranoside (gulo-49) and (1R,2R)-2-O-(2,3,4-
tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-C-allyl-2,4,6-tri-O-benzyl-β-
D-galactopyranoside (galacto-49). A round bottom flask equipped with a 
reflux condenser was charged with Mg powder (3.84 g, 160 mmol), dry Et2O 
(100 mL) and cat. I2 under argon. Allyl bromide (13.8 mL, 160 mmol) was 
added dropwise. After half of the allyl bromide was added, the reaction started 
and the remaining bromide was added dropwise to keep the reaction 
refluxing. Finally, the mixture was heated to reflux for 20 min. After cooling to 
0 °C, a solution of compound 48 (3.85 g, 4.00 mmol) in dry Et2O (100 mL) 
was added dropwise and the resulting suspension was stirred for 3.5 h. Then, 
the suspension was quenched with ice and saturated aqueous NH4Cl          
(200 mL). The phases were separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 150 mL). The combined organic layers were dried over 
Na2SO4, filtered and the volatiles were removed in vacuo. The residue was 
purified by column chromatography (SiO2, petrol ether/Et2O, gradient of 10-
80%) to give first galacto-49 (1.43 g, 36%) as white foam and second gulo-
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49 (1.63 g, 41%). 
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-C-allyl-2,4,6-
tri-O-benzyl-β-D-galactopyranoside (galacto-49): 
 
Rf (petrol ether/Et2O, 2/1) = 0.48;  
 
1H-NMR (500.1 MHz, CDCl3): δ 7.32-7.14 (m, 30 H, Ar-H), 5.90-5.81 (m, 1H, 
allyl-CH), 5.09-5.01 (m, 2H, allyl-CH2), 4.86 (A of AB, 2J = 11.5 Hz, 1H, 1H of 
PhCH2), 4.80 (d, 3J = 2.9 Hz, 1H, Fuc-H1), 4.75-4.65 (m, 3H, 3H of PhCH2), 
4.61-4.54 (m, 4H, 4H of PhCH2), 4.52 (q, 3J = 6.6 Hz, 1H, Fuc-H5), 4.46 (d, 3J 
= 7.9 Hz, 1H, Gal-H1), 4.45-4.39 (m, 2H, 2H of PhCH2), 4.32-4.27 (m, 2H, 2H 
of PhCH2), 3.91-3.85 (m, 2H, Fuc-H2, -H3), 3.73-3.70 (m, 1H, Gal-H5), 3.63 
(br s, 1H, Gal-H4), 3.62-3.47 (m, 4H, Gal-H6a, -H6b, 2H of Cy-CH), 3.37 (d, 
3J = 8.1 Hz, 1H, Gal-H2), 3.35 (br s, 1H, Fuc-H4), 2.73 (dd, 2J = 15.0, 3J = 5.0 
Hz, 1H, 1H of allyl-CH2), 2.26 (br s, 1H, OH), 2.13 (dd, 2J = 15.1, 3J = 9.3 Hz, 
1H, 1H of allyl-CH2), 1.98-1.87 (m, 2H, Cy-CH2), 1.63-1.55 (m, 2H, Cy-CH2), 
1.34-1.08 (m, 4H, Cy-CH2), 1.00 (d, 3J = 6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.2, 139.0, 138.9, 138.4, 138.0 (6C, Ar-Ci), 
133.3 (allyl-CH), 128.5-127.2 (30C, Ar-CH), 118.4 (allyl-CH2), 99.8 (Gal-C1), 
94.6 (Fuc-C1), 82.8 (Gal-C2), 79.9 (Fuc-C3), 78.7 (Fuc-C4), 78.3 (Cy-CH), 
78.0 (Gal-C4), 76.3 (Fuc-C2), 76.0 (Gal-C3), 75.7 (PhCH2), 75.7 (Cy-CH), 
75.4, 75.0, 73.2, 73.0, 72.8 (5C, PhCH2), 70.9 (Gal-C5), 68.5 (Gal-C6), 65.9 
(Fuc-C5), 36.6 (allyl-CH2), 30.0, 29.2, 23.3 (4C, Cy-CH2), 16.7 (Fuc-C6);  
 
HR-MS calcd. for C63H72O11Na [M+Na]+: 1027.4972; found: 1027.4977; 
 
[α]20D = -41.4 (c 0.48, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-C-allyl-2,4,6-
tri-O-benzyl-β-D-gulopyranoside (gulo-49): 
 
Rf (petrol ether/Et2O, 2/1) = 0.37; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.30-7.12 (m, 30 H, Ar-H), 5.92-5.84 (m, 1H, 
allyl-CH), 5.07-4.96 (m, 3H, 2H of allyl-CH2, 1H of PhCH2), 4.77 (br s, 1H, 
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Fuc-H1), 4.70 (d, 3J = 7.7 Hz, 1H, Gul-H1), 4.67-4.56 (m, 6H, Fuc-H5, 5H of 
PhCH2), 4.49-4.41 (m, 4H, 4H of PhCH2), 4.33 (A of AB, 2J = 12.0 Hz, 1H, 1H 
of PhCH2), 4.15-4.11 (m, 2H, Gul-H5, 1H of PhCH2), 3.87-3.83 (m, 2H, Fuc-
H2, -H3), 3.66-3.60 (m, 1H, Cy-CH), 3.57-3.54 (m, 2H, Gul-H6a, -H6b), 3.50-
3.46 (m, 2H, Gul-H4, Cy-CH), 3.25 (br s, 1H, Fuc-H4), 3.19 (d, 3J = 7.6 Hz, 
1H, Gul-H2), 2.58 (dd, 2J = 14.6, 3J = 6.0 Hz, 1H, 1H of allyl-CH2), 2.49 (dd, 2J 
= 14.6, 3J = 8.1 Hz, 1H, 1H of allyl-CH2), 2.18 (br s, 1H, OH), 2.04-1.87 (m, 
2H, Cy-CH2), 1.64-1.55 (m, 2H, Cy-CH2), 1.36-1.08 (m, 4H, Cy-CH2), 1.03 (d, 
3J = 6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.3, 139.2, 138.9, 138.6, 138.2, 138.0 (6C, 
Ar-Ci), 133.7 (allyl-CH), 128.5-127.2 (30C, Ar-CH), 118.7 (allyl-CH2), 99.4 
(Gal-C1), 94.8 (Fuc-C1), 79.9 (Fuc-C3), 79.5 (Gal-C2), 78.9 (Fuc-C4), 78.1 
(Cy-CH), 76.8 (Gal-C4), 76.2 (Gal-C3), 76.1 (Fuc-C2), 75.9 (Cy-CH), 75.1, 
75.0, 74.8, 73.3, 72.9, 72.7 (6C, PhCH2), 71.0 (Gal-C5), 68.3 (Gal-C6), 65.9 
(Fuc-C5), 39.5 (allyl-CH2), 30.3, 29.4, 23.5 (4C, Cy-CH2), 16.6 (Fuc-C6);  
 
[α]20D = -65.0 (c 1.12, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-C-(E-1-
methoxycarbonyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-galactopyrano-
side (50). A round bottom flask equipped with a reflux condenser was 
charged with a solution of compound galacto-49 (1.29 g, 1.28 mmol) in dry 
CH2Cl2 (40 mL). Grubbs catalyst 2nd generation (54.5 mg, 0.06 mmol) was 
added, immediately followed by addition of methyl acrylate (1.16 mL,         
12.8 mmol). After heating the reaction to reflux under argon and stirring for    
1 h, the volatiles were removed in vacuo. The residue was purified by column 
chromatography (SiO2, petrol ether/EtOAc, gradient of 10-100%) to give 50 
(1.24 g, 91%) as white foam. 
 
Rf (petrol ether/EtOAc, 5/2) = 0.33; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.31-7.13 (m, 30 H, Ar-H), 7.02 (ddd, 3J = 5.3, 
3J = 9.3, 3J = 15.3 Hz, 1H, propenyl-H2), 5.79 (d, 3J = 16.1 Hz, 1H, propenyl-
H1), 4.84 (A of AB, 2J = 11.4 Hz, 1H, 1H of PhCH2), 4.80 (d, 3J = 3.3 Hz, 1H, 
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Fuc-H1), 4.75 (A’ of A’B’, 2J = 11.5 Hz, 1H, 1H of PhCH2), 4.71 (A’’ of A’’B’’, 2J 
= 11.5 Hz, 1H, 1H of PhCH2), 4.67 (A’’’ of A’’’B’’’, 2J = 12.1 Hz, 1H, 1H of 
PhCH2), 4.59-4.54 (m, 4H, 4H of PhCH2), 4.48 (q, 3J = 6.3 Hz, 1H, Fuc-H5), 
4.45-4.42 (m, 2H, Gal-H1, 1H of PhCH2), 4.37 (A’’’’ of A’’’’B’’’’, 2J = 12.0 Hz, 
1H, 1H of PhCH2), 4.32-4.28 (m, 2H, 2H of PhCH2), 3.90 (dd, 3J = 3.3, 3J = 
10.1 Hz, 1H, Fuc-H2), 3.86 (dd, 3J = 2.5, 3J = 10.1 Hz, 1H, Fuc-H3), 3.68-3.47 
(m, 9H, Gal-H4, -H5, -H6a, -H6b, 2H of Cy-CH, CH3O-), 3.36 (br s, 1H, Fuc-
H4), 3.34 (d, 3J = 7.9 Hz, 1H, Gal-H2), 2.80 (ddd, 2J = 15.4, 3J = 5.2, 4J = 1.4 
Hz, 1H, propenyl-H3a), 2.30 (br s, 1H, OH), 2.24 (dd, 2J = 15.4, 3J = 9.4 Hz, 
propenyl-H3b), 1.97-1.85 (m, 2H, Cy-CH2), 1.64-1.54 (m, 2H, Cy-CH2), 1.33-
1.07 (m, 4H, Cy-CH2), 0.99 (d, 3J = 6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 166.4 (CO2R), 144.5 (propenyl-C2), 139.2, 
139.1, 138.8, 138.6, 138.0, 137.8 (6C, Ar-Ci), 128.6-127.1 (30C, Ar-CH), 
123.7 (propenyl-C1), 99.7 (Gal-C1), 94.6 (Fuc-C1), 82.5 (Gal-C2), 79.8 (Fuc-
C3), 78.6 (Fuc-C4), 78.4 (Cy-CH), 78.0 (Gal-C4), 76.3 (Fuc-C2), 76.0 (Gal-
C3), 75.8 (PhCH2), 75.6 (Cy-CH), 75.5, 75.0, 73.2, 73.0, 72.8 (5C, PhCH2), 
70.9 (Gal-C5), 68.2 (Gal-C6), 65.9 (Fuc-C5), 51.4 (MeO), 35.0 (propenyl-C3), 
29.7, 29.1, 23.2 (4C, Cy-CH2), 16.7 (Fuc-C6);  
 
HR-MS calcd. for C65H74O13Na [M+Na]+: 1085.5027; found: 1085.5030; 
 
[α]20D = -26.3 (c 1.47, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-C-(E-1-
hydroxymethyl-prop-1-en-3-yl)-2,4,6-tri-O-benzyl-β-D-galactopyranoside 
(51). Compound 50 (42 mg, 40.3 µmol) was dissolved in dry PhMe (2.5 mL) 
and cooled to -78 °C under argon. DIBAl-H (200 µL, 0.20 mmol, 1M in 
cyclohexane) was added dropwise. After stirring for 1 h, the reaction was 
quenched with saturated aqueous NH4Cl (0.5 mL), diluted with CH2Cl2 and 
directly dried over Na2SO4. After filtration, the volatiles were removed in 
vacuo. The residue was purified by column chromatography (SiO2, petrol 
ether/EtOAc, gradient of 13-100%) to give 51 (31.8 mg, 76%) as white foam. 
 
Rf (petrol ether/EtOAc, 4/1) = 0.20;  
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1H-NMR (500.1 MHz, CDCl3): δ 7.31-7.12 (m, 30 H, Ar-H), 5.72-5.55 (m, 2H, 
propenyl-H1, -H2), 4.85 (A of AB, 2J = 11.5 Hz, 1H, 1H of PhCH2), 4.80 (d, 3J 
= 3.2 Hz, 1H, Fuc-H1), 4.76-4.70 (m, 2H, 2H of PhCH2), 4.67 (A’ of A’B’, 2J = 
12.1 Hz, 1H, 1H of PhCH2), 4.59-4.54 (m, 4H, 4H of PhCH2), 4.51 (q, 3J = 5.4 
Hz, 1H, Fuc-H5), 4.45 (d, 3J = 8.0 Hz, 1H, Gal-H1), 4.43 (A’’ of A’’B’’, 2J = 
11.2 Hz, 1H, 1H of PhCH2), 4.37 (A’’’ of A’’’B’’’, 2J = 11.9 Hz, 1H, 1H of 
PhCH2), 4.32-4.28 (m, 2H, 2H of PhCH2), 4.00-3.97 (m, 2H, HOCH2), 3.90 
(dd, 3J = 3.2, 3J = 10.1 Hz, 1H, Fuc-H2), 3.86 (dd, 3J = 2.5, 3J = 10.1 Hz, 1H, 
Fuc-H3), 3.71-3.67 (m, 1H, Gal-H5), 3.63-3.57 (m, 2H, Gal-H4, Cy-CH), 3.55-
3.48 (m, 3H, Gal-H6a, -H6b, Cy-CH), 3.36 (br s, 1H, Fuc-H4), 3.36 (d, 3J = 7.8 
Hz, 1H, Gal-H2), 2.68 (dd, 2J = 14.6, 3J = 4.2 Hz, 1H, propenyl-H3a), 2.24 (br 
s, 1H, OH), 2.13 (dd, 2J = 15.1, 3J = 9.1 Hz, 1H, propenyl-H3b), 1.99-1.86 (m, 
2H, Cy-CH2), 1.63-1.48 (m, 2H, Cy-CH2), 1.33-1.08 (m, 4H, Cy-CH2), 1.00 (d, 
3J = 6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.2, 139.1, 138.9, 138.8, 138.3, 137.8 (6C, 
Ar-Ci), 137.8 (propenyl-C1), 128.3-127.2 (31C, 30 Ar-CH, propenyl-C2), 99.9 
(Gal-C1), 94.6 (Fuc-C1), 82.8 (Gal-C2), 79.9 (Fuc-C3), 78.7 (Fuc-C4), 78.3 
(Cy-CH), 77.7 (Gal-C4), 76.3 (Fuc-C2), 76.0 (Gal-C3), 75.7 (PhCH2), 75.6 
(Cy-CH), 75.4, 74.9, 73.3, 73.0, 72.9 (5C, PhCH2), 70.7 (Gal-C5), 68.3 (Gal-
C6), 65.9 (Fuc-C5), 63.6 (CH2OH), 35.1 (propenyl-C3), 30.0, 29.2, 23.3 (4C, 
Cy-CH2), 16.7 (Fuc-C6);  
 
HR-MS calcd. for C64H74O12Na [M+Na]+: 1057.5078; found: 1057.5078; 
 
[α]20D = -32.2 (c 1.59, CHCl3);  
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-C-(trans-
1-hydroxy-2,3-epoxy-but-4-yl)-2,4,6-tri-O-benzyl-β-D-galactopyranoside 
(52). A mixture of freshly activated molecular sieves (100 mg, 4Å, powder) 
and dry CH2Cl2 (8 mL) was cooled to -20 °C under argon. (-)-DET (40 µL, 
0.23 mmol) and Ti(OiPr)4 (57 µL, 0.19 mmol) were added and the mixture was 
stirred for 30 min. Then, a solution of compound 51 (400 mg, 0.38 mmol) in 
dry CH2Cl2 (8 mL) was added and the mixture was stirred for additional        
30 min. Then, tBuOOH in decane (281 µL, 1.55 mmol, 5.5 M) was added 
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dropwise at -20 °C and the mixture was allowed to warm to 10 °C during 2 h. 
The mixture was cooled to 0 °C and first, H2O (0.40 mL) and after 30 min 
NaOH aq. (0.10 mL, w = 30%) was added. After stirring for further 30 min at  
0 °C, brine was added (50 mL), the phases were separated and the aqueous 
layer was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers 
were dried over Na2SO4, filtered and the volatiles were removed in vacuo. 
The residue was purified by column chromatography (SiO2, petrol 
ether/EtOAc, gradient of 10-100%) to give 52 (177 mg, 44%) as a mixture of 
diastereomers as white foam. 
 
Rf (petrol ether/EtOAc, 2/5) = 0.80; 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.31-7.12 (m, 30 H, Ar-H), 4.86-4.19 (m, 2H, 
Fuc-H1, -H5, Gal-H1, 12H of PhCH2), 3.92-3.85 (m, 2H, Fuc-H2, -H3), 3.81-
3.78 (m, 1H, Gal-H5, major isomer), 3.74, 3.46 (2 m, 2H, butyl-H1, major 
isomer), 3.57, 3.49 (2 m, 2H, butyl-H1, minor isomer), 3.70-3.48 (m, 6H, Gal-
H4, -H5, -H6a, -H6b, 2 Cy-CH), 3.39-3.31 (m, 2H, Fuc-H4, Gal-H2), 3.22-3.18 
(m, 1H, butyl-H3, major isomer), 3.13-3.10 (m, 1H, butyl-H3, minor isomer), 
2.82-2.80 (m, 1H, butyl-H2, major isomer), 2.78-2.75 (m, 1H, butyl-H2, minor 
isomer), 2.49-2.35 (m, 3H, butyl-H4a, 2 OH), 1.96-1.86 (m, 2H, Cy-CH2), 
1.63-1.46 (m, 2H, Cy-CH2), 1.37-1.28 (m, 1H, butyl-H4b), 1.24-1.08 (m, 4H, 
Cy-CH2), 1.01-0.95 (m, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3, selected data): δ 139.2, 139.1, 138.8, 138.7, 
138.1, 137.9 (6C, Ar-Ci), 128.6-127.2 (30C, Ar-CH), 99.7 (Gal-C1), 94.7 (Fuc-
C1), 82.6 (Gal-C2, maj.), 82.4 (Gal-C2, min.), 79.9 (Fuc-C3), […] 76.4 (Gal-
C3, maj.), […], 75.4 (Gal-C3, min.), […], 71.3 (Gal-C5, maj.), 71.0 (Gal-C5, 
min.), 68.4 (Gal-C6, maj.), 68.1 (Gal-C6, min.), 65.9 (Fuc-C5), 61.7 (butyl-C1), 
59.0 (butyl-C2, min.), 57.7 (butyl-C2, maj.), 52.5 (butyl-C3, min.), 52.3 (butyl-
C3, maj.), 34.4 (butyl-C4), 30.0, 29.2, 23.2 (4C, Cy-CH2), 16.7 (Fuc-C6);  
 
ESI-MS (5.0 kV) calcd. for C64H74O13Na [M+Na]+: 1073.5; found: 1073.5; 
 
(1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-(S)-(1,4-
spiro-2R-hydroxymethyl-3S-hydroxy-tetrahydrofuranyl)-2,4,6-tri-O-benz-
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yl-β-D-xylopyranoside (53). Compound 52 (60 mg, 57.1 µmol) was dissolved 
in dry DMF (12 mL) and cooled to 0 °C under argon. NaH (60 mg, suspension 
in mineral oil, w = 50%) was added portionwise. After stirring for  5 h, the 
reaction was quenched with saturated aqueous Na2CO3 (10 mL), diluted with 
brine (40 mL) and extracted with CH2Cl2 (3 x 50 mL). The combined organic 
layers were dried over Na2SO4. After filtration, the volatiles were removed in 
vacuo. The residue was purified by column chromatography (SiO2, petrol 
ether/EtOAc, gradient of 10-100%) to give a diastereomeric mixture of the 
oxetanes 54 (24.8 mg, 41%) and the title compound 53 (12.6 mg, 21%) as 
white foam. 
 
Rf (petrol ether/EtOAc, 2/5) = 0.45;  
 
1H-NMR (500.1 MHz, CDCl3): δ 7.33-7.09 (m, 30 H, Ar-H), 5.01 (A of AB, 2J = 
10.2 Hz, 1H, 1H of PhCH2), 4.86 (A’ of A’B’, 2J = 10.8 Hz, 1H, 1H of PhCH2), 
4.76 (d, 3J = 3.0 Hz, 1H, Fuc-H1), 4.68-4.63 (m, 3H, 3H of PhCH2), 4.59-4.49 
(m, 4H, Fuc-H5, 3H of PhCH2), 4.41 (B’ of A’B’, 2J = 10.9 Hz, 1H, 1H of 
PhCH2), 4.34 (d, 3J = 8.0 Hz, 1H, Gal-H1), 4.29-4.27 (m, 2H, 2H of PhCH2), 
4.18 (A’’’ of A’’’B’’’, 2J = 11.5 Hz, 1H, 1H of PhCH2), 4.07-4.03 (m, 1H, THF-
H3), 4.00-3.96 (m, 1H, THF-H2), 3.87 (dd, 3J = 3.1, 3J = 10.2 Hz, 1H, Fuc-
H2), 3.84 (dd, 3J = 2.2, 3J = 10.4 Hz, 1H, Fuc-H3), 3.78-3.74 (m, 1H, 1H of 
THF-CH2OH), 3.71-3.68 (m, 2H, Gal-H2, 1H of THF-CH2OH), 3.65-3.46 (4H, 
Gal-H6a, -H6b, 2H of Cy-CH), 3.41-3.37 (m, 2H, Gal-H4, -H5), 3.29 (br s, 1H, 
Fuc-H4), 2.11-2.07 (m, 1H, OH), 2.02 (d, 2J = 14.1 Hz, 1H, THF-H4syn), 1.97 
(br s, 1H, OH), 1.94-1.81 (m, 2H, Cy-CH2), 1.70 (dd, 2J = 14.1, 3J = 5.3 Hz, 
THF-H4anti), 1.66-1.60 (m, 2H, Cy-CH2), 1.33-1.11 (m, 4H, Cy-CH2), 1.02 (d, 
3J = 6.5 Hz, 3H, Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.2, 138.9, 138.8, 137.8, 136.9 (6C, Ar-Ci), 
128.6-127.2 (30C, 30 Ar-CH), 100.8 (Gal-C1), 94.7 (Fuc-C1), 87.1 (Gal-C3), 
81.3 (Gal-C2), 79.9 (Fuc-C3), 79.3 (Gal-C4), 78.6 (2C, Fuc-C4, THF-C2), 
78.3 (Cy-CH), 76.2 (PhCH2), 76.1 (Fuc-C2), 75.6 (Cy-CH), 75.5, 75.0, 73.5, 
73.0 (4C, PhCH2), 72.7 (2C, THF-C3, PhCH2), 71.5 (Gal-C5), 68.3 (Gal-C6), 
65.9 (Fuc-C5), 61.9 (THF-CH2OH), 40.2 (THF-C4), 29.7, 29.5, 23.5 (4C, Cy-
CH2), 16.7 (Fuc-C6);  
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ESI-MS (3.5 kV) calcd. for C64H74O13Na [M+Na]+: 1073.5; found: 1073.7; 
 
[α]20D = -55.9 (c 0.60, CHCl3); 
 
Oxetanes 54: 
 
Rf (petrol ether/EtOAc, 2/5) = 0.55, both diastereomers; 
 
Major diastereomer, selected data 
1H-NMR (500.1 MHz, CDCl3): δ 4.70 (m, 1H, oxetane-H2), 3.81 (m, 1H, 
CH(OH)CH2OH), 3.51-3.26 (m, 2H, CH(OH)CH2OH), 3.03 (dd, 2J = 11.6, 3J = 
7.5 Hz, 1H, oxetane-H3a), 1.93 (dd, 2J = 11.7, 3J = 7.7 Hz, 1H, oxetane-H3b); 
 
13C-NMR (125.8 MHz, CDCl3): δ 85.8 (Gal-C3 = oxetane-C4), 77.5 (oxetane-
C2), 72.5 (CH(OH)CH2OH), 61.9 (CH(OH)CH2OH), 24.5 (oxetane-C3); 
 
Minor diastereomer, selected data 
1H-NMR (500.1 MHz, CDCl3): δ 4.57 (m, 1H, oxetane-H2), 3.70 (m, 1H, 
CH(OH)CH2OH), 3.41-3.31 (m, 2H, CH(OH)CH2OH), 2.63 (dd, 2J = 10.8, 3J = 
7.9 Hz, 1H, oxetane-H3a), 2.07 (dd, 2J = 10.9, 3J = 7.0 Hz, 1H, oxetane-H3b); 
 
13C-NMR (125.8 MHz, CDCl3): δ 86.7 (Gal-C3 = oxetane-C4), 77.5 (oxetane-
C2), 73.4 (CH(OH)CH2OH), 61.3 (CH(OH)CH2OH), 26.4 (oxetane-C3); 
 
ESI-MS (3.5 kV) calcd. for C64H74O13Na [M+Na]+: 1073.5; found: 1073.7; both 
diastereomers; 
 
 (1R,2R)-2-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-cyclohexyl 3-(S)-(1,4-
spiro-2R-(3,5-dinitrobenzoyl)oxy-3S-(3,5-dinitrobenzoyl)oxy-tetrahydro-
furanyl)-2,4,6-tri-O-benzyl-β-D-xylopyranoside (55). Compound 53      
(12.6 mg, 12.0 µmol) was dissolved in dry CH2Cl2 (2 mL) under argon. 3,5-
Dinitrobenzoyl chloride (15.2 mg, 66.0 µmol) and DMAP (8.0 mg, 66.0 µmol) 
was added at r.t.. After stirring over night, the reaction was concentrated and 
the residue was purified by column chromatography (SiO2, petrol 
ether/EtOAc, gradient of 4-30%) to give compound 55 (17.3 mg, quant.) as 
white foam. 
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Rf (petrol ether/EtOAc, 4/3) = 0.80; 
 
1H-NMR (500.1 MHz, CDCl3): δ 8.97-8.95 (m, 1H, Ar-H), 8.91-8.88 (m, 3H, Ar-
H), 8.72-8.71 (m, 2H, Ar-H), 7.34-6.75 (m, 30 H, Ar-H), 5.46 (dd, 3J = 3.5, 3J = 
5.1 Hz, 1H, THF-H3), 4.90-4.72 (m, 5H, 2H of CH2O(CO)R, 3H of PhCH2), 
4.67 (d, 3J = 2.8 Hz, 1H, Fuc-H1), 4.62 (A of AB, 2J = 12.3 Hz, 1H, 1H of 
PhCH2), 4.57 (A’ of A’B’, 2J = 11.5 Hz, 1H, 1H of PhCH2), 4.53-4.43 (m, 4H, 
Fuc-H5, THF-H2, 2H of PhCH2), 4.38 (A’’ of A’’B’’, 2J = 11.4 Hz, 1H, 1H of 
PhCH2), 4.35-4.25 (m, 4H, Gal-H1, 3H of PhCH2), 3.93 (A’’’ of A’’’B’’’, 2J = 
11.3 Hz, 1H, 1H of PhCH2), 3.78 (dd, 3J = 3.0, 3J = 10.2 Hz, 1H, Fuc-H2), 
3.75 (dd, 3J = 2.3, 3J = 10.3 Hz, 1H, Fuc-H3), 3.72 (d, 3J = 7.9 Hz, 1H, Gal-
H2), 3.60-3.46 (5H, Gal-H4, -H5, -H6a, -H6b, 1H of Cy-CH), 3.36-3.31 (m, 1H, 
1H of Cy-CH), 3.06 (br s, 1H, Fuc-H4), 2.67 (d, 2J = 14.9 Hz, 1H, THF-H4syn), 
2.06 (dd, 2J = 15.0, 3J = 6.5 Hz, THF-H4anti), 1.94-1.81 (m, 2H, Cy-CH2), 1.66-
1.60 (m, 2H, Cy-CH2), 1.33-1.11 (m, 4H, Cy-CH2), 0.93 (d, 3J = 6.5 Hz, 3H, 
Fuc-H6); 
 
13C-NMR (125.8 MHz, CDCl3): δ 162.1, 162.0 (2C, ArCOOR), 148.4, 148.2, 
139.2, 138.9, 138.8, 138.2, 137.7, 132.8, 132.6 (12C, Ar-Ci), 129.2-126.0 
(34C, Ar-CH), 122.5 (2C, Ar-CH), 100.9 (Gal-C1), 94.5 (Fuc-C1), 88.2 (Gal-
C3), 79.9 (Fuc-C3), 78.7 (Fuc-C4), 78.3 (2C, Gal-C2, -C4), 77.7 (THF-C3), 
77.1 (Cy-CH), 76.2 (THF-C2), 75.9 (Fuc-C2), 75.7 (PhCH2), 75.3 (Cy-CH), 
75.0, 74.4, 73.6, 72.9, 72.5 (5C, PhCH2), 70.8 (Gal-C5), 67.8 (Gal-C6), 65.8 
(Fuc-C5), 64.4 (THF-CH2OR), 36.4 (THF-C4), 30.2, 29.7, 29.4, 23.4 (4C, Cy-
CH2), 16.5 (Fuc-C6);  
 
ESI-MS (5.0 kV) calcd. for C78H78N4O23Na [M+Na]+: 1461.5; found: 1461.6; 
 
[α]20D = -22.9 (c 0.80, CHCl3);  
 
Oxetanes 56. Compound 54 (24.8 mg, 23.6 µmol) was dissolved in dry 
CH2Cl2 (2 mL) under argon. 3,5-Dinitrobenzoyl chloride (41.0 mg, 176 µmol) 
and DMAP (31.7 mg, 260 µmol) was added at r.t.. After stirring for 3 h, the 
reaction was concentrated and the residue was purified by column 
chromatography (SiO2, petrol ether/EtOAc, gradient of 4-30%) to give a 
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mixture of diastereomers 56 (23.7 mg, 70%) as white foam. 
 
Rf (petrol ether/EtOAc, 2/1) = 0.33, both diastereomers;  
 
Major diastereomer, selected data 
1H-NMR (500.1 MHz, CDCl3): δ 5.69 (td, 3J = 6.8, 3J = 2.5 Hz, 
CH(OR)CH2OR), 4.82 (m, 1H, oxetane-H2), 4.42 (m, 1H, CH(OR)CH2OR), 
3.51-3.26 (m, 1H, CH(OR)CH2OR), 2.98-2.93 (m, 1H, oxetane-H3a), 2.27-
2.21 (m, 1H, oxetane-H3b);  
 
Minor diastereomer, selected data 
1H-NMR (500.1 MHz, CDCl3): δ 5.63 (td, 3J = 6.4, 3J = 3.1 Hz, 
CH(OR)CH2OR), 4.93 (m, 1H, oxetane-H2), 4.49 (m, 1H, CH(OR)CH2OR), 
3.51-3.26 (m, 1H, CH(OR)CH2OR), 2.98-2.93 (m, 1H, oxetane-H3a), 2.27-
2.21 (m, 1H, oxetane-H3b);  
 
ESI-MS (5.0 kV) calcd. for C78H78N4O23Na [M+Na]+: 1461.5; found: 1461.5; 
both diastereomers; 
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2.4 Pre-organization of the Lewisx core of sLex as a result of a 
lipophilic stabilization 
 
Lemieux220 postulated an attractive interresidue interaction between lipophilic 
patches of oligosaccharides. To support this hypothesis with experimental 
evidence, sLex derivatives with and without a lipophilic substituent at the 
fucose 5-position were designed, synthesized, and biologically and 
biophysically evaluated and compared to the natural epitope sLex. 
 
This part is in preparation and will be submitted to Angewandte Chemie, 
International Edition in due course. 
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1. Introduction 
 
The selectins play a key role in the early inflammatory cascade. The 
recruitment and extravasation of leukocytes into inflamed tissue mediated by 
E-, P- and L-selectin, a class of closely related cell adhesion molecules, is an 
essential mechanism of the immune defense. The selectin-leukocyte 
interaction leads to the characteristic tethering and rolling process of the white 
blood cells on the vascular endothelium. Upon secondary activation firm 
adhesion and migration to the site of injury through the endothelial cells takes 
place.1,2 However, excessive influx of leukocytes into tissue can cause acute 
or chronic reactions as observed in reperfusion injury, stroke or rheumatoid 
arthritis.3,4 As a result, the antagonism of the selectins is generally considered 
to be a validated approach towards the treatment of inflammatory diseases. 
 
Since all physiological ligands of the selectins bear the terminal 
tetrasaccharide epitope sialyl Lewisx (1, sLex, D-NeuNAc-α-2,3 → D-Gal-β-1,4 
→ (L-Fuc-α-1,3 →) D-GlcNAc, figure 1),5,6 this motif served as a lead 
structure in selectin antagonist research.7 Numerous publications determined 
the essential pharmacophores for binding to E-selectin, which are four 
hydroxyl groups (fucose 3- and 4-OH, galactose 4- and 6-OH) and the 
carboxylic acid of neuraminic acid.8,9 
 
The bioactive conformation of sLex was determined by trNOE NMR 
experiments10,11 and was subsequently confirmed in complex with all three 
selectins by X-ray crystallography.12 Since carbohydrate-protein interactions 
usually are of low affinity (sLex has an IC50 of ca. 1 mM, all IC50s discussed 
here are relative to sLex, i.e. rIC50 of sLex = 1.0) the stabilization of the 
bioactive conformation of sLex and its mimetics was found essential for 
binding.13-16 It was rationalized that a conformational change of a ligand which 
does not adopt the bioactive conformation in solution, would lead to high 
entropic costs upon binding. This ultimately results in a loss of detectable 
binding. For dynamic non-equilibrium processes, such as E-selectin mediated 
rolling of leukocytes on activated endothelium, entropy is expected to play a 
major role. 
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Therefore, special focus was given to the conformational stabilization of the 
Lewisx core in sLex mimetics with modifications at the GlcNAc residue. 
GlcNAc was successfully replaced by 1,2-trans-diols.17-20 But only when 
conformationally locked diols, e.g. (1R,2R)-cyclohexane-diol or (3R,4R)-
tetrahydropyrane-diol, were used, the binding affinity was superior to sLex. 
When flexible diols, e.g. glycol or butane-2,3-diol were introduced as GlcNAc 
replacements, binding was significantly reduced or vanished completely. 
 
In 2001, we reported on the additional conformation-stabilizing effect of 
substituents at the GlcNAc analogs, adjacent to the glycosidic linkage with 
fucose.20 A sLex antagonist with GlcNAc replaced by (3R,4R)-
tetrahydropyrane-diol showed better affinity towards E-selectin when an 
equatorial methyl substituent was introduced at the position analogous to C-2 
of GlcNAc. Its IC50 dropped by a factor of 6 when compared to the 
unsubstituted analog in the static assay. This effect was even more 
pronounced in a dynamic assay (IC50 (dynamic) = 20-30 µM vs. IC50 (static) = 
39 µM). Because the additional methyl group is not believed to have a direct 
contact with the protein surface (as derived from the X-ray structure of sLex in 
complex with E-selectin12), the increased affinity was assigned to lower 
entropic costs upon binding. This is solely resulting from a higher degree of 
pre-organization of the molecule in the bioactive conformation in solution. 
 
In this communication we report on a lipophilic interaction between the fucose 
and the galactose residue in sLex as a second core conformation-stabilizing 
effect in sLex. 
 
Because of the unfavorable pharmacokinetic properties of fucose, i.e. its 
lability towards enzymatic cleavage in the host, many reports addressed this 
issue with fucose replacements in sLex antagonists.7,9 The hydroxyl groups at 
position 3 and 4 are essential and, therefore, analogs were based on 
modifications at positions 2 and 5. Of special interest here are the 
replacements of fucose with D-arabinopyranose and L-galactose (2 and 3, 
figure 1), which were introduced either by chemical synthesis or enzymatically 
using fucosyl-transferases.21-24 Both L-galacto- and D-arabinopyranosides are 
considered stable towards hydrolysis in mammals.22 In L-galactoside analogs 
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of sLex, the 6-position of fucose is hydroxylated and in D-arabinopyranoside 
analogs, the 6-position is absent, leaving two hydrogen atoms at the C-5. The 
L-galactoside derivative 3b bearing a decapeptide as aglycon was reported to 
bind to E-selectin with an rIC50 of 1.25 when compared to the sLex derivative 
(1b, rIC50 = 1).22 The arabinoside 2b also showed binding to the protein with 
an rIC50 of 2.8. However, both analogs showed lower affinities towards E-
selectin than the corresponding sLex 1b. 
 
Lemieux25 reported on the hydrophobic properties of the α-face of L-
fucosides. Therefore and concluded from the results of the Kunz group,22 we 
hypothesized that the methyl group present in sLex stabilizes the internal 
conformation of the pharmacophores of the core in the bioactive conformation 
by a lipophilic interaction with the galactose β-face. Since this methyl group is 
not in direct contact with the protein12,26 when bound, it does not contribute to 
binding enthalpy, but rather has a strong influence on the entropy of binding 
when compared to the D-arabino and to a lesser extent to the L-galacto 
counterparts 2 and 3, respectively. In 3, the hydroxymethyl substituent of L-
galactose could still interact via its lipophilic CH2 with the β-face of the D-
galactose residue, whereas in 2, this stabilizing force should be absent. As a 
result, the affinity of 2 to the receptor would be significantly reduced. This 
tendency in biological activity has indeed been reported by the Kunz group 
(1b, 2b and 3b, figure 1).22 
 
Lipophilic interactions of carbohydrate α- or β- faces with binding partners 
have been reported in the literature and are of current interest.27-30 Aromatic 
amino acid side chains are prevalent in the binding sites of carbohydrate 
recognizing proteins. In galactose-binding proteins, very often D-galactose is 
bound to the indole side chain of tryptophan, or to the phenyl ring of Tyr or 
Phe.31 Recently, Screen32 and co-workers have reported on the interaction 
between galactosides and toluene, based on the crystal structure33,34 of a 
galactose-specific lectin in complex with methyl galactoside. In this model, the 
D-galactose β-face directly interacts with the plane of toluene, as observed in 
the crystal structure, where the same face is bound to a tyrosine side chain. 
Very recently, Terraneo et al. reported on intramolecular conformation-
2. Results and Discussion 
- 140 - 
stabilizing effects of arene rings with carbohydrate faces in glycoconjugates of 
phenyllactic acid, which lead to a significant influence on the overall molecular 
shape.35 
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Figure 1: Sialyl Lewisx (1) and derivatives with modified fucose:  
D-arabinoside 2, L-galactoside 3 and 5C-phenyl arabinoside 4. 
 
To verify the hypothesis of a stabilization of the core as a result of a lipophilic 
interaction between fucose and galactose in sLex, we planned to modify the 
methyl group of fucose by introducing other lipophilic groups and compare the 
biological activity of these analogs to sLex (1c, figure 1) and an analog devoid 
of a lipophilic substituent (2c). In the early 1990s, Gesson and co-workers 
reported on the stereoselective synthesis of L-fucose and 5C-phenyl-L-
arabinose from D-mannose using methyl or phenyl lithium respectively.36 
Attempts to obtain higher alkyl analogs via this organo-lithium route failed. In 
fact, those higher analogs could be obtained with Grignard reagents, but with 
inversed stereoselectivity resulting in D-altrose derivatives as major product. 
 
For the synthesis of the fucose derivative 4 bearing a phenyl ring instead of a 
methyl group at the non-reducing end, we first synthesized building block 13, 
following the strategy developed by Gesson (scheme 1).36 As previously 
demonstrated by Mekki,37 the addition of organolithium reagents (e.g. PhLi, 
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MeLi) to D-mannofuranose diacetonide 5 was selective according to the 
Felkin-Anh model. Allyl ether protection of the resulting hydroxyl functions in 
6, followed by hydrolysis of the two isopropylidene groups in 7 allowed the 
selective cleavage of the terminal diol 8 upon treatment with sodium 
periodate. Then, the formed aldose derivative underwent spontaneous 
cyclization to give the corresponding arabino furanose 9 as a mixture of 
anomers. Removal of the allyl protecting groups gave a mixture of furanose 
and pyranose forms from which the thermodynamically more stable six-
membered ring isomer 10 was isolated after acetylation. Treatment of the 
peracetate 11 with ethanethiol in the presence of TMSOTf afforded the 
corresponding ethyl thioglycoside 12, which was converted into building block 
13 by conventional deacetylation and benzylation. 
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Scheme 1: (i) PhLi, Et2O, -78 to -20 °C, 20 h, 76%, d.r. 4:1; (ii) AllBr, 
NaH, DMF, 0 °C-r.t., 1 h, 93%; (iii) HOAc/H2O (4:1), r.t., 10 h, quant.; (iv) 
NaIO4, CH2Cl2, aq. NaHCO3, 0 °C-r.t., 1 d, 77%; (v) Pd/C, CSA, 
dioxane/H2O, 95 °C, 2 d; (vi) Ac2O, DMAP, pyridine, r.t., 45 min, 69% 
(over 2 steps, α/β 1:2); (vii) EtSH, CH2Cl2, TMSOTf, 0 °C-r.t., 3 h, 65% 
(α/β 1:2); (viii) NaOMe, MeOH, r.t., 3 h; (ix) NaH, BnBr, DMF, 0 °C-r.t.,     
1 h, 88% (over 2 steps); 
 
Initially, the synthesis of 4 was intended as an economically more favorable 
[2+2]-glycosylation approach (scheme 2). Therefore, GlcNAc derivative 14 
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was glycosylated with donor 13 using NIS/TfOH as promoter to give pseudo-
disaccharide 15. However, the subsequent [2+2]-glycosylation with 
disaccharide donor 17 did not give any detectable amounts of tetrasaccharide 
18, neither with NIS/TfOH nor with DMTST as promoter. 
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Scheme 2: (i) NIS, AgOTf, mol. Sieves, CH2Cl2, -78 °C to r.t., 5.5 h, 
66% (α/β 5:1); (ii) BH3•NMe3, AlCl3, H2O, THF, r.t., 3.5 h, 62%; (iii) 
DMTST or DMTST/base or NIS/AgOTf, 0%; 
 
Consequently, we proceeded with a [2+1+1]-strategy (scheme 3). GlcNAc 
derivative 19 was readily obtained by chloroacetylation of its 3-OH 
precursor.38 Selective reductive opening39 of the benzylidene in presence 
water yielded acceptor 20, which was glycosylated with donor 17, to give 
trisaccharide 21 in good yield. The chloroacetyl group was then selectively 
removed using thiourea and the resulting trisaccharide acceptor 22 was 
subjected to glycosylation with phenyl-arabinoside donor 13. The protected 
tetrasaccharide 18 was obtained in reasonable yield under Lemieux in situ 
anomerization conditions. Ester cleavage and careful hydrogenolytic 
deprotection gave 4 in good yield without affecting the hidden benzylic 
position of the ring oxygen in the phenylarabinose moiety. 
 
For the synthesis of 1c and 2c, trisaccharide 2338 was treated with 
fucosyltransferase and GDP-Fuc or GDP-Ara to give selectively the desired 3-
O fucosylated or arabinosylated compounds as reported earlier (scheme 
4).40,41 
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The obtained derivatives of sLex were then tested in a static ELISA based 
assay for E-selectin binding,42 and their affinity was measured relative to sLex  
(1c, rIC50 = 1). Both analogs showed a weaker affinity towards the receptor 
than sLex. Arabinoside 2c lacking any lipophilic substituent was inactive up to 
10 mM, whereas binding could be restored when a lipophilic phenyl group 
was introduced in 4 (rIC50 of 2.8). 
 
19
(i)OO
O
NHAc
O(CH2)2SiMe3
O
Ph
(ii)
20
21, R=ClAc
O
COOR4
O
O
R1O OR1
OR1
AcHN
R1O R1O
OR1
O
OR2
O
OR3
O
NHAc
O(CH2)2SiMe3
O
R3O
OR3
OR3
O
COOBn
O
O
AcO OAc
OAc
AcHN
AcO AcO
OAc
SEt
OBz
17
22, R=H
O
Cl
OHO
O
NHAc
O(CH2)2SiMe3
O
Cl
OBn
O
COOBn
O
O
AcO OAc
OAc
AcHN
AcO AcO
OAc
O
OBz
O
OBn
RO
NHAc
O(CH2)2SiMe3
(iii)
18, R1=Ac, R2=Bz, R3=Bn, R4=Bn
(v)-(vi)
(iv)
O
BnOOBn
OBn
SEt
13
4, R1,R2,R3=H, R4=Na  
 
Scheme 3: (i) BH3•NMe3, AlCl3, H2O, THF, r.t., 2 h, 92%; (ii) DMTST, 
mol. sieves, CH2Cl2, 0 °C, 2.5 d, 68%; (iii) H2NC(S)NH2, 2,6-di-tert.-
butyl-pyridine, DMF, 70 °C, 22 h, 63%; (iv) 1. 13, Br2, CH2Cl2, 0 °C,  
30 min 2. 22, Et4NBr, mol. sieves, DMF/CH2Cl2, r.t., 3 d, 37%; (v) H2 
(1 atm), Pd/C, dioxane/H2O, r.t., 14 h; (vi) NaOMe, MeOH, r.t., 12 h, 
59% (2 steps);  
 
To assess the conformational behavior of the core structure of sLex and its 
analogs we performed NMR measurements (figure 2). The preferred 
conformation of 1c, 2c and 4 in aqueous solution was studied by jump-
symmetrized ROESY43 NMR experiments. The average distance between 
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H5ax in the fucose residue of 1c and in its analogs (2c, 4) and H2 of galactose 
was determined by the intensity of their cross-peak from the nuclear 
Overhauser effect. In sLex (1c) and arabinoside 2c the average distance 
between those two nuclei is very similar (1c: 2.54 Å, 2c: 2.49 Å), whereas in 
phenyl-arabinoside 4 (2.75 Å) this average distance is 10% longer. 
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Scheme 4: (i) FucT-III, for 1c: GDP-Fuc (89%), for 2c: GDP-Ara (81%); 
 
To show that the reduced affinity of 2c results from entropic costs of binding, 
the flexibility of the different fucose analogs will be studied by temperature 
dependent NMR. A correlation between chemical shifts and coupling 
constants in their fucose and arabinose residues with temperature should 
further support the hypothesis of a lipophilic stabilization in 1, and its absence 
in 2. 
 
Considering the information gained from NMR experiments together with the 
biological activity of compounds 1c, 2c and 4, we could show that there is a 
lipophilic core-stabilizing interaction between the fucose α-face with the 
galactose β-face in the sLex motif. Although the average distances of the core 
are similar in sLex (1c) and arabinoside analog 2c, their bioactivity differs 
dramatically. Because the methyl group is not in contact with the protein and 
does therefore not contribute to the binding enthalpy, this strong decrease in 
activity is a direct result of the high degree of flexibility, and hence the 
unfavorable entropy of binding of the non-stabilized arabinose residue in 2c 
when compared with 1c.44 
 
In case of phenyl-arabinoside 4, a lipophilic group was introduced and 
biological activity was regained. Because of the additional phenyl group, 
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conformational stabilization via lipophilic interactions between the two 
saccharide residues was reinstalled although with slight distortion of the 
optimal geometry of sLex. This is probably the reason for the decrease in 
affinity of 4 when compared to sLex (1c). 
 
 
 
Figure 2: Selective ROESY experiments measuring the transfer of 
magnetization from the H5F to H2G in selectin ligands 1c, 2c and 4 at 
equal mixing times.  
 
Nature has chosen sLex as epitope for binding to the selectins. Specificity for 
its receptor is gained through the large number of hydrogen bonds involved in 
the complex of sLex with the selectins.12,45 Because carbohydrates have an 
intrinsically low affinity towards their protein targets, they are usually 
displayed in an oligovalent fashion by the interacting partner. When 
leukocytes bind to the selectins under shear stress conditions, the pre-
organization of the pharmacophores in the bioactive conformation is of 
particular importance for this binding process. In this report, we could show 
that in addition to previously reported factors, this pre-organization has been 
well achieved in the natural epitope sLex via a lipophilic interresidue stabilizing 
interaction between fucose and galactose. The understanding of the effects 
contributing to the conformational pre-organization of the pharmacophores in 
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the bioactive arrangement is essential for the development of functional 
selectin ligands into drugs. 
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Experimental  
 
Conformational analysis by NMR 
 
The samples for the ROESY analysis consisted of approx. 5 mg of either 1c, 
2c or 4, solvated in 99.8% D2O (Armar Chemicals) at a pH of approx. 7.0 
(uncorrected for D2O) and were measured without the addition of a buffer. 
Shigemi NMR tubes were used to reduce the sample volume (200 µL) needed 
for measurement. Measurements were performed at 25 °C using the same 
Bruker AVANCE 500 NMR spectrometer that was used to validate the 
compounds synthesized. Chemical shifts were referenced with respect to 
earlier work,20 which assigned a chemical shift of 4.60 ppm to the H5F 
resonance of 1c. 
 
The doubly-selective homonuclear Hartmann-Hahn scheme46 was used to 
selectively transfer magnetization from H6F to H5F. This scheme allowed a 
highly selective transfer of magnetization from H6F to H5F through their scalar 
coupling. The selective excitation of H5F allowed an accurate quantification of 
this resonance by avoiding the excitation of residual H2O, which has similar 
chemical shift. To remove any remaining magnetization from H6F, a selective 
gradient echo at the frequency of H5F was applied. A 200 ms REBURP47 180° 
refocusing pulse was applied to the H5F resonance. The REBURP pulse was 
sandwiched by a pair of Gaussian shaped gradients of 1 ms each and an 
amplitude of 20 G/cm. This additional spectral filter ensured that the observed 
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ROESY48 peaks were due to magnetization that originated from the H5F 
resonance.49 
 
The jump-symmetrized CW-ROESY variation of the ROESY sequence was 
used in all experiments to minimize TOCSY artefacts.43 This sub-element of 
the pulse sequence was inserted following the selective gradient echo. During 
the ROESY period, the transmitter frequency was shifted up or downfield 
during the first or second half of the mixing-time, respectively. The high-field 
spin lock was applied at 4.9 ppm and the low-field at 0.9 ppm. The spin lock 
was a rectangular pulse of 2 kHz amplitude. For the compounds measured 
(1c, 2c and 4) 10 experiments were run to record a build-up curve of the ROE 
transfer. The 10 experiments were sampled with increasing durations of the 
spin lock, beginning after 50 ms, and repeated after each 50 ms increment, 
resulting in a 500 ms spin lock duration for the final experiment. 
  
Following the application of the spin lock, the transmitter was returned to the 
center of the spectrum, at 2.9 ppm, and the FID measured using 4096 
complex points to sample a bandwidth of 7 ppm. To achieve a high signal-to-
noise ratio, 1024 scans were measured for each mixing time. Using a prescan 
delay of 3 s, on average the experiments lasted approximately 1.2 hours 
each. The NMR data were analyzed using XWINNMR version 3.0 operating 
on a Silicon Graphics O2. The spectra were apodized with an exponential 
decay function with 2 Hz line broadening. An additional advantage of the 
selective experiments was the lack of signal overlap which allowed the 
possibility of integrating the signals without interference from other 
resonances.  
 
To determine the internuclear distances, the rotating-frame cross-relaxation 
rates were calculated from the build up curves. Traditionally, the cross-
relaxation rate is determined from fitting the spectra to a bi-exponential 
function that depends upon both the cross- and auto-relaxation rates.50-52 The 
extent to which accurate cross-relaxation rates can be determined by this 
manner depends upon how well the auto-relaxation rate can be defined. 
Alternatively, it is possible to remove the dependence on the auto-relaxation 
by dividing the target-peak by the source-peak for each value of the mixing 
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time.53-55 The resulting function is a hyperbolic tangent, the argument of which 
is the product of the cross-relaxation rate and the mixing time. For the longest 
mixing times performed and highest rate of cross-relaxation expected for the 
compounds studied herein, the hyperbolic tangent function is 
indistinguishable from a linear function, hence offering the potential to apply 
linear regression to extract the cross-relaxation rate. The above procedure 
resulted in values that were well described by linear functions. Removal of 
auto-relaxation through the conversion of bi-exponential into hyperbolic 
tangent functions has as well been recently applied to determine accurate 
relaxation rates in cross-correlation measurements.56-58 
 
General Methods 
 
Nuclear magnetic resonance spectroscopy was performed on a Bruker 
Avance 500 UltraShield spectrometer at 500.13 MHz (1H) or 125.76 MHz 
(13C). Chemical shifts are given in ppm and were calibrated on residual 
solvent peaks59 or to tetramethyl silane as internal standard. Multiplicities 
were specified as s (singlet), m (multiplet) or interpreted according to 1st 
order60 and higher order where possible. 
 
The signals were assigned with the help of DEPT-135, 1H,1H-COSY/TOCSY 
and 1H,13C-HSQC/HMBC experiments. Assignments are indicated according 
to IUPAC nomenclature. For complex molecules, the following prefixes for 
substructures are used: Ara (arabinose), Gal (galactose), GlcNAc (N-acetyl 
glucosamine), PhAra (5C-phenylarabinose) and Sia (sialic acid, N-
acetylneuraminic acid). Ci indicates the ipso substituted carbons of aromatic 
systems. 
 
Optical rotations were measured on a Perkin Elmer 341 polarimeter in the 
indicated solvents in p.a. quality. ESI mass spectra were recorded on a 
Waters micromass ZQ instrument. High resolution mass spectra were 
obtained on a ESI Bruker Daltonics micrOTOF spectrometer equipped with a 
TOF hexapole detector. Melting points were determined with a capillary 
apparatus and are uncorrected.  
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TLC was performed using silica gel 60 coated glass plates containing 
fluorescence indicator (Merck KGaA, Darmstadt, Germany) using UV light 
(254 nm) and by charring either in aqueous KMnO4 solution or in a molybdate 
solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and 
ammonium molybdate tetrahydrate in aqueous 10% H2SO4) with heating to 
140 °C for 5 min. Column chromatography was performed using silica gel 60 
(0.040-0.063 mm) from Fluka. Solvents were purchased from Fluka and dried 
prior to use. CH2Cl2 was dried by filtration through basic aluminum oxide 
(Fluka) and Et2O by distillation from sodium/benzophenone. DMF was dried 
over activated molecular sieves and MeOH by distillation from sodium 
methoxide. 
 
Biological data were obtained using the published ELISA procedure with 
CGP69669A61 as reference compound.42 
 
(1S)-2,3-5,6-Di-O-acetonide-(1S)-1C-phenyl-D-mannitol (6). To a stirred, 
cooled (-78 °C) suspension of 5 (6.73 g, 25.9 mmol) in anhydrous Et2O       
(25 mL) was added dropwise phenyllithium (68 mL, 129.4 mmol, ca. 1.9 M 
solution in Et2O), the mixture was warmed to -41 °C whereupon a clear brown 
solution was obtained. The mixture was stirred over night and then quenched 
with saturated aqueous NaHCO3 (10 mL) at -20 °C to give a yellow solution. 
After dilution with EtOAc (500 mL) the mixture was washed with half-saturated 
brine (2 x 150 mL). The combined aqueous layers were extracted with EtOAc 
(2 x 500 mL). The combined organic layers were dried (Na2SO4) and 
concentrated. Purification of the residue by column chromatography on silica 
(PhMe/EtOAc, 4/1) yielded the separate (1R) diastereomer and the title 
compound 6 (sum of diastereomers: 6.50 g, 76%, d.r. 1/4). 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.47-7.43 (m, 2H, Ar-H), 7.40-7.36 (m, 2H, Ar-
H), 7.34-7.30 (m, 1H, p-Ar-H), 4.97 (d, 3J = 3.8 Hz, 1H, H-1), 4.52 (dd, 3J = 
3.9, 3J = 7.5 Hz, 1H, H-2), 4.39 (d, 3J = 7.5 Hz, 1H, H-3), 4.11-4.01 (m, 3H, H-
5, H-6a/b), 3.60 (d, 3J = 7.2 Hz, 1H, H-4), 1.60, 1.41, 1.33, 1.27 (4s, 12H, 
CH3); 
 
13C-NMR (125.8 MHz, CDCl3): δ 140.7 (Ar-Ci), 128.9, 128.5, 127.3 (5C, Ar-
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CH), 109.5, 108.8 (2C, ketal-C), 80.3 (C-3), 76.3 (C-5), 76.0 (C-2), 72.2 (C-1), 
70.4 (C-4), 67.3 (C-6), 26.9, 26.7, 25.5, 24.9 (4C, CH3); 
 
elemental analysis calcd. for C18H26O6: C, 63.89; H, 7.74;  
found: C, 63.85; H, 7.62; 
 
ESI-MS calcd. for C18H26O6Na [M+Na]+: 361.2; found: 361.0; 
 
[α]20D = -19.5 (c 1.0, CHCl3);  
 
(1S)-2,3-5,6-Di-O-acetonide-1,4-di-O-allyl-(1S)-1C-phenyl-D-mannitol (7). 
A stirred, cooled (0 °C) solution of 6 (3.28 g, 9.68 mmol) in DMF (27 mL) was 
treated with 5 portions of NaH (in total 2.00 g, 76 mmol, of a 50% dispersion 
in oil) and, after 5 min, allyl bromide (5.0 mL, 58.1 mmol) was added. Stirring 
was continued for 1 h at r.t., then the mixture was quenched with aqueous 
saturated NaHCO3 at 0 °C. The residue was suspended in brine (500 mL) and 
extracted with CH2Cl2 (3 x 300 mL). The combined organic layers were dried 
(Na2SO4) and concentrated. Purification by column chromatography on silica 
(petrol ether/EtOAc, gradient of 0-10%) yielded 7 (3.77 g, 93%) as a colorless 
oil. 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.39-7.30 (m, 5H, Ar-H), 6.01-5.85 (m, 2H, 
All-H), 5.44-5.39 (m, 1H, All-H), 5.29-5.21 (m, 1H, All-H), 5.20-5.12 (m, 2H, 
All-H), 4.76 (d, 3J = 6.3 Hz, 1H, H-1), 4.51 (t, 3J = 6.2 Hz, 1H, H-2), 4.38-4.23 
(m, 2H, All-CH2), 4.08 (dd, 3J = 6.3, 3J =7.9 Hz, 1H, H-4), 4.02-3.92 (m, 4H, H-
3, H-6a/b, 1H of All-CH2), 3.82-3.77 (m, 1H, 1H of All-CH2), 3.54 (t, 3J = 4.6 
Hz, 1H, H-5), 1.60, 1.39, 1.38, 1.29 (4s, 12H, CH3); 
 
13C-NMR (125.8 MHz, CDCl3): δ 138.5 (Ar-Ci), 135.3, 135.1 (2C, All-C), 128.8 
(2C, Ar-CH), 128.6 (p-Ar-CH), 128.4 (2C, Ar-CH), 117.1, 116.4 (2C, All-C), 
109.5, 108.6 (2C, ketal-C), 80.5 (C-2), 79.0 (C-1), 78.9 (C-3), 78.0 (C-5), 77.9 
(C-4), 72.8, 69.1 (2C, All-CH2), 66.8 (C-6), 26.7, 26.4, 26.2, 25.1 (4C, CH3); 
 
HR-MS calcd. for C24H34O6Na [M+Na]+: 441.2253; found: 441.2284; 
 
[α]20D = +33.9 (c 1.0, CHCl3); 
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(1S)-1,4-Di-O-allyl-(1S)-1C-phenyl-D-mannitol (8). A solution of 7 (3.63 g,      
8.66 mmol) in AcOH/H2O (200 mL, 4:1) was stirred at r.t. for 10 h. 
Concentration of the solution gave spectroscopically pure 8 (2.93 g, quant.). A 
small sample was purified on silica gel with Et2O and then EtOAc to give 8 as 
a solid. 
 
m.p. 63-64 °C (Et2O/cyclohexane); 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.39-7.26 (m, 5H, Ar-H), 5.94-5.79 (m, 2H, 
All-H), 5.28-5.10 (m, 4H, All-H), 4.76 (d, 3J = 1.7 Hz, 1H, H-1), 4.11-4.09 (m, 
2H, All-CH2), 4.05-4.00 (m, 1H, All-CH2), 3.94-3.84 (m, 3H, H-3, H-4, 1H of 
All-CH2), 3.81-3.74 (m, 2H, H-5, H-6a), 3.70-3.65 (m, 1H, H-6b), 3.59 (dd, 3J = 
2.0, 3J = 8.9 Hz, 1H, H-2), 2.87 (br s, 4H, OH); 
 
13C-NMR (125.8 MHz, CDCl3): δ 139.5 (Ar-Ci), 134.6 (2C, All-C), 128.7, 128.1, 
127.4 (5C, Ar-CH), 117.8, 117.7 (2C, All-C), 79.2 (C-1), 77.5 (C-5), 75.7 (C-
2), 73.4 (All-CH2), 72.1 (C-4), 70.8 (C-3), 70.4 (All-CH2), 63.9 (C-6); 
 
elemental analysis calcd. for C18H26O6: C 63.89, H 7.74;  
found: C 63.65, H 7.80; 
 
ESI-MS calcd. for C18H26O6Na [M+Na]+: 361.2; found: 361.0; 
 
[α]20D = +68.0 (c 1.0, CHCl3);  
 
2,5-Di-O-allyl-(5S)-5C-phenyl-α ,β-D-arabinofuranose (9). To a vigorously 
stirred mixture of 8 (2.03 g, 8.66 mmol) and saturated aqueous NaHCO3       
(6 mL) in CH2Cl2 (80 mL) was added portionwise NaIO4 (2.41 g, 11.3 mmol) 
at 0 °C. The suspension was stirred at r.t. for 22 h, then diluted with H2O         
(50 mL). The phases were seperated and the aqueous layer was extracted 
with CH2Cl2 (2 x 100 mL). The combined organic layers were dried (Na2SO4) 
and concentrated. The residue was eluted from a column of silica gel 
(CH2Cl2/MeOH, gradient of 2-12%) to give 9 (2.05 g, 77%) as a mixture of 
anomers and recovered starting material (320 mg, 11%). A pure sample of α-
9 was obtained by crystallization; anomeric configurations were assigned 
based on  the chemical shift of the anomeric carbon.62 
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m.p. 97-99 °C (EtOAc/cyclohexane); 
 
[α]20D = +41.4 (c 0.9, CHCl3); 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.38-7.29 (m, 5H, Ar-H), 5.95-5.81 (m, 2H, 
All-CH), 5.36-5.17 (m, 4H, All-CH2), 5.31 (dd, 3J = 4.4, 3J = 8.3 Hz, 1H, H-1), 
4.44 (d, 3J = 5.4 Hz, 1H, H-5), 4.21 (dd, 3J = 5.4, 3J = 6.5 Hz, 1H, H-3) , 4.17-
4.04 (m, 2H, All-CH2), 3.92-3.77 (m, 4H, H-2, H-4, 2H of All-CH2); 
 
13C-NMR (125.8 MHz, CDCl3): δ 137.6 (Ar-Ci), 134.3, 134.2 (2C, All-CH), 
128.9, 128.7, 128.0 (5C, Ar-CH), 118.3, 118.2 (2C, All-CH2), 95.5 (C-1), 85.0 
(C-4), 84.6 (C-2), 81.7 (C-5), 75.2 (C-3), 71.7, 70.0 (2C, All-CH2); 
 
elemental analysis calcd. for C17H22O5: C 66.65; H 7.24;  
found: C 66.81, H 7.28; 
 
ESI-MS calcd. for C17H22O5Na [M+Na]+: 329.1; found: 328.9; 
 
NMR data for β-9 (selected): 
1H-NMR (500.1 MHz, CDCl3): δ 7.38-7.29 (m, 5H, Ar-H), 5.95-5.81 (m, 2H, 
All-CH), 5.43 (br s, 1H, H-1), 4.40 (d, 3J = 8.3 Hz, 1H, H-5), 4.33 (dd, 3J = 4.0, 
3J = 8.1 Hz, 1H, H-4), 4.06-4.02 (m, 2H, All-CH2), 3.83-3.77 (m, 2H, H-2, H-3); 
 
13C-NMR (125.8 MHz, CDCl3): δ 137.9 (Ar-Ci), 134.7, 134.2 (2C, All-CH), 
129.0, 128.8, 128.2 (5C, Ar-CH), 117.6, 117.5 (2C, All-CH2), 101.2 (C-1), 88.1 
(2C, C-2, C-4), 82.4 (C-5), 76.5 (C-3), 70.9, 69.7 (2C, All-CH2);  
 
1,2,3,4-Tetra-O-acetyl-(5S)-5C-phenyl-α,β-D-arabinopyranose (11). A 
mixture of 9 (1.67 g, 5.45 mmol), palladium on activated carbon (1.5 g, 
Degussa catalyst E101 NE/W 10%) and camphorsulfonic acid (0.24 g,      
1.05 mmol) in dioxane/H2O (1:1, 38 mL) was degassed and saturated with 
nitrogen. The suspension was stirred at 95 °C for 45 h in a screw-capped vial, 
then cooled to r.t., diluted with Et3N (0.5 mL) and filtered through a pad of 
celite. The solution was concentrated to give crude phenylarabinose 10. A 
solution of the crude product and DMAP (40 mg) in pyridine (10 mL) and 
acetic anhydride (10 mL) was stirred at r.t. for 45 min. Concentration and 
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purification by column chromatography on silica (petrol ether/EtOAc, 5:2) 
gave 11 (1.49 g, 69%) as a mixture of anomers (α:β = 1:1.8). 
 
NMR data for α-11: 
1H-NMR (500.1 MHz, CDCl3): δ 7.38-7.26 (m, 5H, Ar-H), 6.57 (d, 3J = 3.5 Hz, 
1H, H-1), 5.59 (br s, 1H, H-4), 5.57-5.52 (m, 1H, H-3), 5.48-5.43 (m, 1H, H-2), 
5.24 (br s, 1H, H-5), 2.17, 2.06, 2.01, 1.91 (4 s, 12H, 4 COCH3); 
 
13C-NMR (125.8 MHz, CDCl3): δ 170.4, 170.2, 170.0, 169.2 (4C, CH3CO), 
135.6 (Ar-Ci), 128.5, 128.4, 126.4 (5C, Ar-CH), 90.1 (C-1), 73.0 (C-5), 70.9 
(C-4), 68.0 (C-3), 66.7 (C-2), 21.1, 20.9, 20.8, 20.6 (4C, CH3CO);  
 
NMR data for β-11: 
1H-NMR (500.1 MHz, CDCl3): δ 7.38-7.26 (m, 5H, Ar-H), 5.86 (d, 3J = 8.2 Hz, 
1H, H-1), 5.57-5.52 (m, 1H, H-4), 5.48-5.43 (m, 1H, H-2), 5.28 (dd, 3J = 3.2,3J 
= 10.5 Hz, 1H, H-3), 4.92 (br s, 1H, H-5), 2.15, 2.08, 2.00, 1.93 (4 s, 12H, 4 
CH3CO); 
 
13C-NMR (125.8 MHz, CDCl3): δ 170.3, 170.0, 169.7, 169.3 (4C, CH3CO), 
135.2 (Ar-Ci), 128.5, 128.4, 126.3 (5C, Ar-CH), 92.6 (C-1), 75.8 (C-5), 71.5 
(C-3), 70.2 (C-4), 68.1 (C-2), 21.1, 20.9, 20.8, 20.6 (4C, CH3CO);  
 
ESI-MS calcd. for C19H22O9Na [M+Na]+: 417.1; found: 416.9. 
 
elemental analysis calcd. for C19H22O9 (394.4) C 57.86, H 5.62;  
found: C 58.05, H 5.73. 
 
Ethyl 2,3,4-tri-O-acetyl-(5S)-5C-phenyl-1-thio-α ,β-D-arabinopyranoside 
(12). To a stirred solution of 11 (1.58 g, 4.00 mmol) and ethanethiol (0.89 mL,   
12.0 mmol) in anhydrous CH2Cl2 (20 mL) was added dropwise trimethylsilyl 
triflate (0.73 mL, 4.0 mmol) at 0 °C. The solution was stirred at r.t. for 3 h and 
then diluted with Et3N (1 mL). The reaction was concentrated and the residue 
purified by column chromatography on silica (cyclohexane/EtOAc, 5/1) to give 
α-12 (349 mg, 22%) as a syrup and β-12 (682 mg, 43%) as a solid.  
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data for α-12: 
1H-NMR (500.1 MHz, CDCl3): δ 7.35-7.29 (m, 5H, Ar-H), 5.92 (d, 3J = 4.8 Hz, 
1H, H-1), 5.58-5.56 (m, 1H, H-4), 5.48 (br s, 1H, H-5), 5.42-5.39 (m, 2H, H-2, 
H-3), 2.61-2.47 (m, 2H, SCH2CH3), 2.11, 2.00, 1.91 (3 s, 9H, 3 CH3CO), 1.22 
(t, 3J = 7.4 Hz, 3H, SCH2CH3); 
 
13C-NMR (125.8 MHz, CDCl3): δ 170.6, 170.2, 170.1 (3C, CH3CO), 136.4 (Ar-
Ci), 128.4, 128.2, 126.6 (5C, Ar-CH), 82.4 (C-1), 71.2 (C-4), 70.5 (C-5), 68.9 
(C-2), 68.3 (C-3), 24.4 (SCH2CH3), 21.1, 20.9, 20.6 (3C, CH3CO), 14.9 
(SCH2CH3);  
 
elemental analysis calcd. for C19H24O7S (396.5): C 57.56, H 6.10;  
found: C 57.83, H 6.21; 
 
[α]20D = -192.8 (c 1.0, CHCl3); 
 
data for β-12: 
m.p. 124-125 °C (cyclohexane); 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.36-7.28 (m, 5H, Ar-H), 5.55 (dd, 3J = 1.1, 3J 
= 3.4 Hz, 1H, H-4), 5.37 (t, 3J = 9.9 Hz, 1H, H-2), 5.25 (dd, 3J = 3.3, 3J = 10.2 
Hz, 1H, H-3), 4.80 (br s, 1H, H-5), 4.65 (d, 3J = 10.0 Hz, 1H, H-1), 2.88-2.71 
(m, 2H, SCH2CH3), 2.11, 1.99, 1.92 (3 s, 9H, 3 CH3CO), 1.32 (t, 3J = 7.5 Hz, 
3H, SCH2CH3); 
 
13C-NMR (125.8 MHz, CDCl3): δ 170.4, 170.2, 170.0 (3C, CH3CO), 136.2 (Ar-
Ci), 128.4, 128.3, 126.3 (5C, Ar-CH), 83.9 (C-1), 78.8 (C-5), 72.6 (C-3), 70.7 
(C-4), 67.4 (C-2), 24.3 (SCH2CH3), 21.1, 20.9, 20.7 (3C, CH3CO), 15.2 
(SCH2CH3);  
 
elemental analysis calcd. for C19H24O7S (396.5): C 57.56, H 6.10;  
found: C 57.68, H 6.12; 
 
[α]20D = +15.0 (c 0.9, CHCl3);  
 
Ethyl 2,3,4-tri-O-benzyl-(5S)-5C-phenyl-1-thio-β-D-arabinopyranoside (β-
13). A solution of β-12 (600 mg, 1.52 mmol) in MeOH (16 mL) was treated 
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with freshly prepared NaOMe in MeOH (1 M, 1.0 mL). After 3 h at r.t., the 
solution was neutralized with Amberlite IR 120 and concentrated. A stirred, 
cooled (0 °C) solution of the crude product in DMF (8 mL) was treated with 
NaH (260 mg, 6.8 mmol of a 60% dispersion in oil) for 10 min and then benzyl 
bromide (0.65 mL, 5.4 mmol) was added dropwise. Stirring was continued for 
1 h at r.t., then the mixture was diluted with MeOH (2 mL) and after 10 min 
concentrated in high vacuum. The residue was suspended in H2O (20 mL) 
and extracted with CH2Cl2 (2 x 60 mL). The combined organic layers were 
dried (Na2SO4) and concentrated. The residue was eluted from a column of 
silica gel (cyclohexane/Et2O, 10:1) to give β-13 (720 mg, 88%) as a solid.  
 
m.p. 114-116 °C (MeOH); 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.45-7.41 (m, 2H, Ar-H), 7.38-7.27 (m, 13H, 
Ar-H), 7.17-7.12 (m, 3H, Ar-H), 6.93-6.91 (m, 2H, Ar-H), 4.93, 4.84 (A, B of 
AB, 2J = 10.3 Hz, 2H, PhCH2), 4.73, 4.70 (A’, B’ of A’B’, 2J = 11.9 Hz, 2H, 
PhCH2), 4.58 (d, 3J = 9.6 Hz, 1H, H-1), 4.47 (s, 1H, H-5), 4.45, 4.18 (A’’, B’’ of 
A’’B’’, 2J = 11.8 Hz, 2H, PhCH2), 3.95 (t, 3J = 9.4 Hz, 1H, H-2), 3.92 (d, 3J = 
2.4 Hz, 1H, H-4), 3.74 (dd, 3J = 2.9, 3J = 9.4 Hz, 1H, H-3), 2.90-2.70 (m, 2H, 
SCH2CH3), 1.32 (t, 3J = 7.5 Hz, 3H, SCH2CH3); 
 
13C-NMR (125.8 MHz, CDCl3): δ 138.4-138.2 (4C, Ar-Ci), 128.4-126.4 (20C, 
Ar-CH), 85.1 (C-1), 84.2 (C-3), 79.7 (C-5), 78.0 (C-4), 77.4 (C-2), 75.7, 74.3, 
72.6 (3C, PhCH2), 24.5 (SCH2CH3), 15.2 (SCH2CH3);  
 
elemental analysis calcd. for C34H36O4S (540.7): C 75.52, H 6.71;  
found: C 75.40, H 6.73; 
 
ESI-MS calcd. for C34H36O4SNa [M+Na]+: 563.2; found: 563.3; 
 
[α]20D = +42.3 (c 1.0, CHCl3);  
 
2-Trimethylsilylethyl β-D-2-acetamido-4,6-O-benzylidene-3-O-[2,3,4-tri-O-
benzyl-(5S)-5C-phenyl-α-L-arabinopyranosyl]-2-deoxy-gluco-pyranoside 
(15). A solution of donor 13 (121 mg, 0.22 mmol), GlcNAc acceptor 14        
(84 mg, 0.21 mmol) and freshly activated molecular sieves (4Å, 400 mg) in 
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dry CH2Cl2 (20 mL) was stirred under argon at r.t. over night. After cooling the 
mixture to -70 °C, NIS (126 mg, 0.56 mmol) and silver triflate (23 mg,        
0.09 mmol) were added. The initially colorless reaction was protected from 
light and allowed to warm to r.t. during 5 h. The cherry-red suspension was 
quenched with aqueous satd. Na2SO3 (20 mL), the phases were separated 
and the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried over Na2SO4 and concentrated to give the crude 
product as foam. Purification by column chromatography (PhMe/EtOAc, 5:1) 
gave β-15 (20 mg, 11%) as a side product and α-15 (98 mg, 55%). 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.39-6.78 (m, 25H, Ar-H), 5.60 (d, 3J = 7.6 Hz, 
1H, NH), 5.46 (s, 1H, PhCH(OR)2), 5.36 (d, 3J = 3.4 Hz, 1H, PhAra-H1), 5.11 
(s, 1H, PhAra-H5), 4.94 (A of AB, 2J = 11.2 Hz, 1H, PhCH2), 4.76-4.70 (m, 
3H, GlcNAc-H1, 2H of PhCH2), 4.68 (B of AB, 2J = 11.3 Hz, 1H, PhCH2), 4.41 
(A’ of A’B’, 2J = 11.2 Hz, 1H, PhCH2), 4.31 (dd, 2J = 10.4, 3J = 5.0 Hz, 1H, 
GlcNAc-H6a), 4.23 (t, 3J = 9.6 Hz, 1H, GlcNAc-H3), 4.19 (dd, 3J = 3.5, 3J = 
10.1 Hz, 1H, PhAra-H2), 4.13 (dd, 3J = 2.6, 3J = 10.1 Hz, 1H, PhAra-H3), 3.99 
(B’ of A’B’, 2J = 11.2 Hz, 1H, PhCH2), 3.92 (td, 2J = 10.3, 3J = 4.8 Hz, 1H, 1H 
of OCH2CH2), 3.90 (br s, 1H, PhAra-H4), 3.73 (t, 3J = 10.3 Hz, 1H, GlcNAc-
H6b), 3.60 (t, 3J = 9.3 Hz, 1H, GlcNAc-H4), 3.57-3.47 (m, 2H, GlcNAc-H2, 1H 
of OCH2CH2), 3.43 (td, 3J = 5.0, 3J = 9.7 Hz, 1H, GlcNAc-H5), 1.67 (s, 3H, 
NHAc), 0.97-0.83 (m, 2H, OCH2CH2), 0.00 (s, 9H, Me3Si); 
 
13C-NMR (125.8 MHz, CDCl3): δ 170.7 (CH3CO), 138.8, 138.7, 138.3, 137.3 
(5C, Ar-Ci), 129.0-126.2 (25C, Ar-CH), 101.5 (Ph-CH(OR)2), 100.8 (GlcNAc-
C1), 98.5 (PhAra-C1), 81.1 (GlcNAc-C4), 79.6 (PhAra-C3), 79.1 (PhAra-C4), 
77.4 (PhAra-C2), 75.6 (GlcNAc-C3), 75.1, 74.5 (2C, PhCH2), 72.6 (PhAra-
C5), 72.5 (PhCH2), 69.0 (GlcNAc-C6), 67.5 (OCH2CH2), 66.4 (GlcNAc-C5), 
57.8 (GlcNAc-C2), 23.5 (CH3CO), 18.2 (OCH2CH2), -1.2 (Me3Si);  
 
HR-MS calcd. for C52H61NO10SiNa [M+Na]+: 910.3962; found: 910.3950; 
 
[α]20D = -69.5 (c 1.3, CHCl3);  
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2-Trimethylsilylethyl β-D-2-acetamido-6-O-benzyl-3-O-[2,3,4-tri-O-benzyl-
(5S)-5C-phenyl-α-L-arabinopyranosyl]-2-deoxy-glucopyranoside (16). 
Benzylidene 15 (84 mg, 0.10 mmol) was dissolved in dry THF (2 mL) under 
argon and BH3•Me3N (28 mg, 0.38 mmol) was added, followed by anhydrous 
AlCl3 (76 mg, 0.57 mmol). Water (3.4 µL, 0.19 mmol) was added to the clear 
solution, whereupon the reaction mixture turned turbid. After stirring for 3.5 h 
at r.t., the mixture was quenched with water (1 mL) and aqueous HCl (0.5 M, 
1 mL), followed by extraction of the product with CH2Cl2 (3 x 10 mL). The 
combined organic layers were washed with aqueous satd. NaHCO3 (10 mL), 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified 
by column chromatography on silica (PhMe/EtOAc, 5:1) to give 16 as white 
solid (53 mg, 62%). 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.40-6.85 (m, 25H, Ar-H), 5.44 (d, 3J = 5.4 Hz, 
1H, NH), 5.18 (d, 3J = 2.8 Hz, 1H, PhAra-H1), 5.10 (s, 1H, PhAra-H5), 4.94 (d, 
3J = 8.0 Hz, 1H, GlcNAc-H1), 4.90 (A of AB, 2J = 11.6 Hz, 1H, PhCH2), 4.76, 
4.73 (A’,B’ of A’B’, 2J = 11.8 Hz, 2H, PhCH2), 4.70 (B of AB, 2J = 11.6 Hz, 1H, 
PhCH2), 4.57, 4.55 (A’’, B’’ of A’’B’’, 2J = 12.3 Hz, 2H, PhCH2), 4.46 (A’’’ of 
A’’’B’’’, 2J = 11.3 Hz, 1H, PhCH2), 4.18 (dd, 3J = 3.4, 3J = 10.1 Hz, 1H, PhAra-
H2), 4.14 (dd, 3J = 1.5, 3J = 10.2 Hz, 1H, PhAra-H3), 4.08-4.05 (m, 2H, 
GlcNAc-H3, 1H of PhCH2), 3.98-3.93 (m, 2H, PhAra-H4, 1H of OCH2CH2), 
3.76 (d, 2J = 10.8 Hz, 1H, GlcNAc-H6a), 3.61 (dd, 2J = 10.8, 3J = 5.3 Hz, 1H, 
GlcNAc-H6b), 3.56-3.42 (m, 3H, GlcNAc-H4, -H5, 1H of OCH2CH2), 3.27-3.22 
(m, 1H, GlcNAc-H2), 1.48 (s, 3H, NHAc), 0.98-0.84 (m, 2H, OCH2CH2), -0.02 
(s, 9H, Me3Si); 
 
13C-NMR (125.8 MHz, CDCl3): δ 171.0 (CH3CO), 138.6, 138.5, 138.3, 138.1, 
137.8 (5C, Ar-Ci), 128.8-126.6 (25C, Ar-CH), 99.4 (GlcNAc-C1), 97.6 (PhAra-
C1), 82.5 (GlcNAc-C3), 79.4 (PhAra-C3), 78.6 (PhAra-C4), 76.0 (PhAra-C2), 
75.0 (PhCH2), 74.9 (GlcNAc-C4), 74.6, 73.6 (2C, PhCH2), 73.3 (PhAra-C5), 
72.7 (PhCH2), 69.8 (GlcNAc-C5), 69.7 (GlcNAc-C6), 67.1 (OCH2CH2), 56.5 
(GlcNAc-C2), 23.2 (CH3CO), 18.2 (OCH2CH2), -1.2 (Me3Si);  
 
HR-MS calcd. for C52H63NO10SiNa [M+Na]+: 912.4119; found: 912.4108; 
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[α]20D = -26.1 (c 0.52, CHCl3);  
 
2-Trimethylsilylethyl β-D-2-acetamido-3-O-chloroacetyl-6-O-benzyl-2-
deoxy-glucopyranoside (20). Benzylidene 19 (29 mg, 0.06 mmol) was 
dissolved in dry THF (1.2 mL) under argon and BH3•Me3N (19 mg, 0.26 mmol) 
was added, followed by anhydrous AlCl3 (52 mg, 0.39 mmol). Water (2 µL, 
0.12 mmol) was added to the clear solution, whereupon the reaction mixture 
turned turbid. After stirring for 2 h at r.t., the mixture was quenched with water 
(1 mL) and aqueous HCl (0.5 M, 1 mL), followed by extraction of the product 
with EtOAc (3 x 1 mL). The combined organic layers were washed with brine 
(1 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by column chromatography on silica (PhMe/EtOAc, 1:1 to 2:3) to give 
20 as white foam (27 mg, 92%). 
 
1H-NMR (500.1 MHz, CDCl3): δ 7.35-7.27 (m, 5H, Ar-H), 5.55 (d, 3J = 8.9 Hz, 
1H, NH), 5.16 (t, 3J = 9.8 Hz, 1H, H-3), 4.61-4.52 (m, 3H, H-1, 2H of PhCH2), 
4.09 (s, 2H, ClCH2), 3.96-3.89 (m, 1H, OCH2CH2), 3.89-3.82 (m, 1H, H-2), 
3.81-3.72 (m, 3H, H-4, H-6a,b), 3.57-3.48 (m, 2H, H-5, 1H of OCH2CH2), 3.05 
(br s, 1H, OH), 1.92 (s, 3H, NHAc), 0.96-0.79 (m, 2H, OCH2CH2), -0.02 (s, 
9H, Me3Si); 
 
13C-NMR (125.8 MHz, CDCl3): δ 170.6 (CH3CO), 168.4 (ClCH2CO), 137.6 (Ar-
Ci), 128.8, 128.2, 128.0 (5C, Ar-CH), 100.3 (C-1), 77.4 (C-3), 74.0 (PhCH2), 
73.6 (C-5), 71.3 (C-6), 70.7 (C-4), 67.3 (OCH2CH2), 54.5 (C-2), 41.1 (ClCH2), 
23.6 (CH3CO), 18.2 (OCH2CH2), -1.2 (Me3Si);  
 
HR-MS calcd. for C22H34ClNO7SiNa [M+Na]+: 510.1691; found: 510.1678; 
 
[α]20D = -45.5 (c 1.0, CHCl3);  
 
2-Trimethylsilylethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-
dideoxy-D-glycero-α-D-galacto-2-nonulopyranosidonate)-(2→3)-(2,4-di-
O-acetyl-6-O-benzoyl-β-D-galactopyranosyl)-(1→4)-2-acetamido-6-O-
benzyl-3-O-chloroacetyl-2-deoxy-β-D-glucopyranoside (21). To a solution 
of thioglycoside 17 (96 mg, 0.10 mmol) and acceptor 20 (97 mg, 0.20 mmol) 
in dry CH2Cl2 (4 mL) was added freshly activated molecular sieves (4Å,      
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400 mg). In a separate flask, DMTST (77 mg, 0.30 mmol) was dissolved in 
dry CH2Cl2 (1 mL) and freshly activated molecular sieves (4Å, 350 mg) were 
added. Both mixtures were stirred under argon for 6 h at r.t., then the DMTST 
mixture was transferred to the cooled (0 °C) mixture of donor and acceptor. 
After stirring for 2.5 days at 0 °C, the reaction was diluted with CH2Cl2 and 
filtered over celite. The celite was washed with CH2Cl2 (2 x 20 mL) and the 
solution was dried over Na2SO4 and concentrated to give the crude product 
as foam. Purification by column chromatography (CH2Cl2/acetone, gradient of 
10:1 to 4:1) gave 21 (95 mg, 68%) as foam. 
 
1H-NMR (500.1 MHz, CD2Cl2): δ 8.09-8.05 (m, 2H, Bz-H), 7.60-7.57 (m, 1H, 
Bz-H), 7.50-7.46 (m, 2H, Bz-H), 7.38-7.30 (m, 9H, Ar-H), 7.28-7.23 (m, 1H, 
Ar-H), 5.77 (d, 3J = 9.2 Hz, 1H, GlcNAc-NH), 5.57-5.52 (m, 1H, Sia-H8), 5.33 
(dd, 1H, 3J = 2.6, 3J =10.3 Hz, Sia-H7), 5.30 (A of AB, 2J = 14.4 Hz, 1H, 
PhCH2), 5.23 (d, 3J = 10.0 Hz, 1H, Sia-NH), 5.17 (dd, 3J = 8.8, 3J = 10.5 Hz, 
1H, GlcNAc-H3), 5.14 (d, 3J = 3.2 Hz, 1H, Gal-H4), 4.97 (B of AB, 2J = 12.4 
Hz, 1H, PhCH2), 4.92-4.86 (m, 2H, Gal-H2, Sia-H4), 4.81 (d, 3J = 8.1 Hz, 1H, 
Gal-H1), 4.70-4.66 (m, 2H, Gal-H3, PhCH2), 4.54 (B’ of A’B’, 2J = 12.0 Hz, 1H, 
PhCH2), 4.49 (d, 3J = 8.0 Hz, 1H, GlcNAc-H1), 4.34 (dd, 2J = 11.1, 3J = 6.9 
Hz, 1H, Gal-H6a), 4.28-4.19 (m, 3H, Gal-H6b, Sia-H9a, 1H of ClCH2), 4.14 (d, 
1H, 2J = 14.9 Hz, ClCH2), 4.05-3.92 (m, 5H, Gal-H5, GlcNAc-H4, Sia-H5, -
H9b, 1H of OCH2CH2), 3.89 (‘q’, 3J = 8.9 Hz, 1H, GlcNAc-H2), 3.84-3.80 (m, 
1H, GlcNAc-H6a), 3.74 (dd, 2J = 10.8, 3J = 4.5 Hz, 1H, GlcNAc-H6b), 3.60-
3.51 (m, 3H, GlcNAc-H5, Sia-H6, 1H of OCH2CH2), 2.62 (dd, 2J = 13.0, 3J = 
4.7 Hz, 1H, Sia-H3eq), 2.19, 2.09, 2.08, 2.02, 1.96, 1.94, 1.91, 1.80 (8 s, 24H, 
8 Ac), 1.64 (‘t’, 2J = 3J = 12.4 Hz, 1H, Sia-H3ax), 0.99-0.83 (m, 2H, OCH2CH2), 
0.01 (s, 9H, Me3Si); 
 
13C-NMR (125.8 MHz, CD2Cl2): δ 171.0, 170.9, 170.7, 170.7, 170.6, 170.4, 
170.0, 170.0 (8C, CH3CO), 167.9 (Sia-C1), 167.8 (ClCH2CO), 166.1 (ArCO), 
138.9 (GlcNAc-6-OBn-Ar-Ci), 135.3 (Sia-1O-Bn-Ar-Ci), 133.9 (Bz, Ar-Ci), 
130.2, 129.1, 129.0, 128.8, 128.0 (15C, Ar-CH), 100.9 (Gal-C1), 100.8 
(GlcNAc-C1), 97.3 (Sia-C2), 75.9 (GlcNAc-C3), 75.3 (GlcNAc-C4), 75.0 
(GlcNAc-C5), 73.7 (PhCH2), 72.6 (Sia-C6), 71.9 (Gal-C3), 71.1 (Gal-C5), 70.8 
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(Gal-C2), 69.7 (Sia-C4), 68.9 (PhCH2), 68.7 (GlcNAc-C6), 68.1 (Sia-C8), 67.8 
(Gal-C4), 67.7 (Sia-C7), 67.5 (OCH2CH2Si), 62.9 (Sia-C9), 61.8 (Gal-C6), 
54.3 (GlcNAc-C2), 49.2 (Sia-C5), 41.6 (ClCH2), 37.9 (Sia-C3), 23.7, 23.5, 
21.7, 21.5, 21.2, 21.1, 21.0, 21.0 (8C, CH3CO), 18.4 (OCH2CH2), -1.2 (Me3Si); 
 
HR-MS calcd. for C65H83ClN2O27SiNa [M+Na]+: 1409.4539; found: 1409.4558; 
 
[α]20D = +0.5 (c 0.5, CHCl3);  
 
2-Trimethylsilylethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-
dideoxy-D-glycero-α-D-galacto-2-nonulopyranosidonate)-(2→3)-(2,4-di-
O-acetyl-6-O-benzoyl-β-D-galactopyranosyl)-(1→4)-2-acetamido-6-O-
benzyl-2-deoxy-β-D-glucopyranoside (22). To a solution of chloroacetyl 
protected 21 (77 mg, 55 µmol) in dry DMF/2,6-di-tert. butyl pyridine (11:1,   
1.5 mL) was added thiourea (21 mg, 277 µmol). The colorless solution was 
stirred for 22 h at 70 °C under argon. Then, the volatiles were removed and 
the residue was purified by column chromatography (CH2Cl2/acetone, 
gradient of 7:1 to 2:1) to give 22 (46 mg, 63%) as foam. 
 
1H-NMR (500.1MHz, CD2Cl2): δ 8.13-8.07 (m, 2H, Bz-H), 7.62-7.56 (m, 1H, 
Bz-H), 7.51-7.47 (m, 2H, Bz-H), 7.44-7.27 (m, 10H, Ar-H), 5.62 (d, 3J = 8.5 
Hz, 1H, GlcNAc-NH), 5.54-5.50 (m, 1H, Sia-H8), 5.38 (A of AB, 2J = 12.1 Hz, 
1H, PhCH2), 5.32-5.28 (m, 2H, Sia-H7, Sia-NH), 5.12 (d, 3J = 2.9 Hz, 1H, Gal-
H4), 5.05-5.00 (m, 2H, Gal-H2, 1H of PhCH2), 4.91 (dt, 3J = 4.6, 3J = 11.5 Hz, 
1H, Sia-H4), 4.81 (d, 3J = 8.0 Hz, 1H, Gal-H1), 4.75 (dd, 3J = 3.3, 3J = 10.1 
Hz, 1H, Gal-H3), 4.66, 4.55 (A’,B’ of A’B’, 2J = 11.9 Hz, 2H, PhCH2), 4.47 (d, 
3J = 8.0 Hz, 1H, GlcNAc-H1), 4.43 (dd, 2J = 11.3, 3J = 4.3 Hz, 1H, Gal-H6a), 
4.27-4.10 (m, 3H, Gal-H5, -H6b, Sia-H9a), 4.01 (‘q’, 3J = 10.4 Hz, 1H, Sia-
H5), 3.95 (dt, 2J = 10.1, 3J = 4.7 Hz, 1H, 1H of OCH2CH2), 3.89 (dd, 2J = 12.3, 
3J = 6.2 Hz, 1H, Sia-H9b), 3.80-3.50 (m, 8H, GlcNAc-H2, H-3, -H4, -H5, -
H6a/b, Sia-H6, 1H of OCH2CH2), 2.63 (dd, 2J = 12.6, 3J = 4.5 Hz, 1H, Sia-
H3eq), 2.21, 2.13, 2.09, 2.03, 1.96, 1.94, 1.90, 1.80 (8 s, 24H, 8 Ac), 1.63 (‘t’, 
2J = 3J = 12.3 Hz, 1H, Sia-H3ax), 0.99-0.83 (m, 2H, OCH2CH2), -0.01 (s, 9H, 
Me3Si); 
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13C-NMR (125.8 MHz, CD2Cl2): δ 171.1, 170.9, 170.8, 170.7, 170.7, 170.6, 
170.5, 170.1 (8C, CH3CO), 167.9 (Sia-C1), 166.5 (ArCO), 139.1 (GlcNAc-6-
OBn-Ar-Ci), 135.3 (Sia-1O-Bn-Ar-Ci), 133.9 (Bz, Ar-Ci), 130.4, 130.1, 129.3, 
129.1, 128.8, 128.0 (15C, Ar-CH), 102.1 (Gal-C1), 100.9 (GlcNAc-C1), 97.4 
(Sia-C2), 82.6 (GlcNAc-C3), 74.7 (GlcNAc-C4), 73.8 (PhCH2), 73.5 (GlcNAc-
C5), 72.8 (Sia-C6), 71.9 (Gal-C3), 71.8 (Gal-C5), 70.5 (Gal-C2), 69.8 (Sia-
C4), 69.5 (GlcNAc-C6), 69.0 (PhCH2), 68.4 (Sia-C8), 68.3 (Gal-C4), 67.9 (Sia-
C7), 67.4 (OCH2CH2), 63.1 (Sia-C9), 63.0 (Gal-C6), 56.2 (GlcNAc-C2), 49.2 
(Sia-C5), 38.1 (Sia-C3), 23.9, 23.5, 21.8, 21.5, 21.2, 21.1, 21.1, 21.0 (8C, 
CH3CO), 18.5 (OCH2CH2), -1.2 (Me3Si); 
 
HR-MS calcd. for C63H82N2O26SiNa [M+Na]+: 1333.4823; found: 1333.4813; 
 
[α]20D = +18.9 (c 2.0, CHCl3);  
 
2-Trimethylsilylethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-
dideoxy-D-glycero-α-D-galacto-2-nonulopyranosidonate)-(2→3)-(2,4-di-
O-acetyl-6-O-benzoyl-β-D-galactopyranosyl)-(1→4)-[(2,3,4-tri-O-benzyl-
(5S)-5C-phenyl-α-L-arabinopyranosyl-(1→3)]-2-acetamido-6-O-benzyl-2-
deoxy-β-D-glucopyranoside (18). To a solution of thioglycoside 13 (109 mg, 
0.20 mmol) in dry CH2Cl2 (0.8 mL) was added Br2 (11.7 µL, 0.23 mmol) at      
0 °C. After stirring the mixture for 30 min at 0 °C, excess Br2 was quenched 
with cyclohexene (2 drops). This solution was then transferred to a 
suspension of acceptor 22 (152 mg, 0.116 mmol), Et4NBr (65 mg, 0.31 mmol) 
and activated molecular sieves (4Å, 2.0 g) in dry CH2Cl2 (1.2 mL) and DMF 
(0.9 mL). The reaction was stirred under argon at r.t. for 3 d. The mixture was 
filtered over celite and washed with dry CH2Cl2 (60 mL). The organic phase 
was washed with aqueous satd. NaHCO3 (10 mL) and with brine (5 mL), and 
then dried over Na2SO4. Removal of the volatiles and purification by column 
chromatography (SiO2, EtOAc) gave recovered acceptor 22 (84 mg, 55%) and 
18 as off-white solid (77 mg, 37%). 
 
1H-NMR (500.1 MHz, CD2Cl2): δ 8.07-8.01 (m, 2H, Bz-H), 7.53-7.50 (m, 1H, 
Bz-H), 7.46-7.15 (m, 30H, Ar-H), 6.94-6.89 (m, 2H, PhAra-Ar-H), 6.17 (d, 3J = 
9.3 Hz, 1H, GlcNAc-NH), 5.63-5.60 (m, 1H, Sia-H8), 5.49 (d, 3J = 3.3 Hz, 1H, 
2. Results and Discussion 
- 162 - 
PhAra-H1), 5.32-5.28 (m, 2H, Sia-H7, 1H of PhCH2), 5.15 (d, 3J = 3.1 Hz, 1H, 
Gal-H4), 5.03 (d, 3J = 10.2 Hz, 1H, Sia-NH), 4.98-4.84 (m, 6H, Gal-H2, 
PhAra-H5, Sia-H4, 3H of PhCH2), 4.75-4.71 (m, 4H, Gal-H1, -H3, 2H of 
PhCH2), 4.54 (A of AB, 2J = 11.8 Hz, 1H, 1H of PhCH2), 4.50-4.47 (m, 2H, 
Gal-H5, GlcNAc-H1), 4.39 (B of AB, 2J = 11.8 Hz, 1H, 1H of PhCH2), 4.33 (dd, 
2J = 12.3, 3J = 2.0 Hz, 1H, Sia-H9a), 4.14 (dd, 3J = 3.3, 3J = 10.2 Hz, 1H, 
PhAra-H2), 4.11-4.07 (m, 2H, Gal-H6a, GlcNAc-H2), 4.05-3.86 (m, 11H, Gal-
H6b, GlcNAc-H3, -H4, -H5, -H6b, PhAra-H3, Sia-H5, -H9b, 1H of OCH2CH2, 
2H of PhCH2), 3.84 (br s, 1H, PhAra-H4), 3.81-3.78 (m, 1H, GlcNAc-H6b), 
3.57 (dd, 3J = 2.0, 3J = 10.8 Hz, 1H, Sia-H6), 3.48 (dt, 2J = 10.7, 3J = 6.2 Hz, 
1H, 1H of OCH2CH2TMS), 2.61 (dd, 2J = 12.5, 3J = 4.4 Hz, 1H, Sia-H3eq), 
2.23, 2.12, 2.02, 2.01, 1.96, 1.94, 1.93, 1.80 (8 s, 24H, 8 Ac), 1.68 (‘t’, 2J = 3J 
= 12.3 Hz, 1H, Sia-H3ax), 1.00-0.81 (m, 2H, OCH2CH2), -0.02 (s, 9H, Me3Si); 
 
13C-NMR (125.8 MHz, CD2Cl2): δ 171.2, 171.0, 170.9, 170.8, 170.5, 170.5, 
170.2, 170.1, (8C, CH3CO), 167.9 (Sia-C1), 165.9 (ArCO), 139.8, 139.5, 
139.0, 139.0, 138.9 (5C, Ph-Ci), 135.4 (Sia-1O-Bn-Ar-Ci), 133.8 (Bz, Ar-Ci), 
130.2-127.8 (35C, Ar-CH), 100.5 (GlcNAc-C1), 99.4 (Gal-C1), 97.3 (Sia-C2), 
96.4 (PhAra-C1), 79.9 (PhAra-C4), 79.1 (PhAra-C3), 76.8 (PhAra-C2), 75.4 
(2C, Gal-C5, PhAra-C5), 75.1 (GlcNAc-C3), 74.9 (GlcNAc-C5), 73.6 (GlcNAc-
C2), 73.4, 73.1, 72.8 (4C, PhCH2), 72.5 (Sia-C6), 71.4 (Gal-C3), 71.1 
(GlcNAc-C4), 70.8 (Gal-C2), 70.5 (GlcNAc-C6), 69.8 (Sia-C4), 68.9 (PhCH2), 
68.1 (Sia-C8), 67.8 (2C, Gal-C4, Sia-C7), 67.1 (OCH2CH2Si), 63.3 (Sia-C9), 
61.5 (Gal-C6), 49.2 (Sia-C5), 37.9 (Sia-C3), 23.6, 23.5, 21.8, 21.5, 21.2, 21.1, 
21.1, 20.9 (8C, CH3CO), 18.4 (OCH2CH2Si), -1.2 (Me3Si); 
 
HR-MS calcd. for C95H112N2O30SiNa2 [M+2Na]2+: 917.8449; found: 917.8443; 
 
[α]20D = -35.7 (c 1.0, CHCl3);  
 
2-Trimethylsilylethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosidonate)-(2→3)-β-D-galactopyranosyl-(1→4)-
[(5S)-5C-phenyl-α-L-arabinopyranosyl-(1→3)]-2-acetamido-2-deoxy-β-D-
glucopyranoside (4). To a solution of 18 (8.2 mg, 4.58 µmol) in dry MeOH 
(1.5 mL) was added Pd/C (Degussa E101 NE/W, 10 mg) and the mixture was 
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stirred at r.t. under hydrogen (1 atm) over night. Fresh catalyst was added   
(20 mg) and the mixture was vigorously stirred under hydrogen for 2 h, then 
the mixture was filtered over celite, and concentrated in vacuo. The residue 
was dissolved in dry MeOH (2 mL), and NaOMe in MeOH (0.5 M, 15 µL) was 
added dropwise at r.t.. The reaction was stirred under argon for 20 h, 
concentrated and purified by chromatography on RP18 cartridges 
(H2O/MeOH, gradient of 5-50%). Compound 4 (2.7 mg, 59%) was obtained as 
a white foam after lyophilization. 
 
1H-NMR (500.1 MHz, D2O): δ 7.53-7.34 (m, 5H, Ar-H), 5.70 (s, 1H, PhAra-
H5), 5.38 (d, 3J = 3.8 Hz, 1H, PhAra-H1), 4.53 (d, 3J = 7.9 Hz, 1H, GlcNAc-
H1), 4.46 (d, 3J = 7.9 Hz, 1H, Gal-H1), 4.23 (br s, 1H, PhAra-H4), 4.15 (dd, 3J 
= 3.3, 3J = 10.3 Hz, 1H, PhAra-H3), 4.10-3.50 (m, 21H, Gal-H3, -H4, -H5, -
H6a,b, GlcNAc-H2, -H3, -H4, -H5, -H6a,b, PhAra-H2, Sia-H4, -H5, -H6, -H7, -
H8, -H9a,b, 2H of OCH2CH2), 3.33-3.30 (m, 1H, Gal-H2), 2.76 (dd, 2J = 12.4, 
3J = 4.9 Hz, 1H, Sia-H3eq), 2.03, 2.02 (2 s, 6H, 2 Ac), 1.77 (‘t’, 2J = 3J = 12.2 
Hz, 1H, Sia-H3ax), 1.00-0.81 (m, 2H, OCH2CH2), -0.02 (s, 9H, Me3Si); 
 
13C-NMR (125.8 MHz, D2O): δ 175.7, 174.7, 174.6 (3C, 2 CH3CO, Sia-C1), 
138.6 (Ar-Ci), 129.1-126.8 (5C, Ar-CH), 102.8 (Gal-C1), 100.8 (GlcNAc-C1), 
100.3 (Sia-C2), 98.8 (PhAra-C1), 76.5 (CH), 75.9 (CH), 75.7 (CH), 74.8 (CH), 
74.7 (CH), 73.6 (CH), 72.9 (PhAra-C4), 72.5 (CH), 71.9 (PhAra-C5), 69.9 
(PhAra-C3), 69.8 (Gal-C2), 69.0 (OCH2CH2Si), 68.9, 68.7, 68.5, 68.2 (4 CH), 
63.2 (Sia-C9), 62.1 (GlcNAc-C6), 60.3 (Gal-C6), 52.3 (Sia-C5), 40.4 (Sia-C3), 
23.0, 22.7 (2C, CH3CO), 17.8 (OCH2CH2Si), -1.8 (Me3Si); 
 
HR-MS calcd. for C41H65N2O23SiNa2 [M+Na]+: 1027.3543; found: 1027.3553; 
 
[α]20D = -26.8 (c 0.2, H2O);  
 
2-Trimethylsilylethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosidonate)-(2→3)-β-D-galactopyranosyl-(1→4)-[ 
α-L-fucopyranosyl-(1→3)]-2-acetamido-2-deoxy-β-D-glucopyranoside 
(1c). 1c was synthesized according to the reported procedure21 from 23 in 
89% yield. 
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The NMR data correspond to the values given by Baisch and co-workers21 for 
the Lemieux-spacer analog of 1c. 
 
HR-MS calcd. for C36H63N2O23SiNa2 [M+Na]+: 965.3386; found: 965.3378; 
 
2-Trimethylsilylethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosidonate)-(2→3)-β-D-galactopyranosyl-(1→4)-[ 
α-D-arabinopyranosyl-(1→3)]-2-acetamido-2-deoxy-β-D-glucopyranoside 
(2c). 2c was synthesized according to the reported procedure21 from 23 in 
81% yield. 
 
The NMR data correspond to the values given by Baisch and co-workers21 for 
the Lemieux-spacer analog of 2c. 
 
HR-MS calcd. for C35H61N2O23SiNa2 [M+Na]+: 951.3230; found: 951.3231;  
 
[α]20D = -48.6 (c 0.32, MeOH);  
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3. Summary and Outlook 
 
The selectins play an essential role in the inflammatory cascade. The initial 
tethering and rolling of the leukocytes on the vascular endothelium, mediated 
by the selectins, is a critical mechanism of the host immune defense. 
Excessive efflux of leukocytes from the blood stream into inflamed tissue can, 
however, lead to severe pathological disorders (e.g. rheumatoid arthritis, 
stroke or reperfusion injury). Therefore, blocking of the selectins is a valuable 
pharmaceutical approach to reduce inflammatory disorders. 
 
The tetrasaccharide sialyl Lewisx (sLex) is the natural binding epitope 
common to all selectin ligands, and consequently served as a lead compound 
in selectin antagonist research. As observed for many carbohydrate-protein 
interactions, the affinity of sLex towards the selectins is in the low millimolar 
range. Because binding of the selectins to their ligands occurs under shear 
stress conditions, the stabilization of the pharmacophores in sLex mimetics in 
the bioactive conformation is a prerequisite for binding. 
 
More than 600 publications report on the synthesis and evaluation of potential 
selectin antagonizing substances.221 Furthermore, large research programs at 
major pharmaceutical companies, e.g. Novartis, Höchst and Glaxo, were run 
to develop selectin antagonizing drugs in the 1990s. However, to date there is 
no drug on the market with selectin blocking properties. 
 
The major drawback of most of the developed compounds was the lack of 
functionality. Although being ligands with high affinity, a lack of competitive 
inhibition under dynamic natural shear stress conditions was often observed. 
In this PhD thesis, both, the importance of pre-organization of the acid 
orientation in the bioactive conformation in sLex mimetics, but also the correct 
orientation of the core have been extensively studied. 
 
The stabilization of the acid orientation was studied by a non-covalent 
approach, using (R)- and (S)-adamantyllactic acid as replacements for N-
acetylneuraminic acid in sLex ((R)/(S)-7, chapter 2.1). It could be shown, that 
a (S)-configuration of the C-2 of adamantyllactic acid was essential for 
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binding. The corresponding (R)-diastereomer was deficient in detectable 
binding affinity towards E-selectin, resulting from the pre-organization of the 
acid orientation outside the bioactive conformation. These observations are in 
agreement with the literature on lactate derivatives.167,168 The (S)-lactate 
literature examples display increasing binding affinity with growing steric bulk 
of their substituents. The adamantyl group in (S)-7 was chosen as a more 
bulky substituent to strengthen the binding affinity of these mimetics. 
However, when (S)-7 was tested in the biological assay, the predicted 
increase in affinity was not observed. This behavior might originate from 
unfavorable solvent interactions of the lipophilic adamantyl group, when the in 
silico binding mode is taken into account. 
 
In a second approach to increase binding affinity of the ligands, a large 
unexplored area of the protein surface (figure 2, chapter 2.2) adjacent to the 
binding locus of the carboxylic acid in sLex mimetics was targeted. So far, this 
has not been exploited successfully for increasing binding affinity via 
additional pharmacophores targeting these amino acids. To date, there is one 
report in the literature, where various substituents at the lactate were 
introduced via amine, amide and sulfonamide linkages.222 The various rather 
drug-unlike substituents studied were, however, not successful in increasing 
the binding affinity of the cyclohexyllactate CGP69669A. Since amine and 
amide linkages are prone to influence charge and orientation of the proximate 
acid via salt bridges or hydrogen bonding, a non-participating linking motif 
was foreseen. Consequently, a ‘click chemistry’ library bearing druglike 
heterocycles or aromatic rings, based on a pre-organized (S)-triazololactate 
was investigated (chapter 2.2). The affinities of the library members 
investigated were not superior to CGP69669A or the molecules from the 
literature report.222 Therefore, the idea emerged that the additional 
pharmacophores do interact either with the protein surface or, like aromatic 
amino acid side chains in galactose binding proteins, intramolecularly with the 
α-face of galactose. Both of these cases however, would lead to a mis-
orientation of the carboxylic acid and therefore lower the binding affinity of the 
corresponding library members. 
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Encouraged by these results (chapters 2.1 and 2.2), a project was started 
where the acid orientation is first covalently locked in the bio-active orientation 
(chapter 2.3). Then, additional pharmacophores could be introduced via a 
proximate handle to target the protein surface as discussed before. The 
synthesis of this spiro-cyclic compound 17 involved various stereoselective 
transformations, being C-C bond formation or selective double bond 
oxidation. These transformations were first studied on part of the final 
molecule to reduce complexity and consumption of valuable starting material. 
Finally, a spiro-precursor of 17 could be synthesized, but according to 
Murphy’s law with opposite stereochemistry. However, the concept of the 
synthesis was shown feasible and further studies should allow rapid access to 
the final covalently stabilized acid in 17. 
 
Besides the analysis of the orientation of the carboxylic acid, also the core 
conformation of sLex and mimetics thereof was studied in this work. Literature 
examples showed the importance of the core stabilization when different 
linkers were used to connect fucose and galactose, which bear the essential 
pharmacophores of the core.57 For example, it was found that an additional 
methyl group in the linker region, which is not in contact with the protein but 
rather stabilizes the bioactive conformation, led to a six-fold increase in 
binding affinity when compared to the unsubstituted analog.223 By varying the 
substitution of the fucose C-5 position in the present work, a lipophilic 
interresidue interaction between fucose and galactose was found to be 
responsible for stabilization of the core conformation (chapter 2.4). Molecules 
without substituent at C-5 of fucose (2c, chapter 2.4) were not binding to E-
selectin, whereas molecules with lipophilic substituents were binding to the 
protein (1c, 4, chapter 2.4). It could be shown, that the methyl group chosen 
by nature in sLex possesses an optimal size for stabilizing the bioactive 
conformation. 
 
In general, the shallow binding site of sLex mimetics in E-selectin is a tough 
target for small molecule medicinal chemistry. Nature uses multivalent display 
of sLex on the surface proteins of leukocytes to gain significant binding. In 
order to further improve low molecular weight compounds as selectin 
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antagonists, experimental high resolution structures (e.g. X-ray 
crystallography or NMR) of sLex mimetics in complex with the selectins are 
indispensable. Studies regarding this issue are ongoing at the IMP and will 
give an excellent basis for further structure based medicinal chemistry in the 
selectin field. 
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4. Formula Index 
 
The molecules synthesized in this work are shown on the following pages. 
The formulas are numbered as they appear in the corresponding sections. 
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